Influenza
Conditions
Keywords
influenza infection, Influenza Vaccines, GSK Bio's influenza vaccine GSK2340273A, GSK Bio's influenza vaccine GSK2340274A
Brief summary
The purpose of this study is to characterize the safety and immune response of the H1N1 (swine) flu vaccines GSK2340274A and GSK2340273A in children 6 months to less than 9 years of age. This Protocol Posting has been updated following the Protocol amendment 1 & 2, September and October 2009. The sections impacted are study design, objectives and analysis methods.
Detailed description
Collaborators: United States Department of Health and Human Services, Office of Biomedical Advanced Research and Development Authority
Interventions
BIOLOGICALGSK2340274A
Two intramuscular injections
BIOLOGICALGSK2340273A
Two intramuscular injections
Sponsors
GlaxoSmithKline
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
6 Months to 8 Years
Healthy volunteers
Yes
Inclusion criteria
* Male or female children 6 months to less than 9 years of age at the time of the first vaccination. * Written informed consent obtained from the subject's parent/ legally acceptable representative (LAR); written informed assent obtained from the subject if appropriate. * Good general health as established by medical history and clinical examination before entering into the study. * Safety laboratory test results within the parameters specified in the protocol. * Parent/ LAR access to a consistent means of telephone contact, land line or mobile, but NOT a pay phone or other multiple-user device. * Subjects who the investigator believes that their parent(s)/ LAR can and will comply with the requirements of the protocol. * Female subjects of non-childbearing potential (pre-menarche) may be enrolled in the study.
Exclusion criteria
* Previous vaccination with an H1N1v-like virus vaccine or a medical history of physician-confirmed infection with an H1N1v-like virus. * Presence of evidence of substance abuse or of neurological or psychiatric diagnoses which, even if stable, are deemed by the investigator to render the potential subject or parent(s)/ LAR(s) unable/unlikely to provide accurate safety reports. * Presence of a temperature \>= 38.0ºC (\>=100.4ºF) by any route or method, or acute symptoms greater than mild severity on the scheduled date of first vaccination. * Diagnosed with cancer, or treatment for cancer, within 3 years. * Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination * Receipt of systemic glucocorticoids within 1 month prior to study enrollment, or any other cytotoxic or immunosuppressive drug within 6 months of study enrollment. Topical, intra-articular or inhaled glucocorticoids are allowed. * Receipt of any immunoglobulins and/or any blood products within 3 months of study enrollment or planned administration of any of these products during the study period. * Any significant disorder of coagulation or treatment with warfarin derivatives or heparin. Persons receiving individual doses of low molecular weight heparin are eligible if no such doses are given in the 24 hours before a study vaccination. Persons receiving prophylactic antiplatelet medications, e.g., low-dose acetylsalicylic acid, and without a clinically-apparent bleeding tendency, are eligible. * An acute evolving neurological disorder or history of Guillain-Barré syndrome within 6 weeks of receipt of seasonal influenza vaccine. * Administration of any licensed vaccine within 4 weeks before the first dose of study vaccine, with the exception of seasonal influenza vaccine. * Planned administration of any vaccine not foreseen by the study protocol between Day 0 and the Day 42 phlebotomy, including seasonal influenza vaccine. Routine childhood vaccinations are exempted if they cannot be delayed, but they must not be administered on the same day as the H1N1 vaccine candidate. * Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period. * Any known or suspected allergy to any constituent of influenza vaccines a history of anaphylactic-type reaction to any constituent of influenza vaccines; or a history of severe adverse reaction to a previous influenza vaccine. * Child in care.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Seroconverted Subjects Against Flu A/CAL/7/09 Influenza Strain - Preliminary Analysis | At Day 21 | A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination reciprocal hemagglutination inhibition (HI) titer lower than (\<) 10 and a post-vaccination reciprocal HI titer higher than or equal to (≥) 40, or a pre-vaccination reciprocal hemagglutination inhibition (HI) titer ≥ 10 and at least a 4-fold increase in post vaccination reciprocal titer against the vaccine virus. |
| Number of Seroconverted Subjects Against Flu A/CAL/7/09 Influenza Strain - First Analysis | At Day 21 | A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination reciprocal HI titer \< 10 and a post-vaccination reciprocal titer higher than or equal to (≥) 40, or a pre-vaccination reciprocal hemagglutination inhibition (HI) titer ≥ 10 and at least a 4-fold increase in post vaccination reciprocal titer against the vaccine virus. |
| Number of Seroconverted Subjects Against Flu A/CAL/7/09 Influenza Strain - Second Analysis | At Day 21 | A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination reciprocal HI titer \< 10 and a post-vaccination reciprocal titer higher than or equal to (≥) 40, or a pre-vaccination reciprocal hemagglutination inhibition (HI) titer ≥ 10 and at least a 4-fold increase in post vaccination reciprocal titer against the vaccine virus. |
| Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain - Preliminary Analysis | At Day 0 | A seroprotected subject was defined as a vaccinated subject with reciprocal HI titers higher than or equal to (≥) 40 against the tested virus. |
| Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain - First Analysis | At Day 0 | A seroprotected subject was defined as a vaccinated subject with reciprocal HI titers higher than or equal to (≥) 40 against the tested virus. |
| Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain - Second Analysis | At Day 0 | A seroprotected subject was defined as a vaccinated subject with reciprocal HI titers higher than or equal to (≥) 40 against the tested virus. |
| Number of Seroprotected Subjects Against Flu A/CAL/7/09 Strain - First Analysis | At Day 0 | A seroprotected subject was defined as a vaccinated subject with reciprocal HI titers higher than or equal to (≥) 40 against the tested virus. |
| Number of Seroprotected Subjects Against Flu A/CAL/7/09 Strain - Second Analysis | At Day 0 | A seroprotected subject was defined as a vaccinated subject with reciprocal HI titers higher than or equal to (≥) 40 against the tested virus. |
| Seroconversion Factor (SCF) for HI Antibodies Against Flu A/CAL/7/09 Influenza Strain - Preliminary Analysis | At Day 21 | SCF was defined as the geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the pre-vaccination reciprocal HI titer for the vaccine virus. |
| Seroconversion Factor (SCF) for HI Antibodies Against Flu A/CAL/7/09 Influenza Strain - First Analysis | At Day 21 | SCF was defined as the geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the pre-vaccination reciprocal HI titer for the vaccine virus. |
| Seroconversion Factor (SCF) for HI Antibodies Against Flu A/CAL/7/09 Influenza Strain - Second Analysis | At Day 21 | SCF was defined as the geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the pre-vaccination reciprocal HI titer for the vaccine virus. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Seropositive Subjects for Neutralizing Antibodies Against Flu A/Neth/602/09 Influenza Strain | At Day 0 (PRE) and at Day 21 | A seropositive subject was defined as a subject with antibody titers greater than or equal to (≥) 1:8. The vaccine strain assessed was Flu A/Neth/602/09 H1N1. |
| Titers for Neutralizing Antibodies Against the Flu A/Neth/602/09 Influenza Strain | At Day 0 (PRE) and at Day 21 | Titers are presented as geometric mean titers (GMTs) and measured in titers. |
| Number of Subjects With Vaccine Responses for Neutralizing Antibody Concentrations | At Day 0 (PRE) and at Day 21 | Vaccine responses are defined as the incidence rate of vaccinated subjects with at least a 4-fold increase in post vaccination reciprocal titer relative to that prior to first vaccination. The vaccine strain assessed was Flu A/Neth/602/09 H1N1. |
| Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Preliminary Analysis | During the 7-day (Days 0-6) post-vaccination period | Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site. |
| Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | During the 7-day (Days 0-6) post-vaccination period following each dose and across doses | Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site. |
| Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | During the 7-day (Days 0-6) post-vaccination period following each dose and across doses | Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site. |
| Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | During the 7-day (Days 0-6) post-vaccination period | Assessed solicited general symptoms were drowsiness, irritability, loss of appetite and temperature \[defined as axillary temperature equal to or above (≥) 38 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade or relationship to vaccination. Grade 3 symptom = symptom that prevented normal activity. Grade 3 loss of appetite= not eating at all. Grade 3 fever = fever ≥ 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination. |
| Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | During the 7-day (Days 0-6) post-vaccination period | Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, joint pain at other location, muscle aches, shivering, sweating, temperature \[defined as axillary temperature equal to or above (≥) 38 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever ≥ 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination. |
| Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | During the 7-day (Days 0-6) post-vaccination period following each dose and across doses | Assessed solicited general symptoms were drowsiness, irritability, loss of appetite and temperature \[defined as axillary temperature equal to or above (≥) 38 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever ≥ 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination. |
| Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | During the 7-day (Days 0-6) post-vaccination period following each dose and across doses | Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, joint pain at other location, muscle aches, and shivering, sweating, temperature \[defined as axillary temperature equal to or above (≥) 38 degrees Celsius (° C)\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever ≥ 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination. |
| Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | During the 7-day (Days 0-6) post-vaccination period following each dose and across doses | Assessed solicited general symptoms were drowsiness, irritability, loss of appetite and temperature \[defined as axillary temperature equal to or above (≥) 38 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever ≥ 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination. |
| Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | During the 7-day (Days 0-6) post-vaccination period following each dose and across doses | Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, joint pain at other location, muscle aches, shivering, sweating and temperature \[defined as axillary temperature equal to or above (≥) 38 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever ≥ 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination. |
| Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | At Day 0 (PRE), at Day 7 and at Day 21 | Among haematological parameters assessed were basophils \[BAS\], eosinophils \[EOS\], hematocrit \[HCT\], hemoglobin level \[HGB\], lymphocytes \[LYM\], monocytes \[MON\], neutrophils \[NEU\], platelet count \[PLC\], red blood cells \[RBC\] and white blood cells \[WBC\]. Haematological laboratory values were unknown, below, within or above the laboratory reference range defined for the specified time point and laboratory parameter. |
| Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | At Day 0 (PRE), at Day 7 and at Day 21 | Biochemical parameters assessed for lab abnormalities were alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], bilirubin \[BLR\], bilirubin conjugated/direct \[BCD\], creatinine \[CRE\] and blood urea nitrogen \[BUN\]. Biochemical laboratory values were unknown, below, within or above the laboratory reference range defined for the specified time point and laboratory parameter. |
| Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | At Day 0 (PRE), at Day 7, at Day 21 and at Day 42 | Among haematological parameters assessed were basophils \[BAS\], eosinophils \[EOS\], hematocrit \[HCT\], hemoglobin level \[HGB\], lymphocytes \[LYM\], monocytes \[MON\], neutrophils \[NEU\], platelet count \[PLC\], red blood cells \[RBC\] and white blood cells \[WBC\]. Haematological laboratory values were unknown, below, within or above the laboratory reference range defined for the specified time point and laboratory parameter. |
| Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | At Day 0 (PRE), at Day 7, at Day 21 and at Day 42 | Biochemical parameters assessed for lab abnormalities were alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], bilirubin \[BLR\], bilirubin conjugated/direct \[BCD\], creatinine \[CRE\] and blood urea nitrogen \[BUN\]. Biochemical laboratory values were unknown, below, within or above the laboratory reference range defined for the specified time point and laboratory parameter. |
| Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | At Day 0 (PRE), at Day 7 and at Day 21 | Among haematological parameters assessed were basophils \[BAS\], eosinophils \[EOS\], hematocrit \[HCT\], hemoglobin level \[HGB\], lymphocytes \[LYM\], monocytes \[MON\], neutrophils \[NEU\], platelet count \[PLC\], red blood cells \[RBC\] and white blood cells \[WBC\], Haematological laboratory values were unknown, below, within or above the laboratory reference range defined for the specified time point and laboratory parameter. |
| Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | At Day 0 (PRE), at Day 7, at Day 21 and at Day 42 | Biochemical parameters assessed for lab abnormalities were alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], bilirubin \[BLR\], bilirubin conjugated/direct \[BCD\], creatinine \[CRE\] and blood urea nitrogen \[BUN\]. Biochemical laboratory values were unknown, below, within or above the laboratory reference range defined for the specified time point and laboratory parameter. |
| Number of Subjects With Haematological Laboratory Abnormalities | At Day 182 | Among haematological parameters assessed were basophils \[BAS\], eosinophils \[EOS\], hematocrit \[HCT\], hemoglobin level \[HGB\], lymphocytes \[LYM\], monocytes \[MON\], neutrophils \[NEU\], platelet count \[PLC\], red blood cells \[RBC\] and white blood cells \[WBC\]. Haematological laboratory values were unknown, below, within or above the laboratory reference range defined for the specified time point and laboratory parameter. |
| Number of Subjects With Biochemical Laboratory Abnormalities | At Day 182 | Biochemical parameters assessed for lab abnormalities were alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], bilirubin \[BLR\], bilirubin conjugated/direct \[BCD\], creatinine \[CRE\] and blood urea nitrogen \[BUN\]. Biochemical laboratory values were unknown, below, within or above the laboratory reference range defined for the specified time point and laboratory parameter. |
| Number of Subjects With Any Unsolicited Adverse Events (AEs) - Preliminary Analysis | Within 21 days (Days 0-20) post vaccination | An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. |
| Number of Subjects With Any Unsolicited Adverse Events (AEs) - First Analysis | Within 42 days (Days 0-41) post vaccination | An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. |
| Number of Subjects With Any Unsolicited Adverse Events (AEs) - Second Analysis | Within 41 days (Days 0-40) post vaccination | An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. |
| Number of Subjects With Any Unsolicited Adverse Events (AEs) | Within 84 days (Days 0-83) post vaccination | An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. |
| Number of Subjects With Any Medically-attended Adverse Events (MAEs) - Preliminary Analysis | Within 21 days (Days 0-20) post vaccination | MAEs were defined as events for which the subject received medical attention defined as hospitalization, an emergency room visit, or a visit to or from medical personnel (medical doctor) for any reason. Any MAE(s) = Occurrence of any MAE(s) regardless of intensity grade or relation to vaccination. |
| Number of Seropositive Subjects for HI Antibodies - Preliminary Analysis | At Day 0 (PRE) and at Day 21 | A seropositive subject was defined as a subject with antibody titers greater than or equal to (≥) 1:10. The vaccine strain assessed was Flu A/CAL/7/09. |
| Number of Subjects With Any Medically-attended Adverse Events (MAEs) - Second Analysis | Within 42 days (Days 0-41) post vaccination | MAEs were defined as events for which the subject received medical attention defined as hospitalization, an emergency room visit, or a visit to or from medical personnel (medical doctor) for any reason. Any MAE(s) = Occurrence of any MAE(s) regardless of intensity grade or relation to vaccination. |
| Number of Subjects With Any Medically-attended Adverse Events (MAEs) | Within 182 days (Days 0-181) post vaccination | MAEs were defined as events for which the subject received medical attention defined as hospitalization, an emergency room visit, or a visit to or from medical personnel (medical doctor) for any reason. Any MAE(s) = Occurrence of any MAE(s) regardless of intensity grade or relation to vaccination. |
| Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs) - Preliminary Analysis | Within 21 days (Days 0-20) post vaccination | Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology. |
| Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs) - First Analysis | Within 42 days (Days 0-41) post vaccination | Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology. |
| Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs) - Second Analysis | Within 42 days (Days 0-41) post vaccination | Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology. |
| Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs) | Within 182 days (Days 0-181) post vaccination | Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology. |
| Number of Subjects With Serious Adverse Events (SAEs) - Preliminary Analysis | Within 21 days (Days 0-20) post vaccination | Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. |
| Number of Subjects With Serious Adverse Events (SAEs) - First Analysis | Within 42 days (Days 0-41) post vaccination | Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. |
| Number of Subjects With Serious Adverse Events (SAEs) - Second Analysis | Within 42 days (Day 0-41) post vaccination | Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. |
| Number of Subjects With Serious Adverse Events (SAEs) | Within 182 days (Days 0-181) post vaccination | Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. |
| Number of Subjects With Any Medically-attended Adverse Events (MAEs) - First Analysis | Within 41 days (Days 0-40) post vaccination | MAEs were defined as events for which the subject received medical attention defined as hospitalization, an emergency room visit, or a visit to or from medical personnel (medical doctor) for any reason. Any MAE(s) = Occurrence of any MAE(s) regardless of intensity grade or relation to vaccination. |
| Number of Seropositive Subjects for HI Antibodies - First Analysis | At Day 0 (PRE) and at Day 21 | A seropositive subject was defined as a subject with antibody titers greater than or equal to (≥) 1:10. The vaccine strain assessed was Flu A/CAL/7/09. |
| Number of Seropositive Subjects for HI Antibodies - Second Analysis | At Day 0 (PRE) and at Day 21 | A seropositive subject was defined as a subject with antibody titers greater than or equal to (≥) 1:10. The vaccine strain assessed was Flu A/CAL/7/09. |
| Number of Seropositive Subjects for HI Antibodies | At Day 0 (PRE) and at Day 182 | A seropositive subject was defined as a subject with antibody titers greater than or equal to (≥) 1:10. The vaccine strain assessed was Flu A/CAL/7/09. |
| Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain - Preliminary Analysis | At Day 0 (PRE) and at Day 21 | Titers are presented as geometric mean titers (GMTs) and measured in titers. |
| Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain - First Analysis | At Day 0 (PRE) and at Day 21 | Titers are presented as geometric mean titers (GMTs) and measured in titers. |
| Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain - Second Analysis | At Day 0 (PRE) and at Day 21 | Titers are presented as geometric mean titers (GMTs) and measured in titers. |
| Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain | At Day 0 (PRE) and at Day 182 | Titers are presented as geometric mean titers (GMTs) and measured in titers. |
| Number of Seroconverted Subjects Against Flu A/CAL/7/09 Influenza Strain | At Day 182 | A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination reciprocal hemagglutination inhibition (HI) titer lower than (\<) 10 and a post-vaccination reciprocal titer higher than or equal to (≥) 40, or a pre-vaccination reciprocal hemagglutination inhibition (HI) titer ≥ 10 and at least a 4-fold increase in post vaccination reciprocal titer against the vaccine virus. |
| Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain | At Day 0 (PRE) and at Day 182 | A seroprotected subject was defined as a vaccinated subject with reciprocal HI titers higher than or equal to (≥) 40 against the tested virus. |
| Seroconversion Factor (SCF) for HI Antibodies Against Flu A/CAL/7/09 Influenza Strain | At Day 182 | SCF was defined as the geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the pre-vaccination reciprocal HI titer for the vaccine virus. |
Countries
Canada, United States
Participant flow
Pre-assignment details
Out of the 323 subjects originally enrolled in the study, 1 subject was not included in the Total Vaccinated Cohort.
Participants by arm
| Arm | Count |
|---|---|
| Arepanrix/F1 Group Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age). | 67 |
| Arepanrix/F2 Group Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age). | 128 |
| GSK2340273A/F1 Group Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age). | 64 |
| GSK2340273A/F2 Group Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age). | 63 |
| Total | 322 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 |
|---|---|---|---|---|---|
| Overall Study | Lost to Follow-up | 5 | 16 | 2 | 3 |
| Overall Study | Poor Compliance. Numerous Visits Booked | 1 | 0 | 1 | 0 |
| Overall Study | Withdrawal by Subject | 2 | 4 | 1 | 4 |
Baseline characteristics
| Characteristic | Arepanrix/F1 Group | Arepanrix/F2 Group | GSK2340273A/F1 Group | GSK2340273A/F2 Group | Total |
|---|---|---|---|---|---|
| Age, Continuous | 53.6 Months STANDARD_DEVIATION 31.6 | 47.4 Months STANDARD_DEVIATION 28.6 | 50.3 Months STANDARD_DEVIATION 29 | 54.4 Months STANDARD_DEVIATION 30.4 | 50.6 Months STANDARD_DEVIATION 29.7 |
| Race/Ethnicity, Customized African heritage/African American | 1 Participants | 7 Participants | 1 Participants | 1 Participants | 10 Participants |
| Race/Ethnicity, Customized American Indian or Alaskan native | 1 Participants | 6 Participants | 1 Participants | 2 Participants | 10 Participants |
| Race/Ethnicity, Customized Asian - Central/South Asian heritage | 14 Participants | 16 Participants | 16 Participants | 14 Participants | 60 Participants |
| Race/Ethnicity, Customized Asian - East Asian heritage | 2 Participants | 4 Participants | 0 Participants | 2 Participants | 8 Participants |
| Race/Ethnicity, Customized Asian - South East Asian heritage | 3 Participants | 1 Participants | 2 Participants | 2 Participants | 8 Participants |
| Race/Ethnicity, Customized Not specified | 0 Participants | 5 Participants | 0 Participants | 3 Participants | 8 Participants |
| Race/Ethnicity, Customized White - Arabic/North African heritage | 0 Participants | 3 Participants | 0 Participants | 1 Participants | 4 Participants |
| Race/Ethnicity, Customized White - Caucasian/European heritage | 46 Participants | 86 Participants | 44 Participants | 38 Participants | 214 Participants |
| Sex: Female, Male Female | 27 Participants | 58 Participants | 33 Participants | 30 Participants | 148 Participants |
| Sex: Female, Male Male | 40 Participants | 70 Participants | 31 Participants | 33 Participants | 174 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 67 | 0 / 128 | 0 / 64 | 0 / 63 |
| other Total, other adverse events | 61 / 67 | 125 / 128 | 54 / 64 | 55 / 63 |
| serious Total, serious adverse events | 2 / 67 | 2 / 128 | 0 / 64 | 0 / 63 |
Outcome results
Primary
Number of Seroconverted Subjects Against Flu A/CAL/7/09 Influenza Strain - First Analysis
A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination reciprocal HI titer \< 10 and a post-vaccination reciprocal titer higher than or equal to (≥) 40, or a pre-vaccination reciprocal hemagglutination inhibition (HI) titer ≥ 10 and at least a 4-fold increase in post vaccination reciprocal titer against the vaccine virus.
Time frame: At Day 21
Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 21, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arepanrix/F1 Group | Number of Seroconverted Subjects Against Flu A/CAL/7/09 Influenza Strain - First Analysis | 54 Participants |
| Arepanrix/F2 Group | Number of Seroconverted Subjects Against Flu A/CAL/7/09 Influenza Strain - First Analysis | 45 Participants |
| GSK2340273A/F1 Group | Number of Seroconverted Subjects Against Flu A/CAL/7/09 Influenza Strain - First Analysis | 41 Participants |
| GSK2340273A/F2 Group | Number of Seroconverted Subjects Against Flu A/CAL/7/09 Influenza Strain - First Analysis | 34 Participants |
Primary
Number of Seroconverted Subjects Against Flu A/CAL/7/09 Influenza Strain - First Analysis
A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination reciprocal HI titer \< 10 and a post-vaccination reciprocal titer higher than or equal to (≥) 40, or a pre-vaccination reciprocal hemagglutination inhibition (HI) titer ≥ 10 and at least a 4-fold increase in post vaccination reciprocal titer against the vaccine virus.
Time frame: At Day 42
Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 42, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arepanrix/F1 Group | Number of Seroconverted Subjects Against Flu A/CAL/7/09 Influenza Strain - First Analysis | 43 Participants |
| Arepanrix/F2 Group | Number of Seroconverted Subjects Against Flu A/CAL/7/09 Influenza Strain - First Analysis | 39 Participants |
| GSK2340273A/F1 Group | Number of Seroconverted Subjects Against Flu A/CAL/7/09 Influenza Strain - First Analysis | 46 Participants |
| GSK2340273A/F2 Group | Number of Seroconverted Subjects Against Flu A/CAL/7/09 Influenza Strain - First Analysis | 38 Participants |
Primary
Number of Seroconverted Subjects Against Flu A/CAL/7/09 Influenza Strain - Preliminary Analysis
A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination reciprocal hemagglutination inhibition (HI) titer lower than (\<) 10 and a post-vaccination reciprocal HI titer higher than or equal to (≥) 40, or a pre-vaccination reciprocal hemagglutination inhibition (HI) titer ≥ 10 and at least a 4-fold increase in post vaccination reciprocal titer against the vaccine virus.
Time frame: At Day 21
Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arepanrix/F1 Group | Number of Seroconverted Subjects Against Flu A/CAL/7/09 Influenza Strain - Preliminary Analysis | 60 Participants |
| Arepanrix/F2 Group | Number of Seroconverted Subjects Against Flu A/CAL/7/09 Influenza Strain - Preliminary Analysis | 53 Participants |
| GSK2340273A/F1 Group | Number of Seroconverted Subjects Against Flu A/CAL/7/09 Influenza Strain - Preliminary Analysis | 45 Participants |
| GSK2340273A/F2 Group | Number of Seroconverted Subjects Against Flu A/CAL/7/09 Influenza Strain - Preliminary Analysis | 36 Participants |
Primary
Number of Seroconverted Subjects Against Flu A/CAL/7/09 Influenza Strain - Second Analysis
A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination reciprocal HI titer \< 10 and a post-vaccination reciprocal titer higher than or equal to (≥) 40, or a pre-vaccination reciprocal hemagglutination inhibition (HI) titer ≥ 10 and at least a 4-fold increase in post vaccination reciprocal titer against the vaccine virus.
Time frame: At Day 42
Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 42, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arepanrix/F1 Group | Number of Seroconverted Subjects Against Flu A/CAL/7/09 Influenza Strain - Second Analysis | 44 Participants |
| Arepanrix/F2 Group | Number of Seroconverted Subjects Against Flu A/CAL/7/09 Influenza Strain - Second Analysis | 83 Participants |
| GSK2340273A/F1 Group | Number of Seroconverted Subjects Against Flu A/CAL/7/09 Influenza Strain - Second Analysis | 46 Participants |
| GSK2340273A/F2 Group | Number of Seroconverted Subjects Against Flu A/CAL/7/09 Influenza Strain - Second Analysis | 38 Participants |
Primary
Number of Seroconverted Subjects Against Flu A/CAL/7/09 Influenza Strain - Second Analysis
A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination reciprocal HI titer \< 10 and a post-vaccination reciprocal titer higher than or equal to (≥) 40, or a pre-vaccination reciprocal hemagglutination inhibition (HI) titer ≥ 10 and at least a 4-fold increase in post vaccination reciprocal titer against the vaccine virus.
Time frame: At Day 21
Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 21, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arepanrix/F1 Group | Number of Seroconverted Subjects Against Flu A/CAL/7/09 Influenza Strain - Second Analysis | 56 Participants |
| Arepanrix/F2 Group | Number of Seroconverted Subjects Against Flu A/CAL/7/09 Influenza Strain - Second Analysis | 98 Participants |
| GSK2340273A/F1 Group | Number of Seroconverted Subjects Against Flu A/CAL/7/09 Influenza Strain - Second Analysis | 41 Participants |
| GSK2340273A/F2 Group | Number of Seroconverted Subjects Against Flu A/CAL/7/09 Influenza Strain - Second Analysis | 34 Participants |
Primary
Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain - First Analysis
A seroprotected subject was defined as a vaccinated subject with reciprocal HI titers higher than or equal to (≥) 40 against the tested virus.
Time frame: At Day 42
Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 42, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arepanrix/F1 Group | Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain - First Analysis | 43 Participants |
| Arepanrix/F2 Group | Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain - First Analysis | 42 Participants |
| GSK2340273A/F1 Group | Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain - First Analysis | 46 Participants |
| GSK2340273A/F2 Group | Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain - First Analysis | 41 Participants |
Primary
Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain - First Analysis
A seroprotected subject was defined as a vaccinated subject with reciprocal HI titers higher than or equal to (≥) 40 against the tested virus.
Time frame: At Day 0
Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 21, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arepanrix/F1 Group | Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain - First Analysis | 12 Participants |
| Arepanrix/F2 Group | Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain - First Analysis | 2 Participants |
| GSK2340273A/F1 Group | Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain - First Analysis | 12 Participants |
| GSK2340273A/F2 Group | Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain - First Analysis | 14 Participants |
Primary
Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain - First Analysis
A seroprotected subject was defined as a vaccinated subject with reciprocal HI titers higher than or equal to (≥) 40 against the tested virus.
Time frame: At Day 21
Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 21, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arepanrix/F1 Group | Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain - First Analysis | 56 Participants |
| Arepanrix/F2 Group | Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain - First Analysis | 48 Participants |
| GSK2340273A/F1 Group | Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain - First Analysis | 42 Participants |
| GSK2340273A/F2 Group | Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain - First Analysis | 37 Participants |
Primary
Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain - Preliminary Analysis
A seroprotected subject was defined as a vaccinated subject with reciprocal HI titers higher than or equal to (≥) 40 against the tested virus.
Time frame: At Day 21
Population: The analysis was performed on the Total Vaccinated Cohort at Day 21, which included all subjects who received at least 1 study vaccination.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arepanrix/F1 Group | Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain - Preliminary Analysis | 62 Participants |
| Arepanrix/F2 Group | Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain - Preliminary Analysis | 55 Participants |
| GSK2340273A/F1 Group | Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain - Preliminary Analysis | 46 Participants |
| GSK2340273A/F2 Group | Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain - Preliminary Analysis | 39 Participants |
Primary
Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain - Preliminary Analysis
A seroprotected subject was defined as a vaccinated subject with reciprocal HI titers higher than or equal to (≥) 40 against the tested virus.
Time frame: At Day 0
Population: The analysis was performed on the Total Vaccinated Cohort at Day 21, which included all subjects who received at least 1 study vaccination.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arepanrix/F1 Group | Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain - Preliminary Analysis | 13 Participants |
| Arepanrix/F2 Group | Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain - Preliminary Analysis | 3 Participants |
| GSK2340273A/F1 Group | Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain - Preliminary Analysis | 12 Participants |
| GSK2340273A/F2 Group | Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain - Preliminary Analysis | 15 Participants |
Primary
Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain - Second Analysis
A seroprotected subject was defined as a vaccinated subject with reciprocal HI titers higher than or equal to (≥) 40 against the tested virus.
Time frame: At Day 0
Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 21, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arepanrix/F1 Group | Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain - Second Analysis | 12 Participants |
| Arepanrix/F2 Group | Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain - Second Analysis | 24 Participants |
| GSK2340273A/F1 Group | Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain - Second Analysis | 12 Participants |
| GSK2340273A/F2 Group | Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain - Second Analysis | 14 Participants |
Primary
Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain - Second Analysis
A seroprotected subject was defined as a vaccinated subject with reciprocal HI titers higher than or equal to (≥) 40 against the tested virus.
Time frame: At Day 21
Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 21, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arepanrix/F1 Group | Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain - Second Analysis | 58 Participants |
| Arepanrix/F2 Group | Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain - Second Analysis | 102 Participants |
| GSK2340273A/F1 Group | Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain - Second Analysis | 42 Participants |
| GSK2340273A/F2 Group | Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain - Second Analysis | 37 Participants |
Primary
Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain - Second Analysis
A seroprotected subject was defined as a vaccinated subject with reciprocal HI titers higher than or equal to (≥) 40 against the tested virus.
Time frame: At Day 42
Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 42, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arepanrix/F1 Group | Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain - Second Analysis | 44 Participants |
| Arepanrix/F2 Group | Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain - Second Analysis | 87 Participants |
| GSK2340273A/F1 Group | Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain - Second Analysis | 46 Participants |
| GSK2340273A/F2 Group | Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain - Second Analysis | 41 Participants |
Primary
Number of Seroprotected Subjects Against Flu A/CAL/7/09 Strain - First Analysis
A seroprotected subject was defined as a vaccinated subject with reciprocal HI titers higher than or equal to (≥) 40 against the tested virus.
Time frame: At Day 0
Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 42, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arepanrix/F1 Group | Number of Seroprotected Subjects Against Flu A/CAL/7/09 Strain - First Analysis | 8 Participants |
| Arepanrix/F2 Group | Number of Seroprotected Subjects Against Flu A/CAL/7/09 Strain - First Analysis | 1 Participants |
| GSK2340273A/F1 Group | Number of Seroprotected Subjects Against Flu A/CAL/7/09 Strain - First Analysis | 9 Participants |
| GSK2340273A/F2 Group | Number of Seroprotected Subjects Against Flu A/CAL/7/09 Strain - First Analysis | 9 Participants |
Primary
Number of Seroprotected Subjects Against Flu A/CAL/7/09 Strain - Second Analysis
A seroprotected subject was defined as a vaccinated subject with reciprocal HI titers higher than or equal to (≥) 40 against the tested virus.
Time frame: At Day 0
Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 42, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arepanrix/F1 Group | Number of Seroprotected Subjects Against Flu A/CAL/7/09 Strain - Second Analysis | 8 Participants |
| Arepanrix/F2 Group | Number of Seroprotected Subjects Against Flu A/CAL/7/09 Strain - Second Analysis | 20 Participants |
| GSK2340273A/F1 Group | Number of Seroprotected Subjects Against Flu A/CAL/7/09 Strain - Second Analysis | 9 Participants |
| GSK2340273A/F2 Group | Number of Seroprotected Subjects Against Flu A/CAL/7/09 Strain - Second Analysis | 9 Participants |
Primary
Seroconversion Factor (SCF) for HI Antibodies Against Flu A/CAL/7/09 Influenza Strain - First Analysis
SCF was defined as the geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the pre-vaccination reciprocal HI titer for the vaccine virus.
Time frame: At Day 21
Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 21, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.
| Arm | Measure | Value (GEOMETRIC_MEAN) |
|---|---|---|
| Arepanrix/F1 Group | Seroconversion Factor (SCF) for HI Antibodies Against Flu A/CAL/7/09 Influenza Strain - First Analysis | 35.9 Fold change |
| Arepanrix/F2 Group | Seroconversion Factor (SCF) for HI Antibodies Against Flu A/CAL/7/09 Influenza Strain - First Analysis | 40.8 Fold change |
| GSK2340273A/F1 Group | Seroconversion Factor (SCF) for HI Antibodies Against Flu A/CAL/7/09 Influenza Strain - First Analysis | 13.2 Fold change |
| GSK2340273A/F2 Group | Seroconversion Factor (SCF) for HI Antibodies Against Flu A/CAL/7/09 Influenza Strain - First Analysis | 7.6 Fold change |
Primary
Seroconversion Factor (SCF) for HI Antibodies Against Flu A/CAL/7/09 Influenza Strain - First Analysis
SCF was defined as the geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the pre-vaccination reciprocal HI titer for the vaccine virus.
Time frame: At Day 42
Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 42, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.
| Arm | Measure | Value (GEOMETRIC_MEAN) |
|---|---|---|
| Arepanrix/F1 Group | Seroconversion Factor (SCF) for HI Antibodies Against Flu A/CAL/7/09 Influenza Strain - First Analysis | 155.3 Fold change |
| Arepanrix/F2 Group | Seroconversion Factor (SCF) for HI Antibodies Against Flu A/CAL/7/09 Influenza Strain - First Analysis | 217.2 Fold change |
| GSK2340273A/F1 Group | Seroconversion Factor (SCF) for HI Antibodies Against Flu A/CAL/7/09 Influenza Strain - First Analysis | 44.2 Fold change |
| GSK2340273A/F2 Group | Seroconversion Factor (SCF) for HI Antibodies Against Flu A/CAL/7/09 Influenza Strain - First Analysis | 24.1 Fold change |
Primary
Seroconversion Factor (SCF) for HI Antibodies Against Flu A/CAL/7/09 Influenza Strain - Preliminary Analysis
SCF was defined as the geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the pre-vaccination reciprocal HI titer for the vaccine virus.
Time frame: At Day 21
Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.
| Arm | Measure | Value (GEOMETRIC_MEAN) |
|---|---|---|
| Arepanrix/F1 Group | Seroconversion Factor (SCF) for HI Antibodies Against Flu A/CAL/7/09 Influenza Strain - Preliminary Analysis | 38.6 Fold change |
| Arepanrix/F2 Group | Seroconversion Factor (SCF) for HI Antibodies Against Flu A/CAL/7/09 Influenza Strain - Preliminary Analysis | 39.2 Fold change |
| GSK2340273A/F1 Group | Seroconversion Factor (SCF) for HI Antibodies Against Flu A/CAL/7/09 Influenza Strain - Preliminary Analysis | 14.4 Fold change |
| GSK2340273A/F2 Group | Seroconversion Factor (SCF) for HI Antibodies Against Flu A/CAL/7/09 Influenza Strain - Preliminary Analysis | 7.8 Fold change |
Primary
Seroconversion Factor (SCF) for HI Antibodies Against Flu A/CAL/7/09 Influenza Strain - Second Analysis
SCF was defined as the geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the pre-vaccination reciprocal HI titer for the vaccine virus.
Time frame: At Day 42
Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 42, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.
| Arm | Measure | Value (GEOMETRIC_MEAN) |
|---|---|---|
| Arepanrix/F1 Group | Seroconversion Factor (SCF) for HI Antibodies Against Flu A/CAL/7/09 Influenza Strain - Second Analysis | 157.1 Fold change |
| Arepanrix/F2 Group | Seroconversion Factor (SCF) for HI Antibodies Against Flu A/CAL/7/09 Influenza Strain - Second Analysis | 151.6 Fold change |
| GSK2340273A/F1 Group | Seroconversion Factor (SCF) for HI Antibodies Against Flu A/CAL/7/09 Influenza Strain - Second Analysis | 44.2 Fold change |
| GSK2340273A/F2 Group | Seroconversion Factor (SCF) for HI Antibodies Against Flu A/CAL/7/09 Influenza Strain - Second Analysis | 24.1 Fold change |
Primary
Seroconversion Factor (SCF) for HI Antibodies Against Flu A/CAL/7/09 Influenza Strain - Second Analysis
SCF was defined as the geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the pre-vaccination reciprocal HI titer for the vaccine virus.
Time frame: At Day 21
Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 21, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.
| Arm | Measure | Value (GEOMETRIC_MEAN) |
|---|---|---|
| Arepanrix/F1 Group | Seroconversion Factor (SCF) for HI Antibodies Against Flu A/CAL/7/09 Influenza Strain - Second Analysis | 36.2 Fold change |
| Arepanrix/F2 Group | Seroconversion Factor (SCF) for HI Antibodies Against Flu A/CAL/7/09 Influenza Strain - Second Analysis | 33.6 Fold change |
| GSK2340273A/F1 Group | Seroconversion Factor (SCF) for HI Antibodies Against Flu A/CAL/7/09 Influenza Strain - Second Analysis | 13.8 Fold change |
| GSK2340273A/F2 Group | Seroconversion Factor (SCF) for HI Antibodies Against Flu A/CAL/7/09 Influenza Strain - Second Analysis | 7.6 Fold change |
Secondary
Number of Seroconverted Subjects Against Flu A/CAL/7/09 Influenza Strain
A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination reciprocal hemagglutination inhibition (HI) titer lower than (\<) 10 and a post-vaccination reciprocal titer higher than or equal to (≥) 40, or a pre-vaccination reciprocal hemagglutination inhibition (HI) titer ≥ 10 and at least a 4-fold increase in post vaccination reciprocal titer against the vaccine virus.
Time frame: At Day 182
Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 182, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arepanrix/F1 Group | Number of Seroconverted Subjects Against Flu A/CAL/7/09 Influenza Strain | 50 Participants |
| Arepanrix/F2 Group | Number of Seroconverted Subjects Against Flu A/CAL/7/09 Influenza Strain | 78 Participants |
| GSK2340273A/F1 Group | Number of Seroconverted Subjects Against Flu A/CAL/7/09 Influenza Strain | 35 Participants |
| GSK2340273A/F2 Group | Number of Seroconverted Subjects Against Flu A/CAL/7/09 Influenza Strain | 34 Participants |
Secondary
Number of Seropositive Subjects for HI Antibodies
A seropositive subject was defined as a subject with antibody titers greater than or equal to (≥) 1:10. The vaccine strain assessed was Flu A/CAL/7/09.
Time frame: At Day 0 (PRE) and at Day 182
Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 182, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Arepanrix/F1 Group | Number of Seropositive Subjects for HI Antibodies | Flu A/CAL/7/09, PRE | 13 Participants |
| Arepanrix/F1 Group | Number of Seropositive Subjects for HI Antibodies | Flu A/CAL/7/09, D182 | 54 Participants |
| Arepanrix/F2 Group | Number of Seropositive Subjects for HI Antibodies | Flu A/CAL/7/09, D182 | 84 Participants |
| Arepanrix/F2 Group | Number of Seropositive Subjects for HI Antibodies | Flu A/CAL/7/09, PRE | 18 Participants |
| GSK2340273A/F1 Group | Number of Seropositive Subjects for HI Antibodies | Flu A/CAL/7/09, PRE | 13 Participants |
| GSK2340273A/F1 Group | Number of Seropositive Subjects for HI Antibodies | Flu A/CAL/7/09, D182 | 45 Participants |
| GSK2340273A/F2 Group | Number of Seropositive Subjects for HI Antibodies | Flu A/CAL/7/09, PRE | 12 Participants |
| GSK2340273A/F2 Group | Number of Seropositive Subjects for HI Antibodies | Flu A/CAL/7/09, D182 | 50 Participants |
Secondary
Number of Seropositive Subjects for HI Antibodies - First Analysis
A seropositive subject was defined as a subject with antibody titers greater than or equal to (≥) 1:10. The vaccine strain assessed was Flu A/CAL/7/09.
Time frame: At Day 0 (PRE) and at Day 21
Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 21, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Arepanrix/F1 Group | Number of Seropositive Subjects for HI Antibodies - First Analysis | Flu A/CAL/7/09, PRE | 15 Participants |
| Arepanrix/F1 Group | Number of Seropositive Subjects for HI Antibodies - First Analysis | Flu A/CAL/7/09, D21 | 57 Participants |
| Arepanrix/F2 Group | Number of Seropositive Subjects for HI Antibodies - First Analysis | Flu A/CAL/7/09, D21 | 49 Participants |
| Arepanrix/F2 Group | Number of Seropositive Subjects for HI Antibodies - First Analysis | Flu A/CAL/7/09, PRE | 3 Participants |
| GSK2340273A/F1 Group | Number of Seropositive Subjects for HI Antibodies - First Analysis | Flu A/CAL/7/09, PRE | 13 Participants |
| GSK2340273A/F1 Group | Number of Seropositive Subjects for HI Antibodies - First Analysis | Flu A/CAL/7/09, D21 | 53 Participants |
| GSK2340273A/F2 Group | Number of Seropositive Subjects for HI Antibodies - First Analysis | Flu A/CAL/7/09, PRE | 14 Participants |
| GSK2340273A/F2 Group | Number of Seropositive Subjects for HI Antibodies - First Analysis | Flu A/CAL/7/09, D21 | 54 Participants |
Secondary
Number of Seropositive Subjects for HI Antibodies - First Analysis
A seropositive subject was defined as a subject with antibody titers greater than or equal to (≥) 1:10. The vaccine strain assessed was Flu A/CAL/7/09.
Time frame: At Day 0 (PRE) and at Day 42
Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 42, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Arepanrix/F1 Group | Number of Seropositive Subjects for HI Antibodies - First Analysis | Flu A/CAL/7/09, PRE | 10 Participants |
| Arepanrix/F1 Group | Number of Seropositive Subjects for HI Antibodies - First Analysis | Flu A/CAL/7/09, D42 | 43 Participants |
| Arepanrix/F2 Group | Number of Seropositive Subjects for HI Antibodies - First Analysis | Flu A/CAL/7/09, D42 | 42 Participants |
| Arepanrix/F2 Group | Number of Seropositive Subjects for HI Antibodies - First Analysis | Flu A/CAL/7/09, PRE | 2 Participants |
| GSK2340273A/F1 Group | Number of Seropositive Subjects for HI Antibodies - First Analysis | Flu A/CAL/7/09, PRE | 10 Participants |
| GSK2340273A/F1 Group | Number of Seropositive Subjects for HI Antibodies - First Analysis | Flu A/CAL/7/09, D42 | 46 Participants |
| GSK2340273A/F2 Group | Number of Seropositive Subjects for HI Antibodies - First Analysis | Flu A/CAL/7/09, PRE | 9 Participants |
| GSK2340273A/F2 Group | Number of Seropositive Subjects for HI Antibodies - First Analysis | Flu A/CAL/7/09, D42 | 44 Participants |
Secondary
Number of Seropositive Subjects for HI Antibodies - Preliminary Analysis
A seropositive subject was defined as a subject with antibody titers greater than or equal to (≥) 1:10. The vaccine strain assessed was Flu A/CAL/7/09.
Time frame: At Day 0 (PRE) and at Day 21
Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Arepanrix/F1 Group | Number of Seropositive Subjects for HI Antibodies - Preliminary Analysis | Flu A/CAL/7/09, PRE | 17 Participants |
| Arepanrix/F1 Group | Number of Seropositive Subjects for HI Antibodies - Preliminary Analysis | Flu A/CAL/7/09, D21 | 63 Participants |
| Arepanrix/F2 Group | Number of Seropositive Subjects for HI Antibodies - Preliminary Analysis | Flu A/CAL/7/09, D21 | 56 Participants |
| Arepanrix/F2 Group | Number of Seropositive Subjects for HI Antibodies - Preliminary Analysis | Flu A/CAL/7/09, PRE | 4 Participants |
| GSK2340273A/F1 Group | Number of Seropositive Subjects for HI Antibodies - Preliminary Analysis | Flu A/CAL/7/09, PRE | 13 Participants |
| GSK2340273A/F1 Group | Number of Seropositive Subjects for HI Antibodies - Preliminary Analysis | Flu A/CAL/7/09, D21 | 57 Participants |
| GSK2340273A/F2 Group | Number of Seropositive Subjects for HI Antibodies - Preliminary Analysis | Flu A/CAL/7/09, PRE | 15 Participants |
| GSK2340273A/F2 Group | Number of Seropositive Subjects for HI Antibodies - Preliminary Analysis | Flu A/CAL/7/09, D21 | 56 Participants |
Secondary
Number of Seropositive Subjects for HI Antibodies - Second Analysis
A seropositive subject was defined as a subject with antibody titers greater than or equal to (≥) 1:10. The vaccine strain assessed was Flu A/CAL/7/09.
Time frame: At Day 0 (PRE) and at Day 21
Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 21, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Arepanrix/F1 Group | Number of Seropositive Subjects for HI Antibodies - Second Analysis | Flu A/CAL/7/09, PRE | 15 Participants |
| Arepanrix/F1 Group | Number of Seropositive Subjects for HI Antibodies - Second Analysis | Flu A/CAL/7/09, D21 | 59 Participants |
| Arepanrix/F2 Group | Number of Seropositive Subjects for HI Antibodies - Second Analysis | Flu A/CAL/7/09, D21 | 103 Participants |
| Arepanrix/F2 Group | Number of Seropositive Subjects for HI Antibodies - Second Analysis | Flu A/CAL/7/09, PRE | 27 Participants |
| GSK2340273A/F1 Group | Number of Seropositive Subjects for HI Antibodies - Second Analysis | Flu A/CAL/7/09, PRE | 13 Participants |
| GSK2340273A/F1 Group | Number of Seropositive Subjects for HI Antibodies - Second Analysis | Flu A/CAL/7/09, D21 | 53 Participants |
| GSK2340273A/F2 Group | Number of Seropositive Subjects for HI Antibodies - Second Analysis | Flu A/CAL/7/09, PRE | 14 Participants |
| GSK2340273A/F2 Group | Number of Seropositive Subjects for HI Antibodies - Second Analysis | Flu A/CAL/7/09, D21 | 54 Participants |
Secondary
Number of Seropositive Subjects for HI Antibodies - Second Analysis
A seropositive subject was defined as a subject with antibody titers greater than or equal to (≥) 1:10. The vaccine strain assessed was Flu A/CAL/7/09.
Time frame: At Day 0 (PRE) and at Day 42
Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 42, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Arepanrix/F1 Group | Number of Seropositive Subjects for HI Antibodies - Second Analysis | Flu A/CAL/7/09, PRE | 10 Participants |
| Arepanrix/F1 Group | Number of Seropositive Subjects for HI Antibodies - Second Analysis | Flu A/CAL/7/09, D42 | 44 Participants |
| Arepanrix/F2 Group | Number of Seropositive Subjects for HI Antibodies - Second Analysis | Flu A/CAL/7/09, D42 | 87 Participants |
| Arepanrix/F2 Group | Number of Seropositive Subjects for HI Antibodies - Second Analysis | Flu A/CAL/7/09, PRE | 23 Participants |
| GSK2340273A/F1 Group | Number of Seropositive Subjects for HI Antibodies - Second Analysis | Flu A/CAL/7/09, PRE | 10 Participants |
| GSK2340273A/F1 Group | Number of Seropositive Subjects for HI Antibodies - Second Analysis | Flu A/CAL/7/09, D42 | 46 Participants |
| GSK2340273A/F2 Group | Number of Seropositive Subjects for HI Antibodies - Second Analysis | Flu A/CAL/7/09, PRE | 9 Participants |
| GSK2340273A/F2 Group | Number of Seropositive Subjects for HI Antibodies - Second Analysis | Flu A/CAL/7/09, D42 | 44 Participants |
Secondary
Number of Seropositive Subjects for Neutralizing Antibodies Against Flu A/Neth/602/09 Influenza Strain
A seropositive subject was defined as a subject with antibody titers greater than or equal to (≥) 1:8. The vaccine strain assessed was Flu A/Neth/602/09 H1N1.
Time frame: At Day 0 (PRE) and at Day 21
Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 21, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Arepanrix/F1 Group | Number of Seropositive Subjects for Neutralizing Antibodies Against Flu A/Neth/602/09 Influenza Strain | Flu A/Neth/602/09, PRE | 25 Participants |
| Arepanrix/F1 Group | Number of Seropositive Subjects for Neutralizing Antibodies Against Flu A/Neth/602/09 Influenza Strain | Flu A/Neth/602/09, D21 | 51 Participants |
| Arepanrix/F2 Group | Number of Seropositive Subjects for Neutralizing Antibodies Against Flu A/Neth/602/09 Influenza Strain | Flu A/Neth/602/09, D21 | 82 Participants |
| Arepanrix/F2 Group | Number of Seropositive Subjects for Neutralizing Antibodies Against Flu A/Neth/602/09 Influenza Strain | Flu A/Neth/602/09, PRE | 30 Participants |
| GSK2340273A/F1 Group | Number of Seropositive Subjects for Neutralizing Antibodies Against Flu A/Neth/602/09 Influenza Strain | Flu A/Neth/602/09, PRE | 17 Participants |
| GSK2340273A/F1 Group | Number of Seropositive Subjects for Neutralizing Antibodies Against Flu A/Neth/602/09 Influenza Strain | Flu A/Neth/602/09, D21 | 39 Participants |
| GSK2340273A/F2 Group | Number of Seropositive Subjects for Neutralizing Antibodies Against Flu A/Neth/602/09 Influenza Strain | Flu A/Neth/602/09, PRE | 20 Participants |
| GSK2340273A/F2 Group | Number of Seropositive Subjects for Neutralizing Antibodies Against Flu A/Neth/602/09 Influenza Strain | Flu A/Neth/602/09, D21 | 35 Participants |
Secondary
Number of Seropositive Subjects for Neutralizing Antibodies Against Flu A/Neth/602/09 Influenza Strain
A seropositive subject was defined as a subject with antibody titers greater than or equal to (≥) 1:8. The vaccine strain assessed was Flu A/Neth/602/09 H1N1.
Time frame: At Day 0 (PRE) and at Day 42
Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 42, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Arepanrix/F1 Group | Number of Seropositive Subjects for Neutralizing Antibodies Against Flu A/Neth/602/09 Influenza Strain | Flu A/Neth/602/09, PRE | 18 Participants |
| Arepanrix/F1 Group | Number of Seropositive Subjects for Neutralizing Antibodies Against Flu A/Neth/602/09 Influenza Strain | Flu A/Neth/602/09, D42 | 34 Participants |
| Arepanrix/F2 Group | Number of Seropositive Subjects for Neutralizing Antibodies Against Flu A/Neth/602/09 Influenza Strain | Flu A/Neth/602/09, D42 | 63 Participants |
| Arepanrix/F2 Group | Number of Seropositive Subjects for Neutralizing Antibodies Against Flu A/Neth/602/09 Influenza Strain | Flu A/Neth/602/09, PRE | 26 Participants |
| GSK2340273A/F1 Group | Number of Seropositive Subjects for Neutralizing Antibodies Against Flu A/Neth/602/09 Influenza Strain | Flu A/Neth/602/09, PRE | 13 Participants |
| GSK2340273A/F1 Group | Number of Seropositive Subjects for Neutralizing Antibodies Against Flu A/Neth/602/09 Influenza Strain | Flu A/Neth/602/09, D42 | 35 Participants |
| GSK2340273A/F2 Group | Number of Seropositive Subjects for Neutralizing Antibodies Against Flu A/Neth/602/09 Influenza Strain | Flu A/Neth/602/09, PRE | 13 Participants |
| GSK2340273A/F2 Group | Number of Seropositive Subjects for Neutralizing Antibodies Against Flu A/Neth/602/09 Influenza Strain | Flu A/Neth/602/09, D42 | 33 Participants |
Secondary
Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain
A seroprotected subject was defined as a vaccinated subject with reciprocal HI titers higher than or equal to (≥) 40 against the tested virus.
Time frame: At Day 0 (PRE) and at Day 182
Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 182, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Arepanrix/F1 Group | Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain | Flu A/CAL/7/09, D182 | 53 Participants |
| Arepanrix/F1 Group | Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain | Flu A/CAL/7/09, PRE | 10 Participants |
| Arepanrix/F2 Group | Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain | Flu A/CAL/7/09, D182 | 84 Participants |
| Arepanrix/F2 Group | Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain | Flu A/CAL/7/09, PRE | 16 Participants |
| GSK2340273A/F1 Group | Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain | Flu A/CAL/7/09, D182 | 43 Participants |
| GSK2340273A/F1 Group | Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain | Flu A/CAL/7/09, PRE | 12 Participants |
| GSK2340273A/F2 Group | Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain | Flu A/CAL/7/09, PRE | 12 Participants |
| GSK2340273A/F2 Group | Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain | Flu A/CAL/7/09, D182 | 43 Participants |
Secondary
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis
Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, joint pain at other location, muscle aches, shivering, sweating and temperature \[defined as axillary temperature equal to or above (≥) 38 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever ≥ 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.
Time frame: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses
Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Muscle aches, Dose 2 | 7 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Headache, Across doses | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Headache, Dose 1 | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Headache, Dose 1 | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Fatigue, Dose 2 | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Gastrointestinal symptoms, Dose 1 | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Headache, Dose 1 | 4 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Shivering, Dose 2 | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Fatigue, Dose 1 | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Gastrointestinal symptoms, Dose 1 | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Temperature (Axillary), Across doses | 7 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Shivering, Dose 2 | 4 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Headache, Across doses | 9 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Temperature (Axillary), Across doses | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Temperature (Axillary), Across doses | 9 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Sweating, Dose 2 | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Gastrointestinal symptoms, Across doses | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Sweating, Across doses | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Sweating, Across doses | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Sweating, Dose 2 | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Fatigue, Dose 2 | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Sweating, Across doses | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Shivering, Across doses | 4 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Shivering, Across doses | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Muscle aches, Across doses | 8 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Gastrointestinal symptoms, Across doses | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Gastrointestinal symptoms, Across doses | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Gastrointestinal symptoms, Dose 2 | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Muscle aches, Across doses | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Fatigue, Across doses | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Fatigue, Across doses | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Gastrointestinal symptoms, Dose 2 | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Fatigue, Dose 1 | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Fatigue, Across doses | 6 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Temperature (Axillary), Dose 2 | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Gastrointestinal symptoms, Dose 2 | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Shivering, Across doses | 4 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Temperature (Axillary), Dose 2 | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Temperature (Axillary), Dose 2 | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Headache, Dose 2 | 8 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Muscle aches, Across doses | 8 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Sweating, Dose 2 | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Temperature (Axillary), Dose 1 | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Headache, Dose 2 | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Joint pain at other location, Across doses | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Temperature (Axillary), Dose 1 | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Temperature (Axillary), Dose 1 | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Headache, Dose 2 | 8 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Gastrointestinal symptoms, Dose 1 | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Sweating, Dose 1 | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Sweating, Dose 1 | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Joint pain at other location, Dose 2 | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Joint pain at other location, Across doses | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Sweating, Dose 1 | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Shivering, Dose 1 | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Joint pain at other location, Dose 2 | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Joint pain at other location, Across doses | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Shivering, Dose 1 | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Shivering, Dose 1 | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Joint pain at other location, Dose 2 | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Fatigue, Dose 2 | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Muscle aches, Dose 1 | 4 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Shivering, Dose 2 | 4 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Muscle aches, Dose 1 | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Muscle aches, Dose 2 | 7 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Fatigue, Dose 1 | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Muscle aches, Dose 1 | 4 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Joint pain at other location, Dose 1 | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Muscle aches, Dose 2 | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Headache, Across doses | 9 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Joint pain at other location, Dose 1 | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Joint pain at other location, Dose 1 | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Shivering, Across doses | 5 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Fatigue, Dose 1 | 8 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Fatigue, Dose 1 | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Fatigue, Dose 1 | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Fatigue, Dose 2 | 7 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Fatigue, Dose 2 | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Fatigue, Dose 2 | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Gastrointestinal symptoms, Dose 2 | 6 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Gastrointestinal symptoms, Dose 2 | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Gastrointestinal symptoms, Dose 2 | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Headache, Dose 2 | 7 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Headache, Dose 2 | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Headache, Dose 2 | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Joint pain at other location, Dose 2 | 6 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Joint pain at other location, Dose 2 | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Joint pain at other location, Dose 2 | 5 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Muscle aches, Dose 2 | 8 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Muscle aches, Dose 2 | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Muscle aches, Dose 2 | 6 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Shivering, Dose 2 | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Shivering, Dose 2 | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Shivering, Dose 2 | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Sweating, Dose 2 | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Sweating, Dose 2 | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Shivering, Across doses | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Shivering, Across doses | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Sweating, Across doses | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Sweating, Across doses | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Sweating, Across doses | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Temperature (Axillary), Across doses | 9 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Temperature (Axillary), Across doses | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Temperature (Axillary), Across doses | 6 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Gastrointestinal symptoms, Dose 1 | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Gastrointestinal symptoms, Dose 1 | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Gastrointestinal symptoms, Dose 1 | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Headache, Dose 1 | 9 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Headache, Dose 1 | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Headache, Dose 1 | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Joint pain at other location, Dose 1 | 5 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Joint pain at other location, Dose 1 | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Joint pain at other location, Dose 1 | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Muscle aches, Dose 1 | 7 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Muscle aches, Dose 1 | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Muscle aches, Dose 1 | 5 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Shivering, Dose 1 | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Shivering, Dose 1 | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Shivering, Dose 1 | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Sweating, Dose 1 | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Sweating, Dose 1 | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Sweating, Dose 1 | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Temperature (Axillary), Dose 1 | 6 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Temperature (Axillary), Dose 1 | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Temperature (Axillary), Dose 1 | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Sweating, Dose 2 | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Temperature (Axillary), Dose 2 | 6 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Temperature (Axillary), Dose 2 | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Temperature (Axillary), Dose 2 | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Fatigue, Across doses | 11 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Fatigue, Across doses | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Fatigue, Across doses | 6 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Gastrointestinal symptoms, Across doses | 8 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Gastrointestinal symptoms, Across doses | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Gastrointestinal symptoms, Across doses | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Headache, Across doses | 12 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Headache, Across doses | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Headache, Across doses | 6 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Joint pain at other location, Across doses | 10 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Joint pain at other location, Across doses | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Joint pain at other location, Across doses | 6 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Muscle aches, Across doses | 11 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Muscle aches, Across doses | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Muscle aches, Across doses | 8 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Headache, Across doses | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Muscle aches, Dose 2 | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Headache, Dose 1 | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Joint pain at other location, Dose 1 | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Muscle aches, Dose 2 | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Muscle aches, Across doses | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Joint pain at other location, Dose 1 | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Headache, Across doses | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Joint pain at other location, Dose 1 | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Muscle aches, Dose 2 | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Muscle aches, Dose 1 | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Fatigue, Dose 2 | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Muscle aches, Dose 1 | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Joint pain at other location, Dose 2 | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Muscle aches, Dose 1 | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Headache, Across doses | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Shivering, Dose 1 | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Joint pain at other location, Dose 2 | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Shivering, Dose 1 | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Shivering, Dose 1 | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Joint pain at other location, Dose 2 | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Fatigue, Dose 1 | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Sweating, Dose 1 | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Joint pain at other location, Across doses | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Sweating, Dose 1 | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Headache, Dose 2 | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Sweating, Dose 1 | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Temperature (Axillary), Dose 1 | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Temperature (Axillary), Dose 1 | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Headache, Dose 2 | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Fatigue, Dose 1 | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Temperature (Axillary), Dose 1 | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Joint pain at other location, Across doses | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Sweating, Dose 2 | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Headache, Dose 2 | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Sweating, Dose 2 | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Temperature (Axillary), Dose 2 | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Gastrointestinal symptoms, Dose 2 | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Muscle aches, Across doses | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Temperature (Axillary), Dose 2 | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Joint pain at other location, Across doses | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Temperature (Axillary), Dose 2 | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Gastrointestinal symptoms, Dose 2 | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Fatigue, Across doses | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Fatigue, Dose 1 | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Fatigue, Across doses | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Gastrointestinal symptoms, Dose 2 | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Fatigue, Across doses | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Muscle aches, Across doses | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Gastrointestinal symptoms, Across doses | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Shivering, Across doses | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Shivering, Across doses | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Shivering, Across doses | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Fatigue, Dose 2 | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Sweating, Across doses | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Sweating, Across doses | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Sweating, Dose 2 | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Gastrointestinal symptoms, Across doses | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Sweating, Across doses | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Temperature (Axillary), Across doses | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Shivering, Dose 2 | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Temperature (Axillary), Across doses | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Temperature (Axillary), Across doses | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Gastrointestinal symptoms, Across doses | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Gastrointestinal symptoms, Dose 1 | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Shivering, Dose 2 | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Gastrointestinal symptoms, Dose 1 | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Shivering, Dose 2 | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Fatigue, Dose 2 | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Gastrointestinal symptoms, Dose 1 | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Headache, Dose 1 | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Headache, Dose 1 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Muscle aches, Across doses | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Headache, Dose 1 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Temperature (Axillary), Dose 2 | 2 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Headache, Across doses | 5 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Fatigue, Dose 1 | 4 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Headache, Dose 1 | 2 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Muscle aches, Dose 2 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Fatigue, Dose 2 | 4 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Sweating, Across doses | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Joint pain at other location, Dose 1 | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Muscle aches, Dose 2 | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Temperature (Axillary), Dose 2 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Gastrointestinal symptoms, Dose 2 | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Joint pain at other location, Dose 1 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Muscle aches, Dose 2 | 2 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Gastrointestinal symptoms, Dose 1 | 2 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Headache, Dose 1 | 2 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Joint pain at other location, Dose 1 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Temperature (Axillary), Dose 2 | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Headache, Across doses | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Sweating, Across doses | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Muscle aches, Dose 1 | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Joint pain at other location, Dose 2 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Joint pain at other location, Across doses | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Shivering, Dose 2 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Muscle aches, Dose 1 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Fatigue, Across doses | 8 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Muscle aches, Across doses | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Gastrointestinal symptoms, Dose 2 | 5 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Muscle aches, Dose 1 | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Joint pain at other location, Dose 2 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Gastrointestinal symptoms, Across doses | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Gastrointestinal symptoms, Across doses | 4 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Shivering, Dose 1 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Fatigue, Across doses | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Joint pain at other location, Dose 2 | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Headache, Across doses | 4 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Temperature (Axillary), Across doses | 2 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Shivering, Dose 1 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Temperature (Axillary), Dose 1 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Muscle aches, Across doses | 2 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Shivering, Dose 1 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Gastrointestinal symptoms, Dose 1 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Fatigue, Across doses | 6 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Fatigue, Dose 2 | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Sweating, Dose 1 | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Headache, Dose 2 | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Fatigue, Dose 2 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Gastrointestinal symptoms, Dose 1 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Sweating, Dose 1 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Temperature (Axillary), Across doses | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Joint pain at other location, Across doses | 2 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Shivering, Across doses | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Sweating, Dose 1 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Headache, Dose 2 | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Shivering, Across doses | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Gastrointestinal symptoms, Across doses | 7 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Temperature (Axillary), Dose 1 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Shivering, Dose 2 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Shivering, Across doses | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Fatigue, Dose 1 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Temperature (Axillary), Dose 1 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Headache, Dose 2 | 4 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Shivering, Dose 2 | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Temperature (Axillary), Across doses | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Sweating, Dose 2 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Sweating, Across doses | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Grade 3 Joint pain at other location, Across doses | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Any Sweating, Dose 2 | 2 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Sweating, Dose 2 | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Gastrointestinal symptoms, Dose 2 | 4 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis | Related Fatigue, Dose 1 | 3 Participants |
Secondary
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis
Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, joint pain at other location, muscle aches, and shivering, sweating, temperature \[defined as axillary temperature equal to or above (≥) 38 degrees Celsius (° C)\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever ≥ 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.
Time frame: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses
Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Muscle aches, Dose 2 | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Shivering, Dose 1 | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Fatigue, Dose 1 | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Fatigue, Dose 1 | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Fatigue, Dose 1 | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Gastrointestinal symptoms, Dose 1 | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Gastrointestinal symptoms, Dose 1 | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Gastrointestinal symptoms, Dose 1 | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Headache, Dose 1 | 4 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Headache, Dose 1 | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Headache, Dose 1 | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Joint pain at other location, Dose 1 | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Joint pain at other location, Dose 1 | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Joint pain at other location, Dose 1 | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Muscle aches, Dose 1 | 4 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Muscle aches, Dose 1 | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Muscle aches, Dose 1 | 4 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Joint pain at other location, Dose 2 | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Muscle aches, Dose 2 | 7 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Muscle aches, Dose 2 | 7 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Shivering, Dose 2 | 4 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Shivering, Dose 2 | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Shivering, Dose 2 | 4 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Sweating, Dose 2 | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Sweating, Dose 2 | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Sweating, Dose 2 | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Temperature (Axillary), Dose 2 | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Temperature (Axillary), Dose 2 | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Temperature (Axillary), Dose 2 | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Fatigue, Across doses | 6 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Fatigue, Across doses | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Fatigue, Across doses | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Gastrointestinal symptoms, Across doses | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Gastrointestinal symptoms, Across doses | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Gastrointestinal symptoms, Across doses | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Headache, Across doses | 9 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Shivering, Dose 1 | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Shivering, Dose 1 | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Sweating, Dose 1 | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Sweating, Dose 1 | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Sweating, Dose 1 | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Temperature (Axillary), Dose 1 | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Temperature (Axillary), Dose 1 | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Temperature (Axillary), Dose 1 | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Fatigue, Dose 2 | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Fatigue, Dose 2 | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Fatigue, Dose 2 | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Gastrointestinal symptoms, Dose 2 | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Gastrointestinal symptoms, Dose 2 | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Gastrointestinal symptoms, Dose 2 | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Headache, Dose 2 | 8 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Headache, Dose 2 | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Headache, Dose 2 | 8 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Joint pain at other location, Dose 2 | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Joint pain at other location, Dose 2 | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Headache, Across doses | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Headache, Across doses | 9 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Joint pain at other location, Across doses | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Joint pain at other location, Across doses | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Joint pain at other location, Across doses | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Muscle aches, Across doses | 8 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Muscle aches, Across doses | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Muscle aches, Across doses | 8 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Shivering, Across doses | 4 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Shivering, Across doses | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Shivering, Across doses | 4 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Sweating, Across doses | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Sweating, Across doses | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Sweating, Across doses | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Temperature (Axillary), Across doses | 9 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Temperature (Axillary), Across doses | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Temperature (Axillary), Across doses | 7 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Gastrointestinal symptoms, Dose 1 | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Muscle aches, Dose 2 | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Muscle aches, Dose 2 | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Shivering, Dose 2 | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Joint pain at other location, Across doses | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Shivering, Dose 2 | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Shivering, Dose 2 | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Sweating, Dose 2 | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Temperature (Axillary), Across doses | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Sweating, Dose 2 | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Muscle aches, Across doses | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Sweating, Dose 2 | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Temperature (Axillary), Dose 2 | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Temperature (Axillary), Dose 2 | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Temperature (Axillary), Across doses | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Temperature (Axillary), Dose 2 | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Shivering, Dose 1 | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Muscle aches, Across doses | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Fatigue, Across doses | 5 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Fatigue, Across doses | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Fatigue, Across doses | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Gastrointestinal symptoms, Across doses | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Muscle aches, Across doses | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Gastrointestinal symptoms, Across doses | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Gastrointestinal symptoms, Across doses | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Shivering, Dose 1 | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Shivering, Across doses | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Shivering, Dose 1 | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Sweating, Dose 1 | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Sweating, Dose 1 | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Sweating, Dose 1 | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Shivering, Across doses | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Temperature (Axillary), Dose 1 | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Temperature (Axillary), Dose 1 | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Temperature (Axillary), Dose 1 | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Temperature (Axillary), Across doses | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Fatigue, Dose 2 | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Shivering, Across doses | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Fatigue, Dose 2 | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Fatigue, Dose 2 | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Gastrointestinal symptoms, Dose 2 | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Gastrointestinal symptoms, Dose 2 | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Sweating, Across doses | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Gastrointestinal symptoms, Dose 2 | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Headache, Dose 2 | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Headache, Dose 2 | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Headache, Dose 2 | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Sweating, Across doses | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Joint pain at other location, Dose 2 | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Headache, Across doses | 5 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Fatigue, Dose 1 | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Fatigue, Dose 1 | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Fatigue, Dose 1 | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Headache, Across doses | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Muscle aches, Dose 1 | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Gastrointestinal symptoms, Dose 1 | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Gastrointestinal symptoms, Dose 1 | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Headache, Dose 1 | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Headache, Across doses | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Headache, Dose 1 | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Headache, Dose 1 | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Joint pain at other location, Dose 1 | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Sweating, Across doses | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Joint pain at other location, Dose 1 | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Joint pain at other location, Across doses | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Joint pain at other location, Dose 1 | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Muscle aches, Dose 1 | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Muscle aches, Dose 1 | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Joint pain at other location, Dose 2 | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Joint pain at other location, Across doses | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Joint pain at other location, Dose 2 | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Muscle aches, Dose 2 | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Sweating, Across doses | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Shivering, Dose 1 | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Gastrointestinal symptoms, Dose 1 | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Shivering, Dose 1 | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Shivering, Across doses | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Sweating, Dose 1 | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Sweating, Dose 1 | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Temperature (Axillary), Across doses | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Headache, Dose 1 | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Sweating, Dose 1 | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Muscle aches, Dose 1 | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Temperature (Axillary), Dose 1 | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Shivering, Across doses | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Temperature (Axillary), Dose 1 | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Headache, Dose 1 | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Temperature (Axillary), Dose 1 | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Headache, Across doses | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Fatigue, Dose 2 | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Headache, Dose 1 | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Fatigue, Dose 2 | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Shivering, Across doses | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Fatigue, Dose 2 | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Gastrointestinal symptoms, Dose 2 | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Temperature (Axillary), Across doses | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Joint pain at other location, Across doses | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Gastrointestinal symptoms, Dose 2 | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Joint pain at other location, Dose 1 | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Gastrointestinal symptoms, Dose 2 | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Sweating, Across doses | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Joint pain at other location, Dose 2 | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Headache, Dose 2 | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Headache, Dose 2 | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Joint pain at other location, Dose 1 | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Headache, Dose 2 | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Joint pain at other location, Dose 2 | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Sweating, Across doses | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Muscle aches, Dose 1 | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Muscle aches, Dose 2 | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Muscle aches, Dose 2 | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Muscle aches, Dose 2 | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Shivering, Dose 2 | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Headache, Across doses | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Joint pain at other location, Dose 1 | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Shivering, Dose 2 | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Joint pain at other location, Across doses | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Fatigue, Dose 1 | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Shivering, Dose 2 | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Sweating, Dose 2 | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Sweating, Dose 2 | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Fatigue, Dose 1 | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Sweating, Dose 2 | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Muscle aches, Across doses | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Temperature (Axillary), Dose 2 | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Joint pain at other location, Across doses | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Temperature (Axillary), Dose 2 | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Fatigue, Dose 1 | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Temperature (Axillary), Dose 2 | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Joint pain at other location, Dose 2 | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Muscle aches, Dose 1 | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Gastrointestinal symptoms, Dose 1 | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Fatigue, Across doses | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Muscle aches, Across doses | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Fatigue, Across doses | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Headache, Across doses | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Fatigue, Across doses | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Temperature (Axillary), Across doses | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Gastrointestinal symptoms, Across doses | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Gastrointestinal symptoms, Dose 1 | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Gastrointestinal symptoms, Across doses | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Muscle aches, Across doses | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Gastrointestinal symptoms, Across doses | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Shivering, Dose 1 | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Temperature (Axillary), Dose 2 | 2 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Joint pain at other location, Across doses | 2 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Muscle aches, Across doses | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Shivering, Dose 1 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Muscle aches, Across doses | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Gastrointestinal symptoms, Dose 1 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Muscle aches, Dose 2 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Shivering, Dose 1 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Joint pain at other location, Across doses | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Temperature (Axillary), Across doses | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Muscle aches, Dose 1 | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Sweating, Dose 1 | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Shivering, Across doses | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Joint pain at other location, Dose 2 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Gastrointestinal symptoms, Across doses | 4 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Sweating, Dose 1 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Muscle aches, Dose 2 | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Sweating, Across doses | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Temperature (Axillary), Dose 2 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Sweating, Dose 1 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Headache, Dose 1 | 2 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Gastrointestinal symptoms, Across doses | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Shivering, Dose 2 | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Temperature (Axillary), Dose 1 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Fatigue, Dose 1 | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Muscle aches, Dose 1 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Fatigue, Across doses | 6 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Temperature (Axillary), Dose 1 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Shivering, Across doses | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Muscle aches, Across doses | 2 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Shivering, Dose 2 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Temperature (Axillary), Dose 1 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Headache, Dose 1 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Temperature (Axillary), Dose 2 | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Muscle aches, Dose 1 | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Fatigue, Dose 2 | 4 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Temperature (Axillary), Across doses | 2 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Headache, Across doses | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Shivering, Dose 2 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Fatigue, Dose 2 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Joint pain at other location, Across doses | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Headache, Dose 1 | 2 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Fatigue, Dose 1 | 4 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Fatigue, Dose 2 | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Shivering, Across doses | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Headache, Across doses | 4 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Gastrointestinal symptoms, Across doses | 7 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Gastrointestinal symptoms, Dose 2 | 5 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Sweating, Dose 2 | 2 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Headache, Across doses | 5 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Joint pain at other location, Dose 1 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Gastrointestinal symptoms, Dose 2 | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Fatigue, Across doses | 8 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Joint pain at other location, Dose 1 | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Sweating, Dose 2 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Gastrointestinal symptoms, Dose 2 | 4 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Shivering, Dose 1 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Fatigue, Dose 1 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Gastrointestinal symptoms, Dose 1 | 2 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Headache, Dose 2 | 4 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Sweating, Across doses | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Joint pain at other location, Dose 2 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Sweating, Dose 2 | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Headache, Dose 2 | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Temperature (Axillary), Across doses | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Gastrointestinal symptoms, Dose 1 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Sweating, Across doses | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Headache, Dose 2 | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Joint pain at other location, Dose 1 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Muscle aches, Dose 2 | 2 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Fatigue, Across doses | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Joint pain at other location, Dose 2 | 1 Participants |
Secondary
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis
Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, joint pain at other location, muscle aches, shivering, sweating, temperature \[defined as axillary temperature equal to or above (≥) 38 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever ≥ 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.
Time frame: During the 7-day (Days 0-6) post-vaccination period
Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Any Headache | 4 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Grade 3 Fatigue | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Related Fatigue | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Any Gastro-intestinal symptoms | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Grade 3 Gastro-intestinal symptoms | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Related Gastro-intestinal symptoms | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Any Fatigue | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Grade 3 Headache | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Related Headache | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Any Joint pain at other location | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Grade 3 Joint pain at other location | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Related Joint pain at other location | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Any Muscle aches | 4 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Grade 3 Muscle aches | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Related Muscle aches | 4 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Any Shivering | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Grade 3 Shivering | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Related Shivering | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Any Sweating | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Grade 3 Sweating | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Related Sweating | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Any Temperature (Axillary) | 4 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Grade 3 Temperature (Axillary) | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Related Temperature (Axillary) | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Related Temperature (Axillary) | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Any Muscle aches | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Any Gastro-intestinal symptoms | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Grade 3 Temperature (Axillary) | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Any Temperature (Axillary) | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Grade 3 Muscle aches | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Related Headache | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Grade 3 Shivering | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Related Gastro-intestinal symptoms | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Related Muscle aches | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Related Fatigue | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Any Shivering | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Related Sweating | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Any Joint pain at other location | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Grade 3 Sweating | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Grade 3 Fatigue | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Grade 3 Headache | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Grade 3 Joint pain at other location | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Any Headache | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Any Sweating | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Any Fatigue | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Related Joint pain at other location | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Grade 3 Gastro-intestinal symptoms | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Related Shivering | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Grade 3 Joint pain at other location | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Any Headache | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Grade 3 Headache | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Related Headache | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Any Joint pain at other location | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Related Sweating | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Grade 3 Sweating | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Related Joint pain at other location | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Any Muscle aches | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Grade 3 Muscle aches | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Any Temperature (Axillary) | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Related Muscle aches | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Any Shivering | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Related Temperature (Axillary) | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Grade 3 Shivering | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Related Shivering | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Grade 3 Temperature (Axillary) | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Any Fatigue | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Grade 3 Fatigue | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Any Sweating | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Related Fatigue | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Any Gastro-intestinal symptoms | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Grade 3 Gastro-intestinal symptoms | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Related Gastro-intestinal symptoms | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Grade 3 Temperature (Axillary) | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Related Sweating | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Grade 3 Headache | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Any Fatigue | 4 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Grade 3 Joint pain at other location | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Any Joint pain at other location | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Related Gastro-intestinal symptoms | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Grade 3 Fatigue | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Grade 3 Gastro-intestinal symptoms | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Related Headache | 2 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Grade 3 Sweating | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Related Fatigue | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Any Temperature (Axillary) | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Related Muscle aches | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Any Sweating | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Any Shivering | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Related Temperature (Axillary) | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Grade 3 Muscle aches | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Any Headache | 2 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Grade 3 Shivering | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Any Muscle aches | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Related Joint pain at other location | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Any Gastro-intestinal symptoms | 2 Participants |
| GSK2340273A/F2 Group | Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Related Shivering | 0 Participants |
Secondary
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis
Assessed solicited general symptoms were drowsiness, irritability, loss of appetite and temperature \[defined as axillary temperature equal to or above (≥) 38 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever ≥ 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.
Time frame: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses
Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Loss of appetite, Dose 2 | 15 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Temperature (Axillary), Across doses | 19 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Irritability, Dose 1 | 22 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Drowsiness, Dose 1 | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Temperature (Axillary), Dose 2 | 13 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Loss of appetite, Across doses | 17 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Drowsiness, Dose 1 | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Drowsiness, Dose 1 | 11 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Drowsiness, Across doses | 10 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Temperature (Axillary), Dose 2 | 11 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Loss of appetite, Across doses | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Drowsiness, Across doses | 6 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Drowsiness, Across doses | 17 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Drowsiness, Dose 2 | 9 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Irritability, Across doses | 6 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Loss of appetite, Across doses | 25 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Drowsiness, Dose 2 | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Irritability, Dose 2 | 19 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Irritability, Across doses | 28 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Drowsiness, Dose 2 | 13 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Temperature (Axillary), Dose 1 | 8 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Irritability, Dose 2 | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Temperature (Axillary), Across doses | 16 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Temperature (Axillary), Dose 1 | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Irritability, Dose 2 | 18 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Temperature (Axillary), Across doses | 6 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Temperature (Axillary), Dose 1 | 9 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Loss of appetite, Dose 1 | 9 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Loss of appetite, Dose 2 | 18 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Irritability, Across doses | 25 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Loss of appetite, Dose 1 | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Loss of appetite, Dose 1 | 16 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Loss of appetite, Dose 2 | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Temperature (Axillary), Dose 2 | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Irritability, Dose 1 | 19 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Irritability, Dose 1 | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Temperature (Axillary), Across doses | 8 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Irritability, Across doses | 22 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Irritability, Across doses | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Irritability, Across doses | 20 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Drowsiness, Dose 2 | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Irritability, Dose 2 | 12 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Irritability, Dose 2 | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Irritability, Dose 2 | 11 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Loss of appetite, Dose 2 | 10 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Loss of appetite, Dose 2 | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Loss of appetite, Dose 2 | 8 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Temperature (Axillary), Dose 2 | 7 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Temperature (Axillary), Dose 2 | 6 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Drowsiness, Across doses | 15 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Drowsiness, Across doses | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Drowsiness, Across doses | 9 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Drowsiness, Dose 1 | 11 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Drowsiness, Dose 1 | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Drowsiness, Dose 1 | 8 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Irritability, Dose 1 | 18 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Irritability, Dose 1 | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Irritability, Dose 1 | 15 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Loss of appetite, Dose 1 | 17 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Loss of appetite, Dose 1 | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Loss of appetite, Dose 1 | 12 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Temperature (Axillary), Dose 1 | 6 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Temperature (Axillary), Dose 1 | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Temperature (Axillary), Dose 1 | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Drowsiness, Dose 2 | 6 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Drowsiness, Dose 2 | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Loss of appetite, Across doses | 23 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Loss of appetite, Across doses | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Loss of appetite, Across doses | 17 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Temperature (Axillary), Across doses | 11 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Temperature (Axillary), Across doses | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Temperature (Axillary), Dose 2 | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Loss of appetite, Dose 2 | 5 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Irritability, Dose 2 | 13 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Irritability, Across doses | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Drowsiness, Dose 2 | 7 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Loss of appetite, Dose 1 | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Loss of appetite, Dose 2 | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Temperature (Axillary), Across doses | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Irritability, Across doses | 21 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Drowsiness, Dose 2 | 5 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Irritability, Dose 1 | 12 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Loss of appetite, Across doses | 11 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Loss of appetite, Dose 1 | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Irritability, Dose 1 | 15 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Irritability, Dose 2 | 12 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Irritability, Dose 2 | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Drowsiness, Across doses | 13 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Temperature (Axillary), Dose 2 | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Temperature (Axillary), Dose 2 | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Loss of appetite, Across doses | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Drowsiness, Across doses | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Temperature (Axillary), Dose 1 | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Temperature (Axillary), Across doses | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Irritability, Across doses | 17 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Drowsiness, Across doses | 9 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Temperature (Axillary), Across doses | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Temperature (Axillary), Dose 1 | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Drowsiness, Dose 2 | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Drowsiness, Dose 1 | 8 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Loss of appetite, Dose 1 | 6 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Temperature (Axillary), Dose 2 | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Irritability, Dose 1 | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Drowsiness, Dose 1 | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Loss of appetite, Dose 2 | 7 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Temperature (Axillary), Dose 1 | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Loss of appetite, Across doses | 7 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Drowsiness, Dose 1 | 5 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Temperature (Axillary), Across doses | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Loss of appetite, Across doses | 10 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Irritability, Dose 1 | 8 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Loss of appetite, Dose 2 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Irritability, Dose 1 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Irritability, Dose 1 | 8 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Loss of appetite, Dose 2 | 5 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Loss of appetite, Dose 1 | 9 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Temperature (Axillary), Across doses | 4 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Loss of appetite, Dose 1 | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Irritability, Dose 2 | 11 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Irritability, Across doses | 2 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Loss of appetite, Dose 1 | 8 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Temperature (Axillary), Dose 1 | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Irritability, Dose 2 | 2 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Temperature (Axillary), Dose 1 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Irritability, Dose 2 | 11 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Temperature (Axillary), Across doses | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Temperature (Axillary), Dose 1 | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Drowsiness, Dose 2 | 7 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Drowsiness, Dose 2 | 7 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Irritability, Across doses | 17 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Drowsiness, Dose 1 | 7 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Loss of appetite, Across doses | 11 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Drowsiness, Dose 2 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Temperature (Axillary), Dose 2 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Drowsiness, Across doses | 14 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Drowsiness, Across doses | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Temperature (Axillary), Dose 2 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Loss of appetite, Across doses | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Drowsiness, Across doses | 12 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Temperature (Axillary), Dose 2 | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Drowsiness, Dose 1 | 9 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Any Irritability, Across doses | 17 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Grade 3 Drowsiness, Dose 1 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis | Related Loss of appetite, Dose 2 | 5 Participants |
Secondary
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis
Assessed solicited general symptoms were drowsiness, irritability, loss of appetite and temperature \[defined as axillary temperature equal to or above (≥) 38 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade or relationship to vaccination. Grade 3 symptom = symptom that prevented normal activity. Grade 3 loss of appetite= not eating at all. Grade 3 fever = fever ≥ 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.
Time frame: During the 7-day (Days 0-6) post-vaccination period
Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Any Temperature (Axillary) | 8 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Related Temperature (Axillary) | 6 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Grade 3 Loss of appetite | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Any Drowsiness | 11 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Related Loss of appetite | 9 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Related Drowsiness | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Any Irritability | 22 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Grade 3 Drowsiness | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Grade 3 Temperature (Axillary) | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Grade 3 Irritability | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Related Irritability | 19 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Any Loss of appetite | 16 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Grade 3 Drowsiness | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Any Loss of appetite | 17 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Any Irritability | 18 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Related Loss of appetite | 12 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Any Temperature (Axillary) | 6 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Grade 3 Loss of appetite | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Any Drowsiness | 11 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Related Irritability | 15 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Grade 3 Irritability | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Related Drowsiness | 8 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Related Temperature (Axillary) | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Grade 3 Temperature (Axillary) | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Grade 3 Loss of appetite | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Any Drowsiness | 8 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Grade 3 Drowsiness | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Related Drowsiness | 5 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Any Irritability | 14 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Grade 3 Irritability | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Related Irritability | 12 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Any Loss of appetite | 6 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Related Loss of appetite | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Any Temperature (Axillary) | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Grade 3 Temperature (Axillary) | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Related Temperature (Axillary) | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Related Irritability | 8 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Grade 3 Irritability | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Any Drowsiness | 9 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Any Temperature (Axillary) | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Any Irritability | 8 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Related Drowsiness | 7 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Related Temperature (Axillary) | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Grade 3 Temperature (Axillary) | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Grade 3 Loss of appetite | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Any Loss of appetite | 9 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Grade 3 Drowsiness | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis | Related Loss of appetite | 8 Participants |
Secondary
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis
Assessed solicited general symptoms were drowsiness, irritability, loss of appetite and temperature \[defined as axillary temperature equal to or above (≥) 38 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever ≥ 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.
Time frame: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses
Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Temperature (Axillary), Dose 1 | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Drowsiness, Dose 1 | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Irritability, Across doses | 19 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Drowsiness, Across doses | 4 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Loss of appetite, Dose 2 | 11 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Temperature (Axillary), Dose 2 | 4 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Temperature (Axillary), Across doses | 11 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Temperature (Axillary), Dose 1 | 4 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Loss of appetite, Dose 2 | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Loss of appetite, Dose 1 | 6 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Irritability, Across doses | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Temperature (Axillary), Across doses | 4 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Loss of appetite, Dose 2 | 11 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Temperature (Axillary), Dose 2 | 10 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Irritability, Dose 1 | 13 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Drowsiness, Dose 1 | 6 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Temperature (Axillary), Across doses | 13 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Temperature (Axillary), Dose 1 | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Irritability, Across doses | 18 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Drowsiness, Dose 2 | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Irritability, Dose 2 | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Drowsiness, Across doses | 7 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Drowsiness, Dose 2 | 7 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Loss of appetite, Dose 1 | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Drowsiness, Dose 2 | 8 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Irritability, Dose 2 | 13 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Loss of appetite, Across doses | 15 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Loss of appetite, Across doses | 12 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Drowsiness, Across doses | 10 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Temperature (Axillary), Dose 2 | 9 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Irritability, Dose 1 | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Drowsiness, Dose 1 | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Loss of appetite, Dose 1 | 9 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Irritability, Dose 1 | 14 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Loss of appetite, Across doses | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Irritability, Dose 2 | 13 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Loss of appetite, Across doses | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Drowsiness, Dose 1 | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Irritability, Dose 1 | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Loss of appetite, Dose 2 | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Irritability, Dose 1 | 6 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Loss of appetite, Across doses | 5 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Temperature (Axillary), Across doses | 5 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Drowsiness, Across doses | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Temperature (Axillary), Across doses | 6 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Drowsiness, Dose 1 | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Drowsiness, Across doses | 7 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Irritability, Dose 1 | 8 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Temperature (Axillary), Across doses | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Drowsiness, Dose 2 | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Temperature (Axillary), Dose 1 | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Temperature (Axillary), Dose 1 | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Drowsiness, Dose 2 | 5 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Irritability, Dose 2 | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Temperature (Axillary), Dose 2 | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Irritability, Across doses | 9 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Temperature (Axillary), Dose 2 | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Loss of appetite, Dose 1 | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Irritability, Across doses | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Loss of appetite, Dose 2 | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Drowsiness, Dose 1 | 5 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Drowsiness, Dose 2 | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Irritability, Dose 2 | 6 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Loss of appetite, Dose 1 | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Irritability, Across doses | 7 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Loss of appetite, Dose 2 | 7 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Temperature (Axillary), Dose 1 | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Drowsiness, Across doses | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Loss of appetite, Across doses | 10 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Irritability, Dose 2 | 5 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Loss of appetite, Dose 1 | 7 Participants |
| Arepanrix/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Temperature (Axillary), Dose 2 | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Loss of appetite, Across doses | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Irritability, Dose 2 | 23 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Loss of appetite, Dose 2 | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Irritability, Dose 2 | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Temperature (Axillary), Dose 1 | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Loss of appetite, Dose 2 | 13 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Irritability, Dose 2 | 19 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Drowsiness, Dose 1 | 13 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Temperature (Axillary), Dose 1 | 6 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Drowsiness, Dose 2 | 9 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Irritability, Across doses | 30 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Loss of appetite, Dose 1 | 12 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Irritability, Across doses | 7 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Temperature (Axillary), Dose 1 | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Loss of appetite, Dose 1 | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Irritability, Across doses | 23 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Loss of appetite, Dose 1 | 19 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Loss of appetite, Across doses | 26 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Irritability, Dose 1 | 15 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Loss of appetite, Across doses | 19 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Irritability, Dose 1 | 6 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Drowsiness, Across doses | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Temperature (Axillary), Across doses | 10 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Drowsiness, Across doses | 23 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Temperature (Axillary), Across doses | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Temperature (Axillary), Across doses | 6 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Temperature (Axillary), Dose 2 | 5 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Drowsiness, Across doses | 16 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Drowsiness, Dose 1 | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Drowsiness, Dose 1 | 20 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Temperature (Axillary), Dose 2 | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Temperature (Axillary), Dose 2 | 6 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Drowsiness, Dose 2 | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Irritability, Dose 1 | 22 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Loss of appetite, Dose 2 | 10 Participants |
| GSK2340273A/F1 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Drowsiness, Dose 2 | 5 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Irritability, Dose 1 | 8 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Loss of appetite, Across doses | 19 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Loss of appetite, Dose 1 | 12 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Irritability, Across doses | 14 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Irritability, Dose 2 | 10 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Drowsiness, Across doses | 7 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Irritability, Dose 2 | 8 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Temperature (Axillary), Dose 2 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Loss of appetite, Dose 1 | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Irritability, Across doses | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Loss of appetite, Dose 2 | 10 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Drowsiness, Dose 1 | 13 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Drowsiness, Dose 1 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Loss of appetite, Dose 2 | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Temperature (Axillary), Dose 1 | 2 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Irritability, Across doses | 20 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Loss of appetite, Dose 1 | 5 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Temperature (Axillary), Dose 2 | 8 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Drowsiness, Dose 2 | 5 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Drowsiness, Dose 2 | 9 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Temperature (Axillary), Dose 1 | 9 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Irritability, Dose 1 | 14 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Irritability, Dose 2 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Drowsiness, Dose 2 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Temperature (Axillary), Dose 1 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Temperature (Axillary), Across doses | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Drowsiness, Across doses | 19 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Irritability, Dose 1 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Temperature (Axillary), Across doses | 14 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Temperature (Axillary), Dose 2 | 5 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Drowsiness, Across doses | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Loss of appetite, Across doses | 10 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Drowsiness, Dose 1 | 4 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Temperature (Axillary), Across doses | 6 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Loss of appetite, Across doses | 2 Participants |
| GSK2340273A/F2 Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Loss of appetite, Dose 2 | 7 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Temperature (Axillary), Dose 1 | 0 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Irritability, Dose 1 | 9 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Irritability, Dose 1 | 1 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Drowsiness, Dose 1 | 0 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Drowsiness, Dose 1 | 3 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Drowsiness, Dose 2 | 5 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Irritability, Across doses | 14 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Irritability, Across doses | 2 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Irritability, Across doses | 12 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Loss of appetite, Across doses | 7 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Loss of appetite, Across doses | 0 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Loss of appetite, Across doses | 5 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Temperature (Axillary), Across doses | 2 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Temperature (Axillary), Across doses | 0 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Temperature (Axillary), Across doses | 1 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Drowsiness, Across doses | 6 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Drowsiness, Dose 1 | 4 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Drowsiness, Dose 2 | 0 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Drowsiness, Dose 2 | 4 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Irritability, Dose 2 | 10 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Irritability, Dose 2 | 1 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Irritability, Dose 2 | 9 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Loss of appetite, Dose 2 | 7 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Loss of appetite, Dose 2 | 0 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Loss of appetite, Dose 2 | 5 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Temperature (Axillary), Dose 2 | 2 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Temperature (Axillary), Dose 2 | 0 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Temperature (Axillary), Dose 2 | 1 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Drowsiness, Across doses | 7 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Drowsiness, Across doses | 0 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Irritability, Dose 1 | 8 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Loss of appetite, Dose 1 | 2 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Loss of appetite, Dose 1 | 0 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Loss of appetite, Dose 1 | 1 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Temperature (Axillary), Dose 1 | 0 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Temperature (Axillary), Dose 1 | 0 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Drowsiness, Dose 2 | 0 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Temperature (Axillary), Across doses | 0 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Loss of appetite, Dose 1 | 4 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Irritability, Dose 2 | 3 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Temperature (Axillary), Dose 1 | 0 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Drowsiness, Across doses | 6 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Drowsiness, Dose 2 | 1 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Drowsiness, Dose 1 | 0 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Temperature (Axillary), Across doses | 2 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Loss of appetite, Across doses | 4 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Drowsiness, Dose 2 | 2 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Loss of appetite, Across doses | 2 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Temperature (Axillary), Dose 1 | 2 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Drowsiness, Across doses | 0 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Temperature (Axillary), Dose 2 | 1 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Irritability, Dose 1 | 4 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Irritability, Dose 1 | 0 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Loss of appetite, Dose 2 | 0 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Loss of appetite, Across doses | 0 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Irritability, Dose 1 | 6 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Temperature (Axillary), Dose 1 | 1 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Irritability, Dose 2 | 3 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Drowsiness, Dose 1 | 4 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Drowsiness, Across doses | 3 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Drowsiness, Dose 1 | 2 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Temperature (Axillary), Dose 2 | 0 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Loss of appetite, Dose 2 | 0 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Loss of appetite, Dose 1 | 2 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Irritability, Across doses | 7 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Loss of appetite, Dose 2 | 0 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Temperature (Axillary), Across doses | 1 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Loss of appetite, Dose 1 | 0 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Irritability, Across doses | 1 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Temperature (Axillary), Dose 2 | 1 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Irritability, Dose 2 | 1 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Irritability, Across doses | 5 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Irritability, Dose 2 | 6 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Loss of appetite, Dose 2 | 0 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Drowsiness, Dose 2 | 5 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Drowsiness, Dose 2 | 0 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Loss of appetite, Dose 2 | 4 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Drowsiness, Dose 2 | 5 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Temperature (Axillary), Dose 2 | 1 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Drowsiness, Dose 1 | 6 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Drowsiness, Dose 1 | 0 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Temperature (Axillary), Dose 2 | 0 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Temperature (Axillary), Across doses | 0 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Temperature (Axillary), Dose 2 | 0 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Temperature (Axillary), Across doses | 0 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Temperature (Axillary), Across doses | 1 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Drowsiness, Across doses | 9 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Loss of appetite, Across doses | 8 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Temperature (Axillary), Dose 1 | 0 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Drowsiness, Across doses | 0 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Irritability, Dose 1 | 0 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Loss of appetite, Across doses | 1 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Irritability, Dose 1 | 8 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Loss of appetite, Across doses | 9 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Irritability, Across doses | 12 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Loss of appetite, Dose 1 | 8 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Irritability, Across doses | 1 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Loss of appetite, Dose 1 | 1 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Irritability, Across doses | 12 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Irritability, Dose 1 | 8 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Loss of appetite, Dose 1 | 7 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Drowsiness, Across doses | 8 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Temperature (Axillary), Dose 1 | 0 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Temperature (Axillary), Dose 1 | 0 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Drowsiness, Dose 1 | 5 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Irritability, Dose 2 | 1 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Loss of appetite, Dose 2 | 4 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Irritability, Dose 2 | 6 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Irritability, Across doses | 1 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Drowsiness, Dose 2 | 2 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Drowsiness, Dose 1 | 2 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Irritability, Dose 1 | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Temperature (Axillary), Across doses | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Irritability, Dose 2 | 1 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Loss of appetite, Dose 1 | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Irritability, Across doses | 5 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Drowsiness, Dose 2 | 2 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Temperature (Axillary), Across doses | 1 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Drowsiness, Across doses | 4 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Loss of appetite, Dose 2 | 1 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Temperature (Axillary), Dose 2 | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Temperature (Axillary), Dose 1 | 1 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Loss of appetite, Dose 1 | 1 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Drowsiness, Dose 2 | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Temperature (Axillary), Dose 1 | 1 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Loss of appetite, Dose 2 | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Drowsiness, Dose 1 | 3 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Loss of appetite, Across doses | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Temperature (Axillary), Dose 2 | 2 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Irritability, Dose 1 | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Loss of appetite, Across doses | 2 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Temperature (Axillary), Dose 1 | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Drowsiness, Across doses | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Grade 3 Drowsiness, Dose 1 | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Irritability, Dose 1 | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Loss of appetite, Dose 2 | 1 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Loss of appetite, Across doses | 2 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Irritability, Across doses | 5 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Irritability, Dose 2 | 5 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Drowsiness, Across doses | 5 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Temperature (Axillary), Across doses | 3 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Irritability, Dose 2 | 5 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Any Loss of appetite, Dose 1 | 1 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis | Related Temperature (Axillary), Dose 2 | 0 Participants |
Secondary
Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs)
Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.
Time frame: Within 182 days (Days 0-181) post vaccination
Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arepanrix/F1 Group | Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs) | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs) | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs) | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs) | 0 Participants |
Secondary
Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs)
Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.
Time frame: Throughout the entire study period (Day 0 - Day 385)
Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arepanrix/F1 Group | Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs) | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs) | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs) | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs) | 0 Participants |
Secondary
Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs) - First Analysis
Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.
Time frame: Within 42 days (Days 0-41) post vaccination
Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arepanrix/F1 Group | Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs) - First Analysis | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs) - First Analysis | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs) - First Analysis | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs) - First Analysis | 0 Participants |
Secondary
Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs) - Preliminary Analysis
Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.
Time frame: Within 21 days (Days 0-20) post vaccination
Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arepanrix/F1 Group | Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs) - Preliminary Analysis | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs) - Preliminary Analysis | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs) - Preliminary Analysis | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs) - Preliminary Analysis | 0 Participants |
Secondary
Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs) - Second Analysis
Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.
Time frame: Within 42 days (Days 0-41) post vaccination
Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arepanrix/F1 Group | Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs) - Second Analysis | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs) - Second Analysis | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs) - Second Analysis | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs) - Second Analysis | 0 Participants |
Secondary
Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.
Time frame: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses
Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Arepanrix/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Swelling, Dose 1 | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Pain, Dose 2 | 22 Participants |
| Arepanrix/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Swelling, Dose 1 | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Swelling, Across doses | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Pain, Across doses | 7 Participants |
| Arepanrix/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Pain, Dose 1 | 4 Participants |
| Arepanrix/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Pain, Across doses | 35 Participants |
| Arepanrix/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Swelling, Dose 2 | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Swelling, Dose 2 | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Redness, Dose 1 | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Redness, Dose 2 | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Redness, Across doses | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Redness, Across doses | 7 Participants |
| Arepanrix/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Redness, Dose 1 | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Swelling, Across doses | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Redness, Dose 2 | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Pain, Dose 2 | 4 Participants |
| Arepanrix/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Pain, Dose 1 | 27 Participants |
| Arepanrix/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Redness, Dose 2 | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Pain, Dose 2 | 13 Participants |
| Arepanrix/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Redness, Dose 1 | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Swelling, Dose 1 | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Swelling, Across doses | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Swelling, Across doses | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Redness, Dose 2 | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Pain, Across doses | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Swelling, Dose 1 | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Redness, Across doses | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Pain, Dose 1 | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Pain, Dose 1 | 14 Participants |
| Arepanrix/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Pain, Across doses | 15 Participants |
| Arepanrix/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Redness, Dose 1 | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Swelling, Dose 2 | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Redness, Across doses | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Swelling, Dose 2 | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Pain, Dose 2 | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Swelling, Dose 1 | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Pain, Dose 1 | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Pain, Dose 1 | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Redness, Dose 1 | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Redness, Dose 1 | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Swelling, Dose 1 | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Pain, Dose 2 | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Pain, Dose 2 | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Redness, Dose 2 | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Redness, Across doses | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Redness, Across doses | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Redness, Dose 2 | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Swelling, Dose 2 | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Swelling, Dose 2 | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Pain, Across doses | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Pain, Across doses | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Swelling, Across doses | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Swelling, Across doses | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Redness, Dose 1 | 4 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Redness, Dose 1 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Pain, Dose 1 | 26 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Redness, Dose 2 | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Pain, Across doses | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Redness, Across doses | 6 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Swelling, Dose 2 | 2 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Swelling, Across doses | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Swelling, Dose 2 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Redness, Dose 2 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Redness, Across doses | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Pain, Dose 2 | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Pain, Across doses | 33 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Pain, Dose 1 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Swelling, Across doses | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Swelling, Dose 1 | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Swelling, Dose 1 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Pain, Dose 2 | 25 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Pain, Across doses | 9 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Pain, Dose 1 | 9 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Swelling, Dose 2 | 0 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Pain, Dose 1 | 0 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Pain, Dose 2 | 2 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Pain, Dose 2 | 7 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Redness, Dose 1 | 0 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Redness, Dose 2 | 0 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Swelling, Across doses | 1 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Swelling, Dose 2 | 0 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Redness, Across doses | 2 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Swelling, Dose 1 | 1 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Redness, Across doses | 0 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Redness, Dose 1 | 2 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Swelling, Across doses | 0 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Redness, Dose 2 | 0 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Swelling, Dose 1 | 0 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Pain, Across doses | 2 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Swelling, Dose 1 | 0 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Redness, Dose 1 | 1 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Pain, Dose 2 | 0 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Pain, Dose 2 | 11 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Swelling, Dose 2 | 0 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Redness, Dose 2 | 0 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Pain, Across doses | 1 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Pain, Across doses | 22 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Pain, Dose 1 | 1 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Swelling, Across doses | 1 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Swelling, Dose 1 | 1 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Swelling, Across doses | 0 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Redness, Dose 2 | 0 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Redness, Dose 1 | 0 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Redness, Across doses | 1 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Swelling, Dose 2 | 0 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Pain, Dose 1 | 19 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Redness, Across doses | 0 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Swelling, Across doses | 0 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Pain, Dose 2 | 8 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Redness, Dose 1 | 0 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Pain, Dose 2 | 0 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Pain, Across doses | 1 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Redness, Across doses | 0 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Redness, Dose 1 | 0 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Redness, Dose 2 | 0 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Redness, Dose 2 | 0 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Swelling, Dose 2 | 0 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Pain, Dose 1 | 1 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Swelling, Across doses | 0 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Swelling, Dose 2 | 0 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Pain, Across doses | 12 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Redness, Across doses | 0 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Pain, Dose 1 | 12 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Swelling, Dose 1 | 0 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Swelling, Dose 1 | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Swelling, Dose 2 | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Swelling, Dose 1 | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Pain, Across doses | 18 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Pain, Dose 1 | 15 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Redness, Dose 2 | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Redness, Dose 2 | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Redness, Across doses | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Swelling, Dose 1 | 1 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Redness, Across doses | 1 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Redness, Dose 1 | 1 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Pain, Across doses | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Redness, Dose 1 | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Swelling, Across doses | 1 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Pain, Dose 2 | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Pain, Dose 2 | 9 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Swelling, Dose 2 | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Swelling, Across doses | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Pain, Dose 1 | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Swelling, Dose 2 | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Pain, Dose 1 | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Redness, Dose 1 | 1 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Pain, Across doses | 1 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Pain, Across doses | 12 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Pain, Dose 1 | 10 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Pain, Dose 2 | 7 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Swelling, Across doses | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Redness, Dose 2 | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Pain, Dose 2 | 1 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Redness, Dose 2 | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Swelling, Dose 2 | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Redness, Across doses | 1 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Swelling, Dose 1 | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Redness, Dose 1 | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Grade 3 Redness, Across doses | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Swelling, Dose 1 | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis | Any Swelling, Across doses | 0 Participants |
Secondary
Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Preliminary Analysis
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.
Time frame: During the 7-day (Days 0-6) post-vaccination period
Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Arepanrix/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Preliminary Analysis | Any Pain | 27 Participants |
| Arepanrix/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Preliminary Analysis | Grade 3 Redness | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Preliminary Analysis | Any Redness | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Preliminary Analysis | Grade 3 Swelling | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Preliminary Analysis | Grade 3 Pain | 4 Participants |
| Arepanrix/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Preliminary Analysis | Any Swelling | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Preliminary Analysis | Grade 3 Redness | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Preliminary Analysis | Grade 3 Pain | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Preliminary Analysis | Any Pain | 14 Participants |
| Arepanrix/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Preliminary Analysis | Any Redness | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Preliminary Analysis | Grade 3 Swelling | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Preliminary Analysis | Any Swelling | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Preliminary Analysis | Any Pain | 26 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Preliminary Analysis | Grade 3 Redness | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Preliminary Analysis | Grade 3 Pain | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Preliminary Analysis | Any Swelling | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Preliminary Analysis | Any Redness | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Preliminary Analysis | Grade 3 Swelling | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Preliminary Analysis | Any Redness | 2 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Preliminary Analysis | Grade 3 Pain | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Preliminary Analysis | Grade 3 Redness | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Preliminary Analysis | Any Swelling | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Preliminary Analysis | Grade 3 Swelling | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Preliminary Analysis | Any Pain | 9 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Preliminary Analysis | Any Redness | 1 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Preliminary Analysis | Any Pain | 18 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Preliminary Analysis | Grade 3 Pain | 0 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Preliminary Analysis | Grade 3 Redness | 0 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Preliminary Analysis | Any Swelling | 1 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Preliminary Analysis | Grade 3 Swelling | 0 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Preliminary Analysis | Grade 3 Swelling | 0 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Preliminary Analysis | Any Redness | 0 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Preliminary Analysis | Grade 3 Pain | 1 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Preliminary Analysis | Any Swelling | 0 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Preliminary Analysis | Any Pain | 12 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Preliminary Analysis | Grade 3 Redness | 0 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Preliminary Analysis | Any Pain | 15 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Preliminary Analysis | Grade 3 Swelling | 0 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Preliminary Analysis | Grade 3 Pain | 0 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Preliminary Analysis | Grade 3 Redness | 0 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Preliminary Analysis | Any Redness | 1 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Preliminary Analysis | Any Swelling | 1 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Preliminary Analysis | Grade 3 Redness | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Preliminary Analysis | Any Redness | 1 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Preliminary Analysis | Grade 3 Swelling | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Preliminary Analysis | Any Swelling | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Preliminary Analysis | Grade 3 Pain | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Preliminary Analysis | Any Pain | 10 Participants |
Secondary
Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.
Time frame: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses
Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Arepanrix/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Redness, Dose 1 | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Swelling, Dose 1 | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Swelling, Dose 1 | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Pain, Dose 1 | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Pain, Across Doses | 4 Participants |
| Arepanrix/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Pain, Across Doses | 16 Participants |
| Arepanrix/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Pain, Dose 1 | 12 Participants |
| Arepanrix/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Redness, Across Doses | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Swelling, Dose 2 | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Redness, Across Doses | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Swelling, Dose 2 | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Swelling, Across Doses | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Redness, Dose 2 | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Swelling, Across Doses | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Redness, Dose 2 | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Pain, Dose 2 | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Redness, Dose 1 | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Pain, Dose 2 | 12 Participants |
| Arepanrix/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Redness, Dose 2 | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Swelling, Across Doses | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Redness, Dose 1 | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Swelling, Across Doses | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Redness, Dose 2 | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Redness, Across Doses | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Swelling, Dose 1 | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Pain, Across Doses | 19 Participants |
| Arepanrix/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Swelling, Dose 1 | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Pain, Dose 1 | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Swelling, Dose 2 | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Pain, Across Doses | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Pain, Dose 2 | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Redness, Across Doses | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Redness, Dose 1 | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Pain, Dose 1 | 15 Participants |
| Arepanrix/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Swelling, Dose 2 | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Pain, Dose 2 | 10 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Redness, Dose 1 | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Swelling, Dose 2 | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Swelling, Across Doses | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Swelling, Dose 2 | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Swelling, Across Doses | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Pain, Across Doses | 15 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Pain, Dose 1 | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Pain, Dose 2 | 13 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Redness, Dose 1 | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Redness, Dose 2 | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Swelling, Dose 1 | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Pain, Dose 2 | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Redness, Across Doses | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Pain, Across Doses | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Redness, Dose 2 | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Swelling, Dose 1 | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Redness, Across Doses | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Pain, Dose 1 | 14 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Pain, Across Doses | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Pain, Dose 2 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Pain, Dose 1 | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Redness, Across Doses | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Swelling, Dose 2 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Redness, Dose 1 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Redness, Across Doses | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Swelling, Dose 2 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Swelling, Across Doses | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Pain, Across Doses | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Redness, Dose 2 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Swelling, Across Doses | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Redness, Dose 2 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Redness, Dose 1 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Pain, Dose 2 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Swelling, Dose 1 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Swelling, Dose 1 | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Pain, Dose 1 | 0 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Swelling, Dose 2 | 1 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Swelling, Dose 1 | 0 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Swelling, Dose 2 | 0 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Redness, Dose 2 | 1 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Redness, Across Doses | 0 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Swelling, Dose 1 | 3 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Pain, Dose 2 | 18 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Pain, Dose 1 | 1 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Redness, Across Doses | 5 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Pain, Dose 1 | 20 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Pain, Across Doses | 3 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Redness, Dose 1 | 4 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Pain, Across Doses | 25 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Redness, Dose 2 | 0 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Pain, Dose 2 | 3 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Swelling, Across Doses | 4 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Redness, Dose 1 | 0 Participants |
| GSK2340273A/F1 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Swelling, Across Doses | 0 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Swelling, Dose 2 | 3 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Swelling, Dose 1 | 0 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Redness, Dose 2 | 0 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Redness, Dose 1 | 0 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Pain, Dose 2 | 2 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Redness, Across Doses | 0 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Pain, Dose 1 | 34 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Redness, Dose 1 | 4 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Pain, Across Doses | 44 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Swelling, Across Doses | 0 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Redness, Across Doses | 5 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Pain, Across Doses | 5 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Swelling, Dose 1 | 2 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Pain, Dose 2 | 35 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Pain, Dose 1 | 3 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Redness, Dose 2 | 2 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Swelling, Across Doses | 4 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Swelling, Dose 2 | 0 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Swelling, Dose 2 | 0 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Pain, Across Doses | 22 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Pain, Across Doses | 5 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Redness, Across Doses | 2 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Redness, Across Doses | 0 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Swelling, Across Doses | 3 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Swelling, Across Doses | 0 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Redness, Dose 1 | 2 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Redness, Dose 1 | 0 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Swelling, Dose 1 | 1 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Swelling, Dose 1 | 0 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Pain, Dose 2 | 19 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Pain, Dose 2 | 3 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Redness, Dose 2 | 0 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Redness, Dose 2 | 0 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Swelling, Dose 2 | 2 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Pain, Dose 1 | 22 Participants |
| GSK2340273A/F2 6M-5Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Pain, Dose 1 | 2 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Swelling, Dose 1 | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Swelling, Across Doses | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Pain, Across Doses | 11 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Pain, Across Doses | 1 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Redness, Dose 1 | 1 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Pain, Dose 2 | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Redness, Across Doses | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Swelling, Dose 2 | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Pain, Dose 1 | 10 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Swelling, Dose 2 | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Redness, Dose 1 | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Pain, Dose 2 | 5 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Redness, Dose 2 | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Swelling, Across Doses | 1 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Swelling, Dose 1 | 1 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Redness, Across Doses | 1 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Redness, Dose 2 | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Pain, Dose 1 | 1 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Swelling, Dose 1 | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Redness, Across Doses | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Swelling, Dose 2 | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Pain, Across Doses | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Pain, Dose 2 | 6 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Redness, Dose 1 | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Pain, Across Doses | 11 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Pain, Dose 2 | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Swelling, Across Doses | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Redness, Dose 2 | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Redness, Dose 1 | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Swelling, Across Doses | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Pain, Dose 1 | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Redness, Dose 2 | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Pain, Dose 1 | 9 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Swelling, Dose 1 | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Redness, Across Doses | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Swelling, Dose 2 | 0 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Redness, Across Doses | 0 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Swelling, Dose 1 | 0 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Pain, Dose 2 | 8 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Redness, Dose 2 | 0 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Swelling, Across Doses | 0 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Redness, Across Doses | 0 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Pain, Across Doses | 1 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Pain, Dose 1 | 12 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Pain, Dose 1 | 1 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Redness, Dose 2 | 0 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Swelling, Dose 2 | 0 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Swelling, Dose 2 | 0 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Swelling, Dose 1 | 0 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Pain, Dose 2 | 0 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Redness, Dose 1 | 0 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Pain, Across Doses | 12 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Redness, Dose 1 | 0 Participants |
| GSK2340273A/F1 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Swelling, Across Doses | 0 Participants |
| GSK2340273A/F2 6M-35M Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Pain, Dose 1 | 0 Participants |
| GSK2340273A/F2 6M-35M Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Redness, Dose 1 | 0 Participants |
| GSK2340273A/F2 6M-35M Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Pain, Across Doses | 9 Participants |
| GSK2340273A/F2 6M-35M Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Pain, Dose 2 | 4 Participants |
| GSK2340273A/F2 6M-35M Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Redness, Dose 2 | 0 Participants |
| GSK2340273A/F2 6M-35M Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Redness, Across Doses | 0 Participants |
| GSK2340273A/F2 6M-35M Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Swelling, Dose 2 | 0 Participants |
| GSK2340273A/F2 6M-35M Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Redness, Dose 2 | 0 Participants |
| GSK2340273A/F2 6M-35M Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Redness, Dose 1 | 0 Participants |
| GSK2340273A/F2 6M-35M Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Pain, Dose 1 | 8 Participants |
| GSK2340273A/F2 6M-35M Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Swelling, Dose 1 | 0 Participants |
| GSK2340273A/F2 6M-35M Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Swelling, Across Doses | 0 Participants |
| GSK2340273A/F2 6M-35M Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Redness, Across Doses | 0 Participants |
| GSK2340273A/F2 6M-35M Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Swelling, Across Doses | 0 Participants |
| GSK2340273A/F2 6M-35M Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Swelling, Dose 1 | 0 Participants |
| GSK2340273A/F2 6M-35M Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Swelling, Dose 2 | 0 Participants |
| GSK2340273A/F2 6M-35M Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Pain, Dose 2 | 0 Participants |
| GSK2340273A/F2 6M-35M Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Pain, Across Doses | 0 Participants |
| GSK2340273A/F2 3Y-6Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Redness, Dose 1 | 0 Participants |
| GSK2340273A/F2 3Y-6Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Swelling, Dose 1 | 0 Participants |
| GSK2340273A/F2 3Y-6Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Redness, Dose 1 | 1 Participants |
| GSK2340273A/F2 3Y-6Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Pain, Dose 2 | 5 Participants |
| GSK2340273A/F2 3Y-6Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Pain, Dose 1 | 0 Participants |
| GSK2340273A/F2 3Y-6Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Pain, Dose 2 | 0 Participants |
| GSK2340273A/F2 3Y-6Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Swelling, Across Doses | 0 Participants |
| GSK2340273A/F2 3Y-6Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Redness, Dose 2 | 0 Participants |
| GSK2340273A/F2 3Y-6Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Swelling, Across Doses | 1 Participants |
| GSK2340273A/F2 3Y-6Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Redness, Dose 2 | 0 Participants |
| GSK2340273A/F2 3Y-6Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Redness, Across Doses | 0 Participants |
| GSK2340273A/F2 3Y-6Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Swelling, Dose 2 | 0 Participants |
| GSK2340273A/F2 3Y-6Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Redness, Across Doses | 1 Participants |
| GSK2340273A/F2 3Y-6Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Swelling, Dose 2 | 0 Participants |
| GSK2340273A/F2 3Y-6Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Pain, Across Doses | 0 Participants |
| GSK2340273A/F2 3Y-6Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Pain, Dose 1 | 7 Participants |
| GSK2340273A/F2 3Y-6Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Pain, Across Doses | 9 Participants |
| GSK2340273A/F2 3Y-6Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Swelling, Dose 1 | 1 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Redness, Across Doses | 1 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Redness, Dose 2 | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Redness, Across Doses | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Redness, Dose 2 | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Redness, Dose 1 | 1 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Pain, Dose 1 | 10 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Redness, Dose 1 | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Swelling, Across Doses | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Pain, Dose 2 | 1 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Swelling, Across Doses | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Pain, Dose 1 | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Swelling, Dose 1 | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Swelling, Dose 1 | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Pain, Dose 2 | 7 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Swelling, Dose 2 | 0 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Grade 3 Pain, Across Doses | 1 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Pain, Across Doses | 12 Participants |
| GSK2340273A/F2 6Y-9Y Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis | Any Swelling, Dose 2 | 0 Participants |
Secondary
Number of Subjects With Any Medically-attended Adverse Events (MAEs)
MAEs were defined as events for which the subject received medical attention defined as hospitalization, an emergency room visit, or a visit to or from medical personnel (medical doctor) for any reason. Any MAE(s) = Occurrence of any MAE(s) regardless of intensity grade or relation to vaccination.
Time frame: Within 182 days (Days 0-181) post vaccination
Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arepanrix/F1 Group | Number of Subjects With Any Medically-attended Adverse Events (MAEs) | 32 Participants |
| Arepanrix/F2 Group | Number of Subjects With Any Medically-attended Adverse Events (MAEs) | 62 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Any Medically-attended Adverse Events (MAEs) | 24 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Any Medically-attended Adverse Events (MAEs) | 25 Participants |
Secondary
Number of Subjects With Any Medically-attended Adverse Events (MAEs)
MAEs were defined as events for which the subject received medical attention defined as hospitalization, an emergency room visit, or a visit to or from medical personnel (medical doctor) for any reason. Any MAE(s) = Occurrence of any MAE(s) regardless of intensity grade or relation to vaccination.
Time frame: Throughout the entire study period (Day 0 - Day 385)
Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arepanrix/F1 Group | Number of Subjects With Any Medically-attended Adverse Events (MAEs) | 39 Participants |
| Arepanrix/F2 Group | Number of Subjects With Any Medically-attended Adverse Events (MAEs) | 87 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Any Medically-attended Adverse Events (MAEs) | 39 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Any Medically-attended Adverse Events (MAEs) | 34 Participants |
Secondary
Number of Subjects With Any Medically-attended Adverse Events (MAEs) - First Analysis
MAEs were defined as events for which the subject received medical attention defined as hospitalization, an emergency room visit, or a visit to or from medical personnel (medical doctor) for any reason. Any MAE(s) = Occurrence of any MAE(s) regardless of intensity grade or relation to vaccination.
Time frame: Within 41 days (Days 0-40) post vaccination
Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arepanrix/F1 Group | Number of Subjects With Any Medically-attended Adverse Events (MAEs) - First Analysis | 18 Participants |
| Arepanrix/F2 Group | Number of Subjects With Any Medically-attended Adverse Events (MAEs) - First Analysis | 14 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Any Medically-attended Adverse Events (MAEs) - First Analysis | 8 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Any Medically-attended Adverse Events (MAEs) - First Analysis | 9 Participants |
Secondary
Number of Subjects With Any Medically-attended Adverse Events (MAEs) - Preliminary Analysis
MAEs were defined as events for which the subject received medical attention defined as hospitalization, an emergency room visit, or a visit to or from medical personnel (medical doctor) for any reason. Any MAE(s) = Occurrence of any MAE(s) regardless of intensity grade or relation to vaccination.
Time frame: Within 21 days (Days 0-20) post vaccination
Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arepanrix/F1 Group | Number of Subjects With Any Medically-attended Adverse Events (MAEs) - Preliminary Analysis | 7 Participants |
| Arepanrix/F2 Group | Number of Subjects With Any Medically-attended Adverse Events (MAEs) - Preliminary Analysis | 5 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Any Medically-attended Adverse Events (MAEs) - Preliminary Analysis | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Any Medically-attended Adverse Events (MAEs) - Preliminary Analysis | 4 Participants |
Secondary
Number of Subjects With Any Medically-attended Adverse Events (MAEs) - Second Analysis
MAEs were defined as events for which the subject received medical attention defined as hospitalization, an emergency room visit, or a visit to or from medical personnel (medical doctor) for any reason. Any MAE(s) = Occurrence of any MAE(s) regardless of intensity grade or relation to vaccination.
Time frame: Within 42 days (Days 0-41) post vaccination
Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arepanrix/F1 Group | Number of Subjects With Any Medically-attended Adverse Events (MAEs) - Second Analysis | 18 Participants |
| Arepanrix/F2 Group | Number of Subjects With Any Medically-attended Adverse Events (MAEs) - Second Analysis | 31 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Any Medically-attended Adverse Events (MAEs) - Second Analysis | 8 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Any Medically-attended Adverse Events (MAEs) - Second Analysis | 9 Participants |
Secondary
Number of Subjects With Any Unsolicited Adverse Events (AEs)
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
Time frame: Within 84 days (Days 0-83) post vaccination
Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arepanrix/F1 Group | Number of Subjects With Any Unsolicited Adverse Events (AEs) | 36 Participants |
| Arepanrix/F2 Group | Number of Subjects With Any Unsolicited Adverse Events (AEs) | 76 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Any Unsolicited Adverse Events (AEs) | 30 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Any Unsolicited Adverse Events (AEs) | 32 Participants |
Secondary
Number of Subjects With Any Unsolicited Adverse Events (AEs) - First Analysis
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
Time frame: Within 42 days (Days 0-41) post vaccination
Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arepanrix/F1 Group | Number of Subjects With Any Unsolicited Adverse Events (AEs) - First Analysis | 33 Participants |
| Arepanrix/F2 Group | Number of Subjects With Any Unsolicited Adverse Events (AEs) - First Analysis | 35 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Any Unsolicited Adverse Events (AEs) - First Analysis | 25 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Any Unsolicited Adverse Events (AEs) - First Analysis | 23 Participants |
Secondary
Number of Subjects With Any Unsolicited Adverse Events (AEs) - Preliminary Analysis
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
Time frame: Within 21 days (Days 0-20) post vaccination
Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arepanrix/F1 Group | Number of Subjects With Any Unsolicited Adverse Events (AEs) - Preliminary Analysis | 17 Participants |
| Arepanrix/F2 Group | Number of Subjects With Any Unsolicited Adverse Events (AEs) - Preliminary Analysis | 20 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Any Unsolicited Adverse Events (AEs) - Preliminary Analysis | 16 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Any Unsolicited Adverse Events (AEs) - Preliminary Analysis | 14 Participants |
Secondary
Number of Subjects With Any Unsolicited Adverse Events (AEs) - Second Analysis
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
Time frame: Within 41 days (Days 0-40) post vaccination
Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arepanrix/F1 Group | Number of Subjects With Any Unsolicited Adverse Events (AEs) - Second Analysis | 34 Participants |
| Arepanrix/F2 Group | Number of Subjects With Any Unsolicited Adverse Events (AEs) - Second Analysis | 65 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Any Unsolicited Adverse Events (AEs) - Second Analysis | 24 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Any Unsolicited Adverse Events (AEs) - Second Analysis | 23 Participants |
Secondary
Number of Subjects With Biochemical Laboratory Abnormalities
Biochemical parameters assessed for lab abnormalities were alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], bilirubin \[BLR\], bilirubin conjugated/direct \[BCD\], creatinine \[CRE\] and blood urea nitrogen \[BUN\]. Biochemical laboratory values were unknown, below, within or above the laboratory reference range defined for the specified time point and laboratory parameter.
Time frame: At Day 182
Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities | CRE | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities | BCD | Unknown | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities | ALT | Unknown | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities | BCD | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities | BCD | Within | 58 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities | ALT | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities | CRE | Unknown | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities | BCD | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities | AST | Unknown | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities | ALT | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities | BUN | Unknown | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities | AST | Above | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities | AST | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities | BUN | Within | 51 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities | AST | Within | 57 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities | BUN | Below | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities | BUN | Above | 4 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities | BLR | Unknown | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities | BLR | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities | ALT | Within | 58 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities | CRE | Within | 40 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities | BLR | Within | 58 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities | BLR | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities | CRE | Below | 18 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities | CRE | Within | 72 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities | BLR | Within | 107 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities | BCD | Unknown | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities | AST | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities | CRE | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities | ALT | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities | BCD | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities | BUN | Within | 99 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities | CRE | Unknown | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities | BUN | Below | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities | BCD | Within | 106 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities | BLR | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities | AST | Within | 106 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities | BCD | Above | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities | ALT | Unknown | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities | ALT | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities | BUN | Above | 6 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities | BUN | Unknown | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities | ALT | Within | 107 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities | AST | Unknown | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities | CRE | Below | 35 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities | BLR | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities | BLR | Unknown | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities | AST | Above | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities | AST | Above | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities | ALT | Unknown | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities | ALT | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities | ALT | Within | 51 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities | ALT | Above | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities | AST | Unknown | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities | AST | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities | AST | Within | 50 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities | BLR | Unknown | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities | BLR | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities | BLR | Within | 52 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities | BLR | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities | BCD | Unknown | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities | BCD | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities | BCD | Within | 52 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities | BCD | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities | CRE | Unknown | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities | CRE | Below | 16 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities | CRE | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities | CRE | Within | 36 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities | BUN | Below | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities | BUN | Unknown | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities | BUN | Within | 48 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities | BUN | Above | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities | ALT | Within | 54 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities | BUN | Above | 2 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities | CRE | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities | CRE | Below | 18 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities | BLR | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities | BLR | Unknown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities | BUN | Within | 53 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities | CRE | Within | 37 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities | BUN | Unknown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities | AST | Within | 53 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities | AST | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities | ALT | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities | BUN | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities | AST | Above | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities | AST | Unknown | 2 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities | ALT | Above | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities | BCD | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities | BCD | Within | 55 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities | BCD | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities | ALT | Unknown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities | CRE | Unknown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities | BCD | Unknown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities | BLR | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities | BLR | Within | 55 Participants |
Secondary
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis
Biochemical parameters assessed for lab abnormalities were alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], bilirubin \[BLR\], bilirubin conjugated/direct \[BCD\], creatinine \[CRE\] and blood urea nitrogen \[BUN\]. Biochemical laboratory values were unknown, below, within or above the laboratory reference range defined for the specified time point and laboratory parameter.
Time frame: At Day 0 (PRE), at Day 7, at Day 21 and at Day 42
Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BUN, D21 | Unknown | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BCD, D42 | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BCD, PRE | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BUN, D7 | Above | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | CRE, PRE | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BCD, PRE | Within | 64 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BUN, D7 | Within | 62 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BUN, D7 | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BCD, PRE | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BUN, D7 | Unknown | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BUN, PRE | Above | 4 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | CRE, D7 | Below | 18 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | CRE, PRE | Below | 19 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BUN, PRE | Within | 58 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BUN, PRE | Below | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | CRE, D7 | Within | 47 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BLR, D42 | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BUN, PRE | Unknown | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | CRE, D42 | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | CRE, D7 | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BLR, D42 | Within | 55 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | CRE, D42 | Within | 37 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | CRE, D42 | Below | 18 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | CRE, D21 | Unknown | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | ALT, D42 | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | CRE, D42 | Unknown | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | CRE, D21 | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | CRE, D21 | Below | 22 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | ALT, D42 | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | CRE, D21 | Within | 41 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BLR, D42 | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BLR, D42 | Unknown | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | AST, PRE | Unknown | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | CRE, PRE | Unknown | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BLR, D21 | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BLR, D21 | Within | 63 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | AST, PRE | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BCD, D42 | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BLR, D21 | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BLR, D21 | Unknown | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | ALT, PRE | Unknown | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | AST, D42 | Within | 54 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BLR, D7 | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BLR, D7 | Within | 65 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | ALT, PRE | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BCD, D42 | Within | 55 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BLR, D7 | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BLR, D7 | Unknown | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | ALT, PRE | Within | 64 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BCD, D21 | Within | 63 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BLR, PRE | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BLR, PRE | Within | 64 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | ALT, PRE | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BCD, PRE | Unknown | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BLR, PRE | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BLR, PRE | Unknown | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | ALT, D7 | Unknown | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | ALT, D42 | Unknown | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | AST, D42 | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | AST, D42 | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | ALT, D7 | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BCD, D21 | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | AST, D42 | Unknown | 4 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | AST, D21 | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | ALT, D7 | Within | 64 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | AST, D21 | Within | 61 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BCD, D21 | Unknown | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | AST, D21 | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | ALT, D7 | Above | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BCD, D21 | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | AST, D21 | Unknown | 4 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | AST, D7 | Above | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | ALT, D21 | Unknown | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BCD, D7 | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | AST, D7 | Within | 63 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | AST, D7 | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | ALT, D21 | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BCD, D7 | Within | 65 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | CRE, D7 | Unknown | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | AST, D7 | Unknown | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | AST, PRE | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | ALT, D21 | Within | 63 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BCD, D7 | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | AST, PRE | Within | 61 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BUN, D42 | Above | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | ALT, D21 | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | CRE, PRE | Within | 45 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BUN, D42 | Within | 49 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BUN, D42 | Below | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BUN, D42 | Unknown | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | ALT, D42 | Within | 55 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BCD, D7 | Unknown | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BUN, D21 | Above | 4 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BUN, D21 | Within | 59 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BUN, D21 | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BCD, D42 | Unknown | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BCD, D42 | Unknown | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | ALT, D42 | Unknown | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BCD, PRE | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | CRE, D42 | Within | 34 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | CRE, PRE | Within | 39 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | ALT, D42 | Above | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | AST, PRE | Unknown | 6 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | AST, PRE | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | ALT, PRE | Unknown | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | ALT, PRE | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | ALT, PRE | Within | 61 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | ALT, PRE | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | ALT, D7 | Unknown | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | ALT, D7 | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | ALT, D7 | Within | 59 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | ALT, D7 | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | ALT, D21 | Unknown | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | ALT, D21 | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | ALT, D42 | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | ALT, D21 | Within | 57 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | ALT, D21 | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | ALT, D42 | Within | 53 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BCD, D42 | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | CRE, PRE | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | CRE, D7 | Unknown | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | CRE, D7 | Below | 23 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | CRE, D7 | Within | 36 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | CRE, D7 | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | CRE, D21 | Unknown | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | CRE, D21 | Below | 23 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | CRE, D21 | Within | 34 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | CRE, D21 | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | CRE, D42 | Unknown | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | CRE, D42 | Below | 20 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | CRE, D42 | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BUN, PRE | Unknown | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BUN, PRE | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BUN, PRE | Within | 55 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BUN, PRE | Above | 6 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BUN, D7 | Unknown | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BUN, D7 | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BUN, D7 | Within | 55 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BUN, D7 | Above | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BUN, D21 | Unknown | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BUN, D21 | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BUN, D21 | Within | 54 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BUN, D21 | Above | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BUN, D42 | Unknown | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BUN, D42 | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BUN, D42 | Within | 49 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BUN, D42 | Above | 5 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | AST, PRE | Within | 57 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | AST, PRE | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | AST, D7 | Unknown | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | AST, D7 | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | AST, D7 | Within | 57 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | AST, D7 | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | AST, D21 | Unknown | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | AST, D21 | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | AST, D21 | Within | 56 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | AST, D21 | Above | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | AST, D42 | Unknown | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | AST, D42 | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | AST, D42 | Within | 53 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | AST, D42 | Above | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BLR, PRE | Unknown | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BLR, PRE | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BLR, PRE | Within | 62 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BLR, PRE | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BLR, D7 | Unknown | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BLR, D7 | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BLR, D7 | Within | 59 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BLR, D7 | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BLR, D21 | Unknown | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BLR, D21 | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BLR, D21 | Within | 57 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BLR, D21 | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BLR, D42 | Unknown | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BLR, D42 | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BLR, D42 | Within | 53 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BLR, D42 | Above | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BCD, PRE | Unknown | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BCD, PRE | Within | 61 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BCD, PRE | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BCD, D7 | Unknown | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BCD, D7 | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BCD, D7 | Within | 59 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BCD, D21 | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BCD, D7 | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BCD, D21 | Unknown | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BCD, D21 | Within | 57 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BCD, D21 | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BCD, D42 | Within | 54 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BCD, D42 | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | CRE, PRE | Unknown | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | CRE, PRE | Below | 22 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | CRE, D42 | Within | 44 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BUN, D42 | Unknown | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | ALT, D42 | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BUN, D42 | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | ALT, D21 | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | CRE, PRE | Below | 17 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BUN, D42 | Within | 54 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BCD, D7 | Unknown | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BUN, D42 | Above | 6 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | ALT, D21 | Within | 55 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | AST, PRE | Within | 59 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | CRE, D42 | Below | 16 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | AST, PRE | Above | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | AST, D7 | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | ALT, D21 | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BCD, D42 | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | AST, D7 | Unknown | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BCD, D7 | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | ALT, D21 | Unknown | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | AST, D7 | Within | 57 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | AST, D7 | Above | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | ALT, D7 | Above | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | AST, D21 | Unknown | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BCD, D7 | Within | 60 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | AST, D21 | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | ALT, D7 | Within | 59 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | AST, D21 | Within | 53 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | AST, D21 | Above | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | ALT, D7 | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BCD, D42 | Unknown | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | AST, D42 | Unknown | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | AST, D42 | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BCD, D7 | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | AST, D42 | Within | 57 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | ALT, D7 | Unknown | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | AST, D42 | Above | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BLR, PRE | Unknown | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | ALT, PRE | Above | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | CRE, PRE | Unknown | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BLR, PRE | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BCD, D21 | Unknown | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BLR, PRE | Within | 60 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | ALT, PRE | Within | 59 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BLR, PRE | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BCD, PRE | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BLR, D7 | Unknown | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | ALT, PRE | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BCD, D21 | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BLR, D7 | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BLR, D7 | Within | 60 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | ALT, PRE | Unknown | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BLR, D7 | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BLR, D21 | Unknown | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | AST, PRE | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BCD, D21 | Within | 55 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BLR, D21 | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BLR, D21 | Within | 55 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | AST, PRE | Unknown | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BLR, D21 | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BCD, D42 | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | ALT, D42 | Above | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BLR, D42 | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | CRE, D21 | Below | 15 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BLR, D42 | Unknown | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | CRE, D21 | Within | 40 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BLR, D42 | Within | 60 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | CRE, D21 | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | CRE, D21 | Unknown | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | CRE, D42 | Unknown | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | CRE, PRE | Within | 43 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | CRE, D7 | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | ALT, D42 | Unknown | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | CRE, D42 | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | CRE, D7 | Within | 41 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BLR, D42 | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BUN, PRE | Unknown | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BCD, D42 | Within | 60 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BUN, PRE | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | CRE, D7 | Below | 19 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BCD, PRE | Unknown | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BUN, PRE | Within | 55 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BUN, PRE | Above | 5 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | CRE, D7 | Unknown | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BUN, D7 | Unknown | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BUN, D21 | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BUN, D7 | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | CRE, PRE | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BCD, PRE | Within | 60 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BUN, D7 | Above | 9 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BUN, D21 | Unknown | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BUN, D7 | Within | 51 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BCD, D21 | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BUN, D21 | Within | 49 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | ALT, D42 | Within | 59 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BCD, PRE | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BUN, D21 | Above | 6 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | CRE, D7 | Within | 43 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | ALT, D42 | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BCD, PRE | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BLR, D7 | Within | 60 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BUN, D42 | Unknown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BUN, D7 | Unknown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BUN, PRE | Above | 5 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BLR, D42 | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BUN, D42 | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | CRE, PRE | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BLR, D7 | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | AST, PRE | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BUN, D42 | Within | 50 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | ALT, D21 | Within | 61 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | CRE, PRE | Unknown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | CRE, D42 | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BUN, D42 | Above | 7 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BLR, D21 | Unknown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BCD, D7 | Unknown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BCD, PRE | Within | 63 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | AST, PRE | Within | 63 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | ALT, D21 | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BUN, D21 | Within | 52 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BUN, D7 | Below | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | AST, PRE | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BLR, D21 | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | AST, PRE | Unknown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BCD, D21 | Within | 61 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BUN, PRE | Unknown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | AST, D7 | Unknown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | ALT, D21 | Unknown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BLR, D21 | Within | 61 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | AST, D7 | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | CRE, D7 | Below | 17 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BCD, D7 | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | ALT, D42 | Unknown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | AST, D7 | Within | 58 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | ALT, D7 | Above | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BCD, D42 | Unknown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BUN, D21 | Unknown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | AST, D7 | Above | 2 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BLR, D21 | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BCD, D42 | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | ALT, D42 | Above | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | AST, D21 | Unknown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | ALT, D7 | Within | 59 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BCD, D42 | Within | 57 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BLR, D42 | Unknown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | AST, D21 | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BUN, PRE | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | AST, D21 | Within | 60 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BCD, D42 | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | ALT, D7 | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BCD, D7 | Within | 60 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BUN, D7 | Within | 51 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | AST, D21 | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BLR, D42 | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | ALT, D42 | Within | 56 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | CRE, D21 | Below | 17 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | AST, D42 | Unknown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | ALT, D7 | Unknown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | CRE, PRE | Below | 15 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | CRE, PRE | Within | 48 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BCD, D21 | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | AST, D42 | Within | 57 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BUN, PRE | Within | 58 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | CRE, D21 | Within | 44 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BCD, D7 | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | CRE, D21 | Unknown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | AST, D42 | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | ALT, PRE | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BCD, PRE | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | CRE, D7 | Unknown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BLR, PRE | Unknown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BCD, PRE | Unknown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | CRE, D21 | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | AST, D42 | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BLR, PRE | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | ALT, PRE | Within | 63 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BLR, D42 | Within | 57 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BUN, D7 | Above | 8 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BLR, PRE | Within | 63 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | CRE, D42 | Unknown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BCD, D21 | Unknown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | CRE, D7 | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BLR, PRE | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | ALT, PRE | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BUN, D21 | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | CRE, D42 | Below | 13 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BLR, D7 | Unknown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | ALT, D21 | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BUN, D21 | Above | 9 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | CRE, D42 | Within | 44 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BLR, D7 | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | ALT, PRE | Unknown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis | BCD, D21 | Below | 0 Participants |
Secondary
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis
Biochemical parameters assessed for lab abnormalities were alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], bilirubin \[BLR\], bilirubin conjugated/direct \[BCD\], creatinine \[CRE\] and blood urea nitrogen \[BUN\]. Biochemical laboratory values were unknown, below, within or above the laboratory reference range defined for the specified time point and laboratory parameter.
Time frame: At Day 0 (PRE), at Day 7 and at Day 21
Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | AST, D7 | Above | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BUN, D21 | Unkown | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | AST, PRE | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BLR, D7 | Within | 65 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BUN, D21 | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BUN, D21 | Within | 59 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | ALT, PRE | Unkown | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | ALT, D7 | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BLR, D7 | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | ALT, PRE | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BUN, PRE | Unkown | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | ALT, PRE | Within | 37 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | AST, D7 | Unkown | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | ALT, D21 | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BLR, D7 | Unkown | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | ALT, D21 | Within | 63 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | ALT, D21 | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BLR, PRE | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | AST, PRE | Unkown | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BLR, PRE | Within | 37 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | AST, D21 | Unkown | 4 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | AST, D7 | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | AST, D21 | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | CRE, D21 | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | AST, D7 | Within | 63 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | AST, D21 | Within | 61 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | ALT, D7 | Within | 64 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | AST, D21 | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | CRE, D21 | Within | 41 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BLR, PRE | Unkown | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | CRE, D7 | Within | 47 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BLR, PRE | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BLR, D21 | Unkown | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BUN, D7 | Within | 62 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | CRE, D7 | Below | 18 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BLR, D21 | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | ALT, D7 | Above | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BLR, D21 | Within | 63 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | CRE, D7 | Unkown | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BCD, PRE | Within | 37 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BUN, D21 | Above | 4 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BCD, PRE | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | CRE, PRE | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BCD, D7 | Unkown | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | ALT, D21 | Unkown | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BCD, D7 | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BCD, D21 | Unkown | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BCD, D21 | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | ALT, D7 | Unkown | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BCD, D21 | Within | 63 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BUN, D7 | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BCD, D7 | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BCD, D21 | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | CRE, PRE | Unkown | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BCD, D7 | Within | 65 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | CRE, PRE | Below | 13 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | CRE, PRE | Within | 24 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | AST, PRE | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BCD, PRE | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | CRE, D7 | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | ALT, PRE | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | CRE, D21 | Unkown | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BUN, D7 | Unkown | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BCD, PRE | Unkown | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | CRE, D21 | Below | 22 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BUN, PRE | Below | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | AST, PRE | Within | 34 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BLR, D21 | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BUN, PRE | Within | 35 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BUN, PRE | Above | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BUN, D7 | Above | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BLR, D7 | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BUN, D7 | Above | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BLR, D7 | Within | 59 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | CRE, D7 | Unkown | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BUN, D21 | Unkown | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BUN, PRE | Above | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BLR, D21 | Within | 57 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | ALT, D7 | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BUN, D21 | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | AST, PRE | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BLR, D7 | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | CRE, PRE | Below | 15 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BUN, D21 | Within | 54 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BUN, D7 | Unkown | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | ALT, PRE | Unkown | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BCD, PRE | Within | 35 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BCD, D7 | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | CRE, PRE | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | ALT, PRE | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BUN, PRE | Within | 33 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BLR, D7 | Unkown | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BCD, PRE | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | ALT, PRE | Within | 35 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BUN, D7 | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | CRE, PRE | Within | 20 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | ALT, D21 | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | CRE, D21 | Below | 23 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BCD, D7 | Unkown | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | ALT, D21 | Within | 57 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | AST, D7 | Unkown | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BLR, PRE | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BCD, PRE | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | ALT, D21 | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | ALT, D7 | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BCD, D21 | Unkown | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | CRE, D7 | Within | 36 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BLR, PRE | Within | 35 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BUN, PRE | Unkown | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | AST, D7 | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | CRE, D21 | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | ALT, D21 | Unkown | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | AST, PRE | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | AST, D21 | Unkown | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BLR, D21 | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BLR, PRE | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BCD, D21 | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | AST, D21 | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | AST, D7 | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | ALT, PRE | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | AST, PRE | Within | 32 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BCD, D7 | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | AST, D7 | Within | 57 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BUN, D7 | Within | 55 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | CRE, D7 | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | AST, D21 | Within | 56 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BCD, D21 | Within | 57 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | CRE, D21 | Within | 34 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BUN, PRE | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | AST, D21 | Above | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | ALT, D7 | Within | 59 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BCD, PRE | Unkown | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BLR, D7 | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BLR, PRE | Unkown | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BUN, D21 | Above | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BCD, D21 | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | AST, PRE | Unkown | 5 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | CRE, D7 | Below | 23 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BCD, D7 | Within | 59 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BLR, D21 | Unkown | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | CRE, D21 | Unkown | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | CRE, PRE | Unkown | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | ALT, D7 | Unkown | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BLR, D21 | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BUN, D7 | Above | 9 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | ALT, PRE | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | ALT, D7 | Unkown | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | ALT, D7 | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | ALT, D7 | Within | 59 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | ALT, D7 | Above | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | ALT, D21 | Unkown | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | AST, PRE | Unkown | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | AST, PRE | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | AST, PRE | Within | 26 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | AST, PRE | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | AST, D7 | Unkown | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | AST, D7 | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | AST, D7 | Within | 57 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | AST, D21 | Within | 52 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | AST, D21 | Above | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BLR, PRE | Unkown | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BLR, D21 | Unkown | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BLR, D21 | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BLR, D21 | Within | 54 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BCD, PRE | Within | 27 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BCD, PRE | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BCD, D7 | Unkown | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BCD, D21 | Unkown | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BCD, D21 | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BCD, D21 | Within | 54 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BCD, D21 | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | CRE, PRE | Unkown | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | CRE, PRE | Below | 10 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | CRE, PRE | Within | 17 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | CRE, D7 | Within | 41 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | CRE, D7 | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | CRE, D21 | Unkown | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BUN, PRE | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BUN, PRE | Within | 23 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BUN, PRE | Above | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | ALT, PRE | Within | 27 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BUN, D21 | Unkown | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BUN, D21 | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | ALT, PRE | Unkown | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | ALT, PRE | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | ALT, D21 | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | ALT, D21 | Within | 54 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | ALT, D21 | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | AST, D7 | Above | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | AST, D21 | Unkown | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | AST, D21 | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BLR, PRE | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BLR, PRE | Within | 27 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BLR, PRE | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BLR, D7 | Unkown | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BLR, D7 | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BLR, D7 | Within | 60 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BLR, D7 | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BLR, D21 | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BCD, PRE | Unkown | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BCD, PRE | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BCD, D7 | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BCD, D7 | Within | 60 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BCD, D7 | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | CRE, PRE | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | CRE, D7 | Unkown | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | CRE, D7 | Below | 19 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | CRE, D21 | Below | 15 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | CRE, D21 | Within | 39 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | CRE, D21 | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BUN, PRE | Unkown | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BUN, D7 | Unkown | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BUN, D7 | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BUN, D7 | Within | 51 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BUN, D21 | Within | 48 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BUN, D21 | Above | 6 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BUN, PRE | Within | 25 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | AST, PRE | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BUN, PRE | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BUN, PRE | Unkown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | AST, PRE | Unkown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BLR, D21 | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | CRE, D21 | Unkown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | CRE, D7 | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BUN, D21 | Within | 52 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BCD, PRE | Unkown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | CRE, D7 | Within | 43 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | CRE, PRE | Within | 21 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BUN, D7 | Unkown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BCD, PRE | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | CRE, PRE | Below | 7 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | ALT, D21 | Unkown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BCD, D7 | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | CRE, PRE | Unkown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BCD, D21 | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | ALT, D7 | Above | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BCD, D7 | Within | 60 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BCD, D21 | Within | 61 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BCD, D21 | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | ALT, PRE | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BCD, D7 | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BCD, D21 | Unkown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BCD, D7 | Unkown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BCD, PRE | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BCD, PRE | Within | 28 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BUN, D7 | Below | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | CRE, PRE | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BLR, D21 | Within | 61 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BLR, D21 | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | ALT, D7 | Within | 59 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | CRE, D7 | Unkown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BLR, D21 | Unkown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BLR, D7 | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | ALT, D7 | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | CRE, D7 | Below | 17 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BLR, PRE | Unkown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | ALT, PRE | Within | 28 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | CRE, D21 | Below | 17 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | AST, D21 | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | AST, D21 | Within | 60 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BUN, D7 | Within | 51 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | CRE, D21 | Within | 44 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | AST, D7 | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | AST, D21 | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | AST, D21 | Unkown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | AST, D7 | Unkown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BLR, PRE | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | AST, D7 | Above | 2 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | AST, D7 | Within | 58 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | ALT, D7 | Unkown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BLR, PRE | Within | 28 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | ALT, D21 | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | ALT, D21 | Within | 61 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | CRE, D21 | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BLR, PRE | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | ALT, D21 | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | ALT, PRE | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | AST, PRE | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BLR, D7 | Unkown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | ALT, PRE | Unkown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BUN, D21 | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | AST, PRE | Within | 28 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BLR, D7 | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BUN, D21 | Unkown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BUN, D7 | Above | 8 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BUN, D21 | Above | 9 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BLR, D7 | Within | 60 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis | BUN, PRE | Above | 3 Participants |
Secondary
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis
Biochemical parameters assessed for lab abnormalities were alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], bilirubin \[BLR\], bilirubin conjugated/direct \[BCD\], creatinine \[CRE\] and blood urea nitrogen \[BUN\]. Biochemical laboratory values were unknown, below, within or above the laboratory reference range defined for the specified time point and laboratory parameter.
Time frame: At Day 0 (PRE), at Day 7, at Day 21 and at Day 42
Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | ALT, D42 | Within | 55 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | CRE, D7 | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BCD, PRE | Unknown | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BCD, PRE | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | CRE, D7 | Within | 47 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BCD, PRE | Within | 64 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BUN, D21 | Within | 59 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BCD, PRE | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | ALT, D42 | Unknown | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | CRE, D7 | Below | 18 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BCD, D7 | Unknown | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BCD, D7 | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | ALT, PRE | Unknown | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BCD, D7 | Within | 65 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | CRE, PRE | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BCD, D7 | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | ALT, D42 | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | CRE, D7 | Unknown | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BCD, D21 | Unknown | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BCD, D21 | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | CRE, PRE | Within | 45 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BCD, D21 | Within | 63 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BUN, D21 | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BCD, D21 | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | ALT, D21 | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | CRE, PRE | Below | 19 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BCD, D42 | Unknown | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BCD, D42 | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | ALT, PRE | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | CRE, PRE | Unknown | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BCD, D42 | Within | 55 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BCD, D42 | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | ALT, D42 | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BUN, D21 | Unknown | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | AST, PRE | Unknown | 4 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | AST, PRE | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BUN, D42 | Within | 49 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BUN, D7 | Above | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | AST, PRE | Within | 62 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | ALT, D7 | Unknown | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | AST, PRE | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BUN, D7 | Within | 62 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | AST, D7 | Unknown | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | AST, D7 | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BUN, D7 | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | AST, D7 | Within | 63 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | AST, D7 | Above | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | ALT, D7 | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BUN, D7 | Unknown | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | AST, D21 | Unknown | 4 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | AST, D21 | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BUN, PRE | Above | 4 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | AST, D21 | Within | 61 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | AST, D21 | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BUN, D42 | Below | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BUN, PRE | Within | 58 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | AST, D42 | Unknown | 4 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | ALT, D7 | Within | 64 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | AST, D42 | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | ALT, PRE | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BUN, PRE | Below | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | AST, D42 | Within | 54 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BLR, PRE | Unknown | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | AST, D42 | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | ALT, D7 | Above | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BUN, PRE | Unknown | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BLR, PRE | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | CRE, D42 | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BLR, PRE | Within | 64 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BUN, D42 | Unknown | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BLR, PRE | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | ALT, D21 | Unknown | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | CRE, D42 | Within | 37 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BLR, D7 | Unknown | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BLR, D7 | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | CRE, D42 | Below | 18 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BLR, D7 | Within | 65 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | ALT, D21 | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BLR, D7 | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | CRE, D42 | Unknown | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BLR, D21 | Unknown | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | CRE, D21 | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BLR, D21 | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BUN, D42 | Above | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BLR, D21 | Within | 63 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BUN, D21 | Above | 4 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | CRE, D21 | Within | 41 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BLR, D21 | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | ALT, D21 | Within | 63 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BLR, D42 | Unknown | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | CRE, D21 | Below | 22 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BLR, D42 | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | ALT, PRE | Within | 64 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | CRE, D21 | Unknown | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BLR, D42 | Within | 55 Participants |
| Arepanrix/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BLR, D42 | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BLR, PRE | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BLR, D21 | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | ALT, D21 | Unknown | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BCD, PRE | Unknown | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | ALT, D21 | Above | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | CRE, D7 | Within | 80 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | AST, D21 | Unknown | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BCD, PRE | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | ALT, PRE | Within | 124 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | ALT, D7 | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BUN, PRE | Above | 10 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BCD, PRE | Within | 124 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BLR, D42 | Above | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | CRE, D7 | Below | 38 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | AST, D21 | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BCD, PRE | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | ALT, D7 | Within | 118 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | CRE, D21 | Within | 76 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BLR, D7 | Unknown | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BCD, D7 | Unknown | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | ALT, D42 | Unknown | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | CRE, D7 | Unknown | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | AST, D21 | Within | 112 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BCD, D7 | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BUN, D42 | Above | 11 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | CRE, PRE | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BUN, PRE | Within | 110 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BCD, D7 | Within | 118 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BUN, D21 | Below | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | CRE, D21 | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | AST, D21 | Above | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BCD, D7 | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | CRE, D42 | Below | 37 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BLR, D42 | Unknown | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BLR, D7 | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BCD, D21 | Unknown | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | ALT, D42 | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | CRE, PRE | Within | 86 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | AST, D42 | Unknown | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BCD, D21 | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BUN, D42 | Within | 96 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BUN, D21 | Above | 5 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BUN, PRE | Below | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BCD, D21 | Within | 116 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BLR, D21 | Within | 116 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | CRE, PRE | Below | 38 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | AST, D42 | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BCD, D21 | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | ALT, D21 | Within | 115 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BLR, D7 | Within | 118 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BLR, D42 | Within | 110 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BCD, D42 | Unknown | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | ALT, D42 | Within | 110 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | CRE, PRE | Unknown | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | AST, D42 | Within | 105 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BCD, D42 | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | CRE, D42 | Unknown | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BUN, D42 | Unknown | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BUN, PRE | Unknown | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BCD, D42 | Within | 111 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BUN, D21 | Unknown | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BCD, D42 | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BLR, D42 | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | AST, D42 | Above | 6 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | ALT, D42 | Above | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | ALT, PRE | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BLR, D7 | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | ALT, D21 | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | AST, PRE | Unknown | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | ALT, PRE | Unknown | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BUN, D7 | Above | 7 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BLR, PRE | Unknown | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | AST, PRE | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | ALT, D7 | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | CRE, D42 | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BLR, D21 | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | AST, PRE | Within | 117 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BLR, PRE | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BUN, D7 | Within | 110 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | ALT, PRE | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | AST, PRE | Above | 5 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | ALT, D7 | Unknown | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BUN, D21 | Within | 107 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BLR, D21 | Unknown | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | AST, D7 | Unknown | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | CRE, D21 | Unknown | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BUN, D7 | Below | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BLR, PRE | Within | 124 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | AST, D7 | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | CRE, D21 | Below | 40 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | CRE, D42 | Within | 74 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | AST, D7 | Within | 113 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BUN, D42 | Below | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BUN, D7 | Unknown | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | CRE, D7 | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | AST, D7 | Above | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | AST, D7 | Above | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | ALT, PRE | Unknown | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | ALT, PRE | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | ALT, PRE | Within | 59 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | ALT, PRE | Above | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | ALT, D7 | Unknown | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | ALT, D7 | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | ALT, D7 | Within | 59 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | ALT, D7 | Above | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | ALT, D21 | Unknown | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | ALT, D21 | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | ALT, D21 | Within | 55 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | ALT, D21 | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | ALT, D42 | Unknown | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | ALT, D42 | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | ALT, D42 | Within | 59 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | ALT, D42 | Above | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | AST, PRE | Unknown | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | AST, PRE | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | AST, PRE | Within | 59 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | AST, PRE | Above | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | AST, D7 | Unknown | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | AST, D7 | Within | 57 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | AST, D7 | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | AST, D21 | Unknown | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | AST, D21 | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | AST, D21 | Within | 53 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | AST, D21 | Above | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | AST, D42 | Unknown | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | AST, D42 | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | AST, D42 | Within | 57 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | AST, D42 | Above | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BLR, PRE | Unknown | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BLR, PRE | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BLR, PRE | Within | 60 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BLR, PRE | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BLR, D21 | Unknown | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BLR, D7 | Unknown | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BLR, D7 | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BLR, D7 | Within | 60 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BLR, D7 | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BLR, D21 | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BLR, D21 | Within | 55 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BLR, D21 | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BLR, D42 | Unknown | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BLR, D42 | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BLR, D42 | Within | 60 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BLR, D42 | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BCD, PRE | Unknown | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BCD, PRE | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BCD, PRE | Within | 60 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BCD, PRE | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BCD, D7 | Unknown | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BCD, D7 | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BCD, D7 | Within | 60 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BCD, D7 | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BCD, D21 | Unknown | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BCD, D21 | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BCD, D21 | Within | 55 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BCD, D21 | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BCD, D42 | Unknown | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BCD, D42 | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BCD, D42 | Within | 60 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BCD, D42 | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | CRE, PRE | Unknown | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | CRE, PRE | Below | 17 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | CRE, PRE | Within | 43 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | CRE, PRE | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | CRE, D7 | Unknown | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | CRE, D7 | Below | 19 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | CRE, D7 | Within | 41 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | CRE, D7 | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | CRE, D21 | Unknown | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | CRE, D21 | Below | 15 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | CRE, D21 | Within | 40 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | CRE, D21 | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | CRE, D42 | Unknown | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | CRE, D42 | Below | 16 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | CRE, D42 | Within | 44 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | CRE, D42 | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BUN, PRE | Unknown | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BUN, PRE | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BUN, PRE | Within | 56 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BUN, PRE | Above | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BUN, D7 | Unknown | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BUN, D7 | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BUN, D7 | Within | 51 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BUN, D7 | Above | 9 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BUN, D21 | Unknown | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BUN, D21 | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BUN, D21 | Within | 49 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BUN, D21 | Above | 6 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BUN, D42 | Unknown | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BUN, D42 | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BUN, D42 | Within | 54 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BUN, D42 | Above | 6 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BUN, D21 | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | CRE, D7 | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BLR, D42 | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | ALT, D21 | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | CRE, D21 | Unknown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BLR, D42 | Unknown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BLR, D21 | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | ALT, D21 | Within | 61 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | CRE, D21 | Below | 17 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BLR, D21 | Within | 61 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BLR, D21 | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BUN, D42 | Above | 7 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | CRE, D21 | Within | 44 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BLR, D21 | Unknown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BUN, D21 | Within | 52 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | CRE, D21 | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BLR, D7 | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BLR, D7 | Within | 60 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | ALT, D21 | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | CRE, D42 | Unknown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BLR, D7 | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BLR, D7 | Unknown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | ALT, D21 | Unknown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | CRE, D42 | Below | 13 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BLR, PRE | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BLR, PRE | Within | 63 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BUN, D42 | Within | 50 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | CRE, D42 | Within | 44 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BLR, PRE | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BLR, PRE | Unknown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BUN, D21 | Above | 9 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | CRE, D42 | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | AST, D42 | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | AST, D42 | Within | 57 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | ALT, D7 | Above | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BUN, PRE | Unknown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | AST, D42 | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | AST, D42 | Unknown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | ALT, D7 | Within | 59 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BUN, PRE | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | AST, D21 | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | AST, D21 | Within | 60 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | ALT, PRE | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BUN, PRE | Within | 58 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | AST, D21 | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | AST, D21 | Unknown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BUN, D42 | Unknown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BUN, PRE | Above | 5 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | AST, D7 | Above | 2 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | AST, D7 | Within | 58 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | ALT, D7 | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BUN, D7 | Unknown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | AST, D7 | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | AST, D7 | Unknown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | ALT, D7 | Unknown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BUN, D7 | Below | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | AST, PRE | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | AST, PRE | Within | 63 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | ALT, PRE | Unknown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BUN, D7 | Within | 51 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | AST, PRE | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | AST, PRE | Unknown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BUN, D42 | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BCD, D42 | Within | 57 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BUN, D7 | Above | 8 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BCD, D42 | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BCD, D42 | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BCD, D42 | Unknown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | ALT, D42 | Above | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | CRE, PRE | Unknown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BCD, D21 | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BCD, D21 | Within | 61 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | ALT, D42 | Within | 56 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | CRE, PRE | Below | 15 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BCD, D21 | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BCD, D21 | Unknown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BCD, D7 | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | ALT, PRE | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | CRE, PRE | Within | 48 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BCD, D7 | Within | 60 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BCD, D7 | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BUN, D21 | Unknown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | CRE, PRE | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BCD, D7 | Unknown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | ALT, D42 | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | CRE, D7 | Unknown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BCD, PRE | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BCD, PRE | Within | 63 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | ALT, D42 | Unknown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | CRE, D7 | Below | 17 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BCD, PRE | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BCD, PRE | Unknown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | ALT, PRE | Within | 63 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | CRE, D7 | Within | 43 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BLR, D42 | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis | BLR, D42 | Within | 57 Participants |
Secondary
Number of Subjects With Haematological Laboratory Abnormalities
Among haematological parameters assessed were basophils \[BAS\], eosinophils \[EOS\], hematocrit \[HCT\], hemoglobin level \[HGB\], lymphocytes \[LYM\], monocytes \[MON\], neutrophils \[NEU\], platelet count \[PLC\], red blood cells \[RBC\] and white blood cells \[WBC\]. Haematological laboratory values were unknown, below, within or above the laboratory reference range defined for the specified time point and laboratory parameter.
Time frame: At Day 182
Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | NEU | Unknown | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | MON | Below | 18 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | MON | Within | 35 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | BAS | Within | 54 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | PLC | Within | 48 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | MON | Above | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | EOS | Above | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | NEU | Below | 4 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | WBC | Within | 49 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | PLC | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | NEU | Within | 48 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | EOS | Unknown | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | NEU | Above | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | PLC | Unknown | 6 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | WBC | Below | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | HCT | Unknown | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | HCT | Below | 8 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | EOS | Below | 6 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | WBC | Unknown | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | HCT | Within | 43 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | HCT | Above | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | RBC | Above | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | HGB | Unknown | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | HGB | Below | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | BAS | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | RBC | Within | 51 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | HGB | Within | 50 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | BAS | Unknown | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | HGB | Above | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | RBC | Below | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | LYM | Unknown | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | EOS | Within | 43 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | LYM | Below | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | WBC | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | LYM | Within | 40 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | BAS | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | RBC | Unknown | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | LYM | Above | 13 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | MON | Unknown | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | PLC | Above | 5 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | BAS | Within | 100 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | RBC | Above | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | MON | Below | 18 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | WBC | Within | 98 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | PLC | Within | 92 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | BAS | Unknown | 8 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | MON | Within | 82 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | HCT | Above | 12 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | EOS | Within | 83 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | LYM | Above | 28 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | MON | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | BAS | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | NEU | Unknown | 8 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | LYM | Within | 72 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | PLC | Below | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | HGB | Unknown | 8 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | NEU | Below | 8 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | WBC | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | RBC | Within | 91 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | LYM | Unknown | 8 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | NEU | Within | 92 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | HGB | Below | 8 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | PLC | Unknown | 9 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | BAS | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | NEU | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | EOS | Unknown | 8 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | RBC | Unknown | 9 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | WBC | Below | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | EOS | Below | 10 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | PLC | Above | 6 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | HGB | Within | 79 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | HCT | Unknown | 9 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | EOS | Above | 7 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | WBC | Unknown | 8 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | LYM | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | HCT | Below | 17 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | RBC | Below | 6 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | MON | Unknown | 8 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | HGB | Above | 13 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | HCT | Within | 70 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | HGB | Above | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | EOS | Below | 8 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | EOS | Above | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | BAS | Within | 51 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | BAS | Unknown | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | BAS | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | BAS | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | HCT | Unknown | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | HCT | Below | 5 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | HCT | Within | 42 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | HCT | Above | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | HGB | Unknown | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | HGB | Below | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | HGB | Within | 44 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | EOS | Unknown | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | LYM | Unknown | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | LYM | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | LYM | Within | 37 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | LYM | Above | 14 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | MON | Unknown | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | MON | Below | 12 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | MON | Within | 39 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | MON | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | NEU | Unknown | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | NEU | Below | 5 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | NEU | Within | 43 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | NEU | Above | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | PLC | Unknown | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | PLC | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | PLC | Within | 51 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | PLC | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | RBC | Unknown | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | RBC | Below | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | RBC | Within | 47 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | RBC | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | WBC | Unknown | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | WBC | Below | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | WBC | Within | 47 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | WBC | Above | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities | EOS | Within | 39 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | LYM | Above | 12 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | WBC | Within | 51 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | PLC | Above | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | LYM | Within | 41 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | LYM | Unknown | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | BAS | Unknown | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | RBC | Unknown | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | HGB | Above | 4 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | HGB | Within | 45 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | BAS | Within | 53 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | RBC | Below | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | HGB | Below | 4 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | HGB | Unknown | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | EOS | Within | 47 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | RBC | Within | 51 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | HCT | Above | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | HCT | Within | 43 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | WBC | Above | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | RBC | Above | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | HCT | Below | 7 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | HCT | Unknown | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | EOS | Below | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | WBC | Unknown | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | EOS | Above | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | EOS | Unknown | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | MON | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | WBC | Below | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | NEU | Above | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | NEU | Within | 51 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | BAS | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | PLC | Unknown | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | NEU | Below | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | NEU | Unknown | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | BAS | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | PLC | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | MON | Within | 40 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | MON | Below | 13 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | LYM | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | PLC | Within | 52 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities | MON | Unknown | 3 Participants |
Secondary
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis
Among haematological parameters assessed were basophils \[BAS\], eosinophils \[EOS\], hematocrit \[HCT\], hemoglobin level \[HGB\], lymphocytes \[LYM\], monocytes \[MON\], neutrophils \[NEU\], platelet count \[PLC\], red blood cells \[RBC\] and white blood cells \[WBC\]. Haematological laboratory values were unknown, below, within or above the laboratory reference range defined for the specified time point and laboratory parameter.
Time frame: At Day 0 (PRE), at Day 7, at Day 21 and at Day 42
Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | LYM, D21 | Within | 43 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | WBC, D7 | Above | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | NEU, PRE | Within | 54 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | PLC, D21 | Within | 57 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | BAS, PRE | Within | 65 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | EOS, D7 | Within | 50 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | BAS, PRE | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | PLC, D21 | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | BAS, D7 | Unknown | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | BAS, D7 | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | PLC, D21 | Unknown | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | BAS, D7 | Within | 61 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | EOS, D7 | Above | 4 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | BAS, D7 | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | PLC, D7 | Above | 9 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | BAS, D21 | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | BAS, D42 | Unknown | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | WBC, D7 | Within | 54 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | EOS, D21 | Unknown | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | PLC, D7 | Within | 51 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | BAS, D42 | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | BAS, D21 | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | PLC, D7 | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | BAS, D21 | Within | 64 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | NEU, PRE | Unknown | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | EOS, PRE | Unknown | 4 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | PLC, D7 | Unknown | 6 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | NEU, PRE | Above | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | EOS, D21 | Below | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | NEU, D7 | Unknown | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | PLC, PRE | Above | 11 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | BAS, PRE | Unknown | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | MON, D42 | Within | 41 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | BAS, PRE | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | EOS, D42 | Below | 4 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | PLC, PRE | Within | 51 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | BAS, D21 | Unknown | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | WBC, D7 | Below | 6 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | NEU, D7 | Below | 10 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | EOS, D21 | Within | 54 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | PLC, PRE | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | NEU, D7 | Within | 50 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | WBC, D42 | Within | 52 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | NEU, D7 | Above | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | PLC, PRE | Unknown | 4 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | NEU, D21 | Unknown | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | EOS, D21 | Above | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | NEU, D21 | Below | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | NEU, D42 | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | NEU, D21 | Within | 62 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | NEU, D42 | Within | 50 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | NEU, D21 | Above | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | NEU, D42 | Unknown | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | WBC, D7 | Unknown | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | NEU, D42 | Below | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HCT, D42 | Below | 9 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HCT, D7 | Within | 52 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HCT, D42 | Above | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | WBC, PRE | Above | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HCT, D21 | Below | 7 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HCT, D7 | Above | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HCT, PRE | Unknown | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | WBC, PRE | Unknown | 6 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HCT, D21 | Unknown | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | EOS, D42 | Unknown | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | WBC, PRE | Within | 55 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HCT, D42 | Within | 45 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HCT, D21 | Within | 54 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | LYM, D21 | Above | 21 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HCT, D21 | Above | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | WBC, D42 | Below | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | WBC, PRE | Below | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HGB, PRE | Unknown | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | EOS, D42 | Within | 42 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HGB, PRE | Above | 4 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | RBC, D42 | Above | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HGB, D7 | Unknown | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | EOS, PRE | Below | 12 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HGB, PRE | Below | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | RBC, D42 | Within | 51 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HGB, D7 | Below | 4 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HGB, PRE | Within | 58 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | EOS, D42 | Above | 9 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | RBC, D42 | Below | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HGB, D7 | Within | 55 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | WBC, D42 | Unknown | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HGB, D21 | Below | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HGB, D7 | Above | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | EOS, PRE | Within | 46 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | RBC, D42 | Unknown | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HGB, D21 | Unknown | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | RBC, D21 | Above | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HGB, D21 | Within | 55 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HGB, D21 | Above | 4 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HCT, PRE | Below | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HGB, D42 | Unknown | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | RBC, D21 | Within | 62 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HGB, D42 | Within | 49 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HGB, D42 | Below | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | RBC, D21 | Below | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | WBC, D21 | Above | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HCT, PRE | Within | 53 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HGB, D42 | Above | 4 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | LYM, PRE | Unknown | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | LYM, PRE | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | RBC, D21 | Unknown | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | LYM, PRE | Above | 18 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | LYM, PRE | Within | 46 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HCT, PRE | Above | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | RBC, D7 | Above | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | LYM, D7 | Below | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | RBC, D7 | Within | 56 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | LYM, D7 | Within | 38 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | LYM, D7 | Above | 22 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | WBC, D21 | Within | 61 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | LYM, D21 | Unknown | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | EOS, PRE | Above | 4 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | RBC, D7 | Below | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | LYM, D21 | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | BAS, D42 | Within | 55 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | RBC, D7 | Unknown | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | LYM, D7 | Unknown | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | EOS, D7 | Unknown | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | RBC, PRE | Above | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | MON, PRE | Unknown | 4 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | LYM, D42 | Below | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | WBC, D21 | Below | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | MON, PRE | Below | 10 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | MON, PRE | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | RBC, PRE | Within | 59 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | MON, PRE | Within | 52 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | EOS, D7 | Below | 7 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | LYM, D42 | Unknown | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | RBC, PRE | Below | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | RBC, PRE | Unknown | 4 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | LYM, D42 | Within | 36 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | MON, D7 | Below | 13 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HCT, D7 | Unknown | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | MON, D7 | Unknown | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | MON, D7 | Within | 48 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | WBC, D42 | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | PLC, D42 | Above | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | MON, D7 | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HCT, D42 | Unknown | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | LYM, D42 | Above | 18 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | WBC, D21 | Unknown | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | MON, D21 | Unknown | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | PLC, D42 | Within | 50 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | MON, D21 | Below | 19 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HCT, D7 | Below | 6 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | PLC, D42 | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | MON, D21 | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | MON, D42 | Below | 13 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | MON, D42 | Unknown | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | BAS, D42 | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | PLC, D42 | Unknown | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | MON, D21 | Within | 45 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | MON, D42 | Above | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | PLC, D21 | Above | 6 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | NEU, PRE | Below | 5 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | MON, D21 | Within | 46 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HGB, D7 | Within | 50 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | MON, D7 | Unknown | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | LYM, D42 | Unknown | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | LYM, D42 | Above | 22 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | BAS, PRE | Within | 60 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | RBC, D42 | Unknown | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | PLC, D21 | Below | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HGB, D7 | Unknown | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | BAS, PRE | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | EOS, D7 | Within | 42 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HGB, D21 | Below | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | MON, D7 | Within | 46 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | BAS, D7 | Unknown | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | LYM, D21 | Above | 26 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | PLC, D21 | Unknown | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | EOS, D7 | Unknown | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | BAS, D7 | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | WBC, D7 | Within | 53 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HGB, D7 | Above | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | RBC, PRE | Above | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | BAS, D7 | Within | 56 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | MON, D21 | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | PLC, D7 | Above | 8 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | BAS, D42 | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | BAS, D7 | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | BAS, D21 | Within | 54 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | EOS, D7 | Above | 6 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HGB, D21 | Unknown | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | EOS, PRE | Within | 53 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | BAS, D21 | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | WBC, D42 | Within | 51 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | PLC, D7 | Within | 49 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | EOS, D42 | Within | 46 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | BAS, D42 | Unknown | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | RBC, D21 | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | MON, PRE | Unknown | 5 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HCT, D7 | Below | 7 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HGB, D21 | Within | 48 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | PLC, D7 | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | WBC, D21 | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | BAS, D21 | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | EOS, D21 | Unknown | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | RBC, D21 | Within | 51 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | MON, D7 | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | PLC, D7 | Unknown | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HGB, D21 | Above | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | NEU, PRE | Below | 6 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | RBC, PRE | Within | 54 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | NEU, PRE | Within | 52 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | WBC, D7 | Below | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | PLC, D42 | Within | 47 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HGB, D42 | Unknown | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | NEU, PRE | Above | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | PLC, D42 | Unknown | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | PLC, PRE | Above | 6 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | MON, PRE | Below | 10 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | BAS, D42 | Within | 54 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HCT, PRE | Below | 8 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | BAS, PRE | Unknown | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | EOS, D21 | Below | 6 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HGB, D42 | Within | 43 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | PLC, PRE | Within | 49 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | BAS, D42 | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | BAS, PRE | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | RBC, D21 | Below | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | PLC, D21 | Above | 9 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HGB, D42 | Below | 8 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | MON, D42 | Within | 37 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | BAS, D21 | Unknown | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | NEU, D7 | Unknown | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | MON, D42 | Below | 17 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | PLC, PRE | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HGB, D42 | Above | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | NEU, D7 | Below | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | RBC, D21 | Unknown | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | MON, PRE | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HCT, PRE | Within | 44 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | NEU, D7 | Within | 52 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | EOS, D21 | Within | 42 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | PLC, PRE | Unknown | 8 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | WBC, D21 | Unknown | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | MON, PRE | Within | 48 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | NEU, D7 | Above | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | WBC, D7 | Unknown | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | LYM, PRE | Unknown | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | MON, D42 | Unknown | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | NEU, D21 | Unknown | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | LYM, PRE | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | NEU, D42 | Above | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | RBC, PRE | Below | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | NEU, D21 | Below | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | EOS, D21 | Above | 6 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HCT, D42 | Unknown | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | LYM, D42 | Below | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | NEU, D42 | Within | 48 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | EOS, D7 | Below | 8 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | NEU, D21 | Within | 51 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | EOS, D42 | Above | 5 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | LYM, PRE | Within | 38 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | EOS, D42 | Unknown | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | NEU, D21 | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | NEU, D42 | Below | 5 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | RBC, D7 | Above | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | NEU, D42 | Unknown | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | WBC, D21 | Within | 53 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | LYM, D7 | Unknown | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | MON, D21 | Unknown | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HCT, D42 | Below | 12 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | EOS, D42 | Below | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | WBC, PRE | Above | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | WBC, PRE | Within | 57 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | WBC, D7 | Above | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HCT, D7 | Within | 47 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | WBC, D42 | Below | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | LYM, PRE | Above | 21 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | RBC, D7 | Within | 52 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | RBC, PRE | Unknown | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | LYM, D7 | Below | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HCT, D7 | Above | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HCT, PRE | Above | 6 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | MON, D42 | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | MON, D21 | Below | 8 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HCT, D21 | Unknown | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | LYM, D7 | Within | 28 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | WBC, D42 | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HCT, D21 | Below | 10 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | RBC, D7 | Below | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HCT, PRE | Unknown | 5 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | WBC, PRE | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | LYM, D42 | Within | 31 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HCT, D21 | Within | 41 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | LYM, D7 | Above | 26 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | RBC, D42 | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | NEU, PRE | Unknown | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HCT, D21 | Above | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HCT, D42 | Above | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | PLC, D42 | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | LYM, D21 | Unknown | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HCT, D42 | Within | 41 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HGB, PRE | Within | 45 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | EOS, PRE | Unknown | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | EOS, PRE | Above | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | WBC, PRE | Unknown | 5 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | MON, D7 | Below | 10 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HGB, PRE | Above | 7 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | WBC, D42 | Unknown | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HCT, D7 | Unknown | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | LYM, D21 | Below | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HGB, PRE | Unknown | 6 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | PLC, D42 | Above | 6 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | RBC, D42 | Within | 52 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | RBC, D7 | Unknown | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HGB, PRE | Below | 5 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | PLC, D21 | Within | 43 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | EOS, PRE | Below | 5 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | RBC, D42 | Below | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | LYM, D21 | Within | 27 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | WBC, D21 | Below | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HGB, D7 | Below | 5 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | EOS, D21 | Above | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | EOS, D42 | Unknown | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | EOS, D42 | Below | 5 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | BAS, D42 | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | BAS, D42 | Within | 59 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | BAS, D42 | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | EOS, D42 | Within | 50 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | EOS, D42 | Above | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HCT, D21 | Above | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HCT, PRE | Unknown | 6 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | EOS, PRE | Unknown | 6 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | EOS, PRE | Below | 7 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | EOS, PRE | Within | 45 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HCT, PRE | Below | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HCT, PRE | Within | 48 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HCT, PRE | Above | 5 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | EOS, PRE | Above | 5 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | EOS, D7 | Unknown | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | EOS, D7 | Below | 8 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HCT, D7 | Unknown | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HCT, D7 | Below | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HCT, D42 | Within | 48 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | EOS, D7 | Within | 46 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | EOS, D7 | Above | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | EOS, D21 | Unknown | 6 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | EOS, D21 | Below | 5 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | EOS, D21 | Within | 47 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HCT, D42 | Unknown | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HCT, D42 | Below | 5 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HCT, D7 | Within | 48 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HCT, D7 | Above | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HCT, D21 | Unknown | 6 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HCT, D21 | Below | 7 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HCT, D21 | Within | 43 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HCT, D42 | Above | 6 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HGB, PRE | Within | 52 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HGB, D7 | Unknown | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HGB, PRE | Above | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HGB, PRE | Unknown | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HGB, PRE | Below | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HGB, D7 | Below | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HGB, D7 | Within | 51 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HGB, D7 | Above | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HGB, D21 | Unknown | 6 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HGB, D21 | Below | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HGB, D21 | Within | 47 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HGB, D21 | Above | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HGB, D42 | Unknown | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HGB, D42 | Within | 49 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HGB, D42 | Below | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HGB, D42 | Above | 6 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | LYM, PRE | Unknown | 6 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | LYM, PRE | Within | 35 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | LYM, PRE | Below | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | LYM, D7 | Unknown | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | LYM, D7 | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | LYM, D7 | Within | 33 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | LYM, D7 | Above | 23 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | LYM, PRE | Above | 21 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | LYM, D21 | Unknown | 6 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | LYM, D21 | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | LYM, D21 | Within | 36 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | LYM, D42 | Unknown | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | LYM, D42 | Above | 23 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | MON, PRE | Unknown | 6 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | MON, PRE | Below | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | MON, PRE | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | MON, PRE | Within | 53 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | MON, D7 | Unknown | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | LYM, D42 | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | LYM, D42 | Within | 36 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | MON, D7 | Below | 11 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | MON, D7 | Within | 44 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | MON, D7 | Above | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | MON, D21 | Unknown | 6 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | MON, D21 | Within | 43 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | MON, D21 | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | MON, D42 | Unknown | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | MON, D42 | Below | 21 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | MON, D42 | Within | 38 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | NEU, PRE | Unknown | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | BAS, PRE | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | BAS, PRE | Within | 56 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | BAS, PRE | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | BAS, D7 | Unknown | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | BAS, D7 | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | BAS, D7 | Within | 56 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | BAS, D21 | Within | 53 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | BAS, D21 | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | BAS, D42 | Unknown | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | MON, D42 | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | BAS, D21 | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | NEU, PRE | Below | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | NEU, PRE | Within | 51 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | NEU, PRE | Above | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | BAS, PRE | Unknown | 7 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | BAS, D7 | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | NEU, D7 | Unknown | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | NEU, D7 | Below | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | NEU, D7 | Within | 54 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | RBC, D42 | Within | 55 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | NEU, D7 | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | NEU, D21 | Unknown | 6 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | NEU, D21 | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | NEU, D21 | Below | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | NEU, D21 | Within | 50 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | NEU, D42 | Unknown | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | NEU, D42 | Below | 10 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | NEU, D42 | Within | 48 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | NEU, D42 | Above | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | PLC, PRE | Unknown | 8 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | PLC, PRE | Below | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | PLC, PRE | Within | 48 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | PLC, PRE | Above | 6 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | PLC, D7 | Unknown | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | PLC, D7 | Below | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | PLC, D7 | Within | 50 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | PLC, D7 | Above | 5 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | PLC, D21 | Unknown | 6 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | PLC, D21 | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | PLC, D21 | Within | 52 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | PLC, D21 | Above | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | PLC, D42 | Unknown | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | PLC, D42 | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | PLC, D42 | Within | 59 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | PLC, D42 | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | RBC, PRE | Unknown | 5 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | RBC, PRE | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | RBC, PRE | Within | 56 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | RBC, PRE | Above | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | RBC, D7 | Unknown | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | RBC, D7 | Below | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | RBC, D7 | Within | 54 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | RBC, D7 | Above | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | RBC, D21 | Unknown | 6 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | RBC, D21 | Below | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | RBC, D21 | Within | 49 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | RBC, D21 | Above | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | RBC, D42 | Unknown | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | RBC, D42 | Below | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | WBC, PRE | Unknown | 6 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | WBC, PRE | Below | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | RBC, D42 | Above | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | WBC, PRE | Within | 54 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | WBC, PRE | Above | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | WBC, D7 | Unknown | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | WBC, D7 | Below | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | WBC, D7 | Within | 55 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | WBC, D7 | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | WBC, D21 | Unknown | 6 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | WBC, D21 | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | WBC, D21 | Within | 53 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | WBC, D21 | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | WBC, D42 | Unknown | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | WBC, D42 | Below | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | WBC, D42 | Within | 56 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | WBC, D42 | Above | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | LYM, D21 | Above | 17 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | MON, D21 | Below | 10 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | BAS, D21 | Unknown | 6 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | NEU, PRE | Below | 6 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | WBC, D21 | Unknown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | PLC, D21 | Within | 57 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | NEU, PRE | Unknown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | MON, D42 | Within | 41 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HCT, D21 | Above | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | PLC, D21 | Above | 4 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | MON, D21 | Below | 13 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | MON, D21 | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | EOS, PRE | Above | 5 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | PLC, D42 | Unknown | 2 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | MON, D21 | Within | 48 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | MON, D42 | Unknown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HGB, D42 | Unknown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | PLC, D42 | Below | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | MON, D21 | Unknown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | LYM, D42 | Within | 40 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | WBC, D21 | Below | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | PLC, D42 | Within | 53 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | MON, D7 | Within | 51 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | MON, D7 | Below | 7 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HCT, PRE | Above | 4 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | PLC, D42 | Above | 2 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | MON, D7 | Unknown | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | MON, PRE | Above | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HCT, PRE | Within | 52 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | RBC, PRE | Unknown | 2 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | LYM, D42 | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | MON, PRE | Within | 46 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | LYM, D21 | Within | 38 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | RBC, PRE | Below | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | MON, PRE | Below | 15 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | MON, PRE | Unknown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | WBC, D21 | Within | 60 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | RBC, PRE | Within | 55 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | LYM, D42 | Above | 17 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | LYM, D42 | Unknown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HCT, PRE | Below | 5 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | RBC, PRE | Above | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | LYM, PRE | Above | 18 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | LYM, D21 | Below | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | EOS, PRE | Within | 51 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | RBC, D7 | Unknown | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | LYM, D21 | Unknown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | LYM, D7 | Within | 44 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | EOS, PRE | Below | 6 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | RBC, D7 | Below | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | LYM, D7 | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | LYM, D7 | Unknown | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | EOS, D42 | Below | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | RBC, D7 | Within | 54 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | LYM, D7 | Above | 14 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | LYM, PRE | Within | 43 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | RBC, D7 | Above | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | WBC, D21 | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | LYM, PRE | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | LYM, PRE | Unknown | 2 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | EOS, PRE | Unknown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | RBC, D21 | Unknown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HGB, D42 | Within | 50 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HGB, D42 | Above | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | EOS, D42 | Unknown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | RBC, D21 | Below | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HGB, D42 | Below | 4 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HGB, D21 | Within | 56 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | WBC, D42 | Unknown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | RBC, D21 | Within | 57 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HGB, D21 | Below | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HGB, D21 | Unknown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HCT, PRE | Unknown | 2 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | RBC, D21 | Above | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HGB, D7 | Above | 4 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HGB, D7 | Within | 52 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | EOS, D42 | Above | 7 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | RBC, D42 | Unknown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HGB, D7 | Below | 2 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HGB, PRE | Below | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | MON, D7 | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | RBC, D42 | Below | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HGB, D7 | Unknown | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HGB, PRE | Unknown | 2 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HGB, PRE | Above | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HGB, PRE | Within | 55 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | WBC, D42 | Below | 5 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HCT, D42 | Above | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HCT, D21 | Within | 53 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HCT, D21 | Below | 7 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | WBC, PRE | Unknown | 2 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | EOS, D42 | Within | 47 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | WBC, PRE | Below | 2 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HCT, D21 | Unknown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | BAS, D42 | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | RBC, D42 | Above | 2 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HCT, D7 | Above | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HCT, D7 | Within | 49 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HCT, D7 | Below | 6 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | LYM, D21 | Above | 22 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | WBC, PRE | Within | 59 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HCT, D42 | Below | 10 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | WBC, D42 | Within | 50 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | WBC, PRE | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HCT, D42 | Unknown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | EOS, D21 | Within | 51 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | BAS, D42 | Within | 57 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | WBC, D7 | Unknown | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | EOS, D21 | Below | 7 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | EOS, D21 | Unknown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | NEU, D42 | Unknown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | NEU, D21 | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | BAS, D42 | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | NEU, D42 | Below | 13 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | NEU, D21 | Within | 59 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | NEU, D21 | Below | 2 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | WBC, D7 | Below | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | NEU, D42 | Within | 40 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | RBC, D42 | Within | 52 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | NEU, D21 | Unknown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | EOS, D7 | Above | 7 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | NEU, D42 | Above | 4 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | NEU, D7 | Above | 2 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | NEU, D7 | Within | 50 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | EOS, D7 | Within | 45 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | PLC, PRE | Unknown | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | NEU, D7 | Below | 6 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | NEU, D7 | Unknown | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | EOS, D21 | Above | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | PLC, PRE | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | BAS, D7 | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | BAS, PRE | Unknown | 2 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | WBC, D7 | Within | 56 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | PLC, PRE | Within | 56 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | MON, D42 | Below | 16 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | NEU, PRE | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | EOS, D7 | Below | 6 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | PLC, PRE | Above | 4 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | NEU, PRE | Within | 56 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | MON, D42 | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HCT, D42 | Within | 46 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | PLC, D7 | Unknown | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | BAS, D21 | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | BAS, D21 | Unknown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | WBC, D42 | Above | 2 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | PLC, D7 | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | BAS, D42 | Unknown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | BAS, D21 | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | WBC, D7 | Above | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | PLC, D7 | Within | 51 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | BAS, D21 | Within | 61 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | BAS, D7 | Within | 58 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HCT, D7 | Unknown | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | PLC, D7 | Above | 7 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | BAS, D7 | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | BAS, D7 | Unknown | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | EOS, D7 | Unknown | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | PLC, D21 | Unknown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | BAS, PRE | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | BAS, PRE | Within | 61 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | HGB, D21 | Above | 2 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | PLC, D21 | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - First Analysis | BAS, PRE | Below | 0 Participants |
Secondary
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis
Among haematological parameters assessed were basophils \[BAS\], eosinophils \[EOS\], hematocrit \[HCT\], hemoglobin level \[HGB\], lymphocytes \[LYM\], monocytes \[MON\], neutrophils \[NEU\], platelet count \[PLC\], red blood cells \[RBC\] and white blood cells \[WBC\]. Haematological laboratory values were unknown, below, within or above the laboratory reference range defined for the specified time point and laboratory parameter.
Time frame: At Day 0 (PRE), at Day 7 and at Day 21
Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | MON, D21 | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | RBC, D7 | Within | 56 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | LYM, PRE | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HGB, PRE | Below | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | BAS, D7 | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | RBC, D7 | Unknown | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | LYM, PRE | Within | 27 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | NEU, D7 | Within | 50 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | MON, D7 | Below | 13 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HCT, D21 | Unknown | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | LYM, PRE | Above | 8 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HCT, D7 | Below | 6 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | MON, D21 | Within | 45 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | LYM, D7 | Unknown | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | MON, D7 | Within | 48 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | WBC, D21 | Below | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | LYM, D21 | Within | 43 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | LYM, D7 | Below | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | BAS, PRE | Within | 35 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | WBC, D7 | Above | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | RBC, PRE | Above | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | LYM, D7 | Within | 38 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HCT, D21 | Below | 7 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | BAS, D7 | Within | 61 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | RBC, PRE | Within | 34 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | LYM, D7 | Above | 22 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | MON, D7 | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HCT, D21 | Within | 54 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | RBC, PRE | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | LYM, D21 | Unknown | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | NEU, D21 | Unknown | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | NEU, PRE | Above | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | MON, D21 | Below | 19 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | LYM, D21 | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | MON, D21 | Unknown | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | LYM, D21 | Above | 21 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | RBC, PRE | Unknown | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | NEU, D21 | Within | 62 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HGB, PRE | Within | 31 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | BAS, D7 | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HCT, D7 | Above | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | NEU, D21 | Above | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HCT, D7 | Unknown | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | RBC, D21 | Within | 62 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | PLC, D21 | Above | 6 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | PLC, PRE | Unknown | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HGB, PRE | Above | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | WBC, D21 | Above | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HCT, PRE | Above | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | PLC, PRE | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | MON, PRE | Unknown | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | WBC, D7 | Within | 54 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | NEU, D7 | Below | 10 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | PLC, PRE | Within | 33 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HGB, D7 | Unknown | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | BAS, D21 | Unknown | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | PLC, D21 | Within | 57 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | PLC, PRE | Above | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | WBC, PRE | Unknown | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HGB, PRE | Unknown | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | NEU, PRE | Within | 31 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | RBC, D21 | Below | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | WBC, PRE | Below | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HGB, D7 | Below | 4 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | BAS, PRE | Unknown | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | PLC, D21 | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | WBC, PRE | Within | 33 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | EOS, PRE | Above | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | EOS, D7 | Below | 7 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | MON, PRE | Below | 4 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | BAS, PRE | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | NEU, PRE | Below | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | EOS, PRE | Within | 28 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HGB, D7 | Within | 55 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | BAS, D21 | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | PLC, D21 | Unknown | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | BAS, PRE | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HCT, D7 | Within | 52 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | MON, PRE | Within | 31 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | EOS, D7 | Unknown | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HGB, D7 | Above | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | NEU, D7 | Above | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | PLC, D7 | Above | 9 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | WBC, D7 | Below | 6 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | PLC, D7 | Within | 51 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | EOS, D7 | Within | 50 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | WBC, D21 | Within | 61 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | BAS, D21 | Within | 64 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | RBC, D21 | Unknown | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | EOS, D7 | Above | 4 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HGB, D21 | Unknown | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | NEU, PRE | Unknown | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | WBC, D21 | Unknown | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | EOS, D21 | Unknown | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | MON, PRE | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HGB, D21 | Below | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | PLC, D7 | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | EOS, D21 | Below | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | WBC, PRE | Above | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | BAS, D7 | Unknown | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HGB, D21 | Within | 55 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | EOS, D21 | Within | 54 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HCT, D21 | Above | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | BAS, D21 | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | RBC, D7 | Below | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | EOS, D21 | Above | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | RBC, D7 | Above | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HGB, D21 | Above | 4 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | PLC, D7 | Unknown | 6 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HCT, PRE | Unknown | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | EOS, PRE | Below | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | MON, D7 | Unknown | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | NEU, D21 | Below | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HCT, PRE | Below | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | NEU, D7 | Unknown | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | WBC, D7 | Unknown | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | LYM, PRE | Unknown | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HCT, PRE | Within | 31 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | RBC, D21 | Above | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | EOS, PRE | Unknown | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | LYM, D21 | Unknown | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HCT, PRE | Above | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | MON, PRE | Within | 26 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | EOS, PRE | Unknown | 6 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | NEU, D7 | Above | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HCT, D7 | Unknown | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HCT, D7 | Below | 7 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | WBC, PRE | Above | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | NEU, D7 | Within | 52 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HCT, D7 | Within | 47 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | NEU, D7 | Below | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HCT, D7 | Above | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HCT, D21 | Within | 41 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HCT, D21 | Below | 10 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HCT, D21 | Unknown | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | BAS, PRE | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | NEU, D7 | Unknown | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | LYM, D21 | Below | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HCT, D21 | Above | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | NEU, PRE | Above | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | LYM, D21 | Within | 27 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | LYM, D21 | Above | 26 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | WBC, PRE | Within | 30 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | NEU, PRE | Within | 27 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | MON, PRE | Unknown | 6 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HGB, PRE | Unknown | 6 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | NEU, PRE | Unknown | 6 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | MON, PRE | Below | 5 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | NEU, PRE | Below | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | MON, PRE | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | MON, D21 | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | MON, D7 | Unknown | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | MON, D21 | Within | 46 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | MON, D7 | Below | 10 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HGB, PRE | Below | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | MON, D7 | Within | 46 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | MON, D21 | Below | 8 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | MON, D7 | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | RBC, D21 | Within | 51 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | MON, D21 | Unknown | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HGB, PRE | Within | 25 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | BAS, PRE | Within | 31 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HGB, PRE | Above | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | EOS, PRE | Below | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | RBC, D21 | Below | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HGB, D7 | Unknown | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | WBC, D21 | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HGB, D7 | Below | 5 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | RBC, D21 | Unknown | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HGB, D7 | Within | 50 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | BAS, PRE | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | RBC, D21 | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HGB, D7 | Above | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HGB, D21 | Unknown | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | RBC, D7 | Above | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HGB, D21 | Below | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HGB, D21 | Within | 48 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | BAS, D7 | Unknown | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HGB, D21 | Above | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | WBC, D21 | Within | 53 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | RBC, D7 | Within | 52 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | LYM, PRE | Unknown | 6 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | WBC, D7 | Above | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | LYM, PRE | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | LYM, PRE | Within | 23 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | BAS, D7 | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | RBC, D7 | Unknown | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | LYM, PRE | Above | 8 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | RBC, PRE | Within | 29 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | LYM, D7 | Unknown | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | RBC, PRE | Above | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | LYM, D7 | Below | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | LYM, D7 | Within | 28 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | LYM, D7 | Above | 26 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | BAS, D7 | Within | 56 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | WBC, D21 | Unknown | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | RBC, PRE | Below | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | NEU, D21 | Below | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | WBC, D7 | Within | 53 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | NEU, D21 | Within | 51 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | RBC, PRE | Unknown | 6 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | NEU, D21 | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | BAS, D7 | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | PLC, PRE | Unknown | 7 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | PLC, D21 | Above | 9 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | PLC, PRE | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | PLC, D21 | Within | 43 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | PLC, PRE | Within | 26 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | WBC, PRE | Unknown | 6 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | BAS, D21 | Unknown | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | PLC, D21 | Below | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | WBC, PRE | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | EOS, D7 | Below | 8 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | WBC, D7 | Below | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | PLC, D21 | Unknown | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | EOS, PRE | Within | 28 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | EOS, PRE | Above | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | BAS, D21 | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | PLC, D7 | Above | 8 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | EOS, D7 | Unknown | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | BAS, PRE | Unknown | 6 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | EOS, D7 | Within | 42 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | PLC, D7 | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | EOS, D7 | Above | 6 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | BAS, D21 | Within | 54 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | PLC, D7 | Within | 49 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | EOS, D21 | Unknown | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | WBC, D21 | Below | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | EOS, D21 | Below | 6 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | WBC, D7 | Unknown | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | PLC, D7 | Unknown | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | EOS, D21 | Within | 42 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | PLC, PRE | Above | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | EOS, D21 | Above | 6 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | BAS, D21 | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HCT, PRE | Unknown | 6 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | RBC, D7 | Below | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HCT, PRE | Below | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | NEU, D21 | Unknown | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HCT, PRE | Within | 24 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | LYM, PRE | Unknown | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | WBC, D21 | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | WBC, D21 | Within | 52 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | BAS, PRE | Unknown | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | BAS, PRE | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | BAS, PRE | Within | 24 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | BAS, PRE | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | BAS, D7 | Unknown | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | BAS, D7 | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | BAS, D7 | Within | 56 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | BAS, D7 | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | BAS, D21 | Unknown | 6 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | BAS, D21 | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | BAS, D21 | Within | 52 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | BAS, D21 | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | EOS, PRE | Unknown | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HCT, D21 | Within | 42 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HCT, D21 | Above | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HGB, PRE | Unknown | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HGB, PRE | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HGB, PRE | Within | 22 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HGB, PRE | Above | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HGB, D7 | Unknown | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HGB, D7 | Below | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HGB, D7 | Within | 51 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HGB, D7 | Above | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HGB, D21 | Unknown | 6 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HGB, D21 | Below | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HGB, D21 | Within | 46 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HGB, D21 | Above | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | WBC, D21 | Unknown | 6 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | LYM, PRE | Below | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | LYM, PRE | Within | 17 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | LYM, D7 | Unknown | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | LYM, D7 | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | LYM, D7 | Within | 33 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | LYM, D7 | Above | 23 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | LYM, D21 | Unknown | 6 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | NEU, D21 | Below | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | NEU, D21 | Within | 49 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | NEU, D21 | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | PLC, PRE | Unknown | 5 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | PLC, PRE | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | PLC, PRE | Within | 20 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | WBC, PRE | Unknown | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | WBC, PRE | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | EOS, PRE | Below | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | EOS, PRE | Within | 20 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | EOS, PRE | Above | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | EOS, D7 | Unknown | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | EOS, D7 | Below | 8 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | EOS, D7 | Within | 46 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | EOS, D7 | Above | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | EOS, D21 | Unknown | 6 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | EOS, D21 | Below | 5 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | EOS, D21 | Within | 46 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | EOS, D21 | Above | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HCT, PRE | Unknown | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HCT, PRE | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HCT, PRE | Within | 22 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HCT, PRE | Above | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HCT, D7 | Unknown | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HCT, D7 | Below | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HCT, D7 | Within | 48 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HCT, D7 | Above | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HCT, D21 | Unknown | 6 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | MON, PRE | Within | 21 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HCT, D21 | Below | 7 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | LYM, D21 | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | LYM, D21 | Within | 35 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | LYM, D21 | Above | 17 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | MON, PRE | Unknown | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | MON, PRE | Below | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | MON, PRE | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | MON, D7 | Unknown | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | NEU, PRE | Within | 21 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | MON, D7 | Below | 11 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | MON, D7 | Within | 44 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | MON, D7 | Above | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | MON, D21 | Unknown | 6 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | MON, D21 | Below | 10 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | NEU, PRE | Unknown | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | MON, D21 | Within | 42 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | MON, D21 | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | NEU, PRE | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | NEU, PRE | Above | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | NEU, D7 | Unknown | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | NEU, D7 | Below | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | NEU, D7 | Within | 54 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | NEU, D7 | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | NEU, D21 | Unknown | 6 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | PLC, PRE | Above | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | PLC, D7 | Unknown | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | PLC, D7 | Below | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | PLC, D7 | Within | 50 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | PLC, D7 | Above | 5 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | PLC, D21 | Unknown | 6 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | PLC, D21 | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | PLC, D21 | Within | 51 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | PLC, D21 | Above | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | RBC, PRE | Unknown | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | RBC, D7 | Below | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | RBC, PRE | Within | 23 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | RBC, PRE | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | RBC, PRE | Above | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | RBC, D7 | Unknown | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | RBC, D7 | Within | 54 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | RBC, D7 | Above | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | RBC, D21 | Unknown | 6 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | RBC, D21 | Below | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | RBC, D21 | Within | 48 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | WBC, PRE | Within | 22 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | WBC, PRE | Above | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | WBC, D7 | Unknown | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | WBC, D7 | Below | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | WBC, D7 | Within | 55 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | WBC, D7 | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | WBC, D21 | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | LYM, PRE | Above | 6 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | RBC, D21 | Above | 2 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HCT, PRE | Within | 24 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HCT, PRE | Below | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | BAS, D21 | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | NEU, D21 | Unknown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HCT, PRE | Unknown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | EOS, D21 | Above | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | EOS, D21 | Within | 51 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | BAS, D21 | Within | 61 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | PLC, PRE | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | EOS, D21 | Below | 7 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | PLC, D7 | Unknown | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | EOS, D21 | Unknown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | WBC, D21 | Within | 60 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | EOS, D7 | Above | 7 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | WBC, D7 | Unknown | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | EOS, D7 | Within | 45 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | PLC, D7 | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | EOS, D7 | Below | 6 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | EOS, D7 | Unknown | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | BAS, D21 | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | PLC, D7 | Within | 51 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | EOS, PRE | Above | 4 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | PLC, D7 | Above | 7 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | BAS, D21 | Unknown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | EOS, PRE | Within | 20 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | EOS, PRE | Below | 4 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | WBC, D21 | Below | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | PLC, D21 | Unknown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | WBC, PRE | Below | 2 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | WBC, PRE | Unknown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | WBC, D7 | Below | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | PLC, D21 | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | PLC, PRE | Within | 27 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | BAS, D7 | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | PLC, PRE | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | PLC, D21 | Within | 57 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | PLC, PRE | Unknown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | NEU, D21 | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | PLC, D21 | Above | 4 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | BAS, D7 | Within | 58 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | NEU, D21 | Within | 59 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | WBC, D21 | Unknown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | RBC, PRE | Unknown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | NEU, D21 | Below | 2 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | LYM, D21 | Unknown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | LYM, D7 | Above | 14 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | RBC, PRE | Below | 2 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | WBC, D7 | Within | 56 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | LYM, D7 | Within | 44 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | BAS, D7 | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | BAS, D7 | Unknown | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | LYM, D7 | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | RBC, PRE | Within | 25 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HGB, D21 | Below | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | LYM, D7 | Unknown | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | LYM, PRE | Above | 6 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | LYM, PRE | Within | 22 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | LYM, PRE | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | WBC, D7 | Above | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | RBC, PRE | Above | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | RBC, D7 | Below | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | LYM, PRE | Unknown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HGB, D21 | Above | 2 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | BAS, PRE | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | RBC, D7 | Within | 54 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HGB, D21 | Within | 56 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HGB, D21 | Unknown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | BAS, PRE | Within | 28 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | RBC, D7 | Above | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HGB, D7 | Above | 4 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HGB, D7 | Within | 52 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HGB, D7 | Below | 2 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | RBC, D21 | Above | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | RBC, D21 | Unknown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HGB, D7 | Unknown | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HGB, PRE | Above | 2 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | WBC, D21 | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | RBC, D21 | Below | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HGB, PRE | Within | 23 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HGB, PRE | Below | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | MON, D21 | Unknown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | MON, D7 | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | MON, D7 | Within | 51 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | RBC, D7 | Unknown | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | MON, D21 | Below | 13 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | MON, D7 | Below | 7 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | RBC, D21 | Within | 57 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | NEU, PRE | Within | 25 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HGB, PRE | Unknown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | MON, D21 | Within | 48 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | MON, D7 | Unknown | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | MON, PRE | Above | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HCT, D21 | Above | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | MON, D21 | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | MON, PRE | Within | 22 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | MON, PRE | Below | 5 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | BAS, PRE | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | NEU, PRE | Below | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | MON, PRE | Unknown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | LYM, D21 | Above | 22 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | LYM, D21 | Within | 38 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | LYM, D21 | Below | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | WBC, PRE | Within | 26 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | NEU, PRE | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HCT, D21 | Below | 7 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | NEU, PRE | Unknown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HCT, D21 | Within | 53 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | NEU, D7 | Unknown | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HCT, D7 | Above | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HCT, D21 | Unknown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | EOS, PRE | Unknown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | NEU, D7 | Below | 6 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HCT, D7 | Within | 49 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HCT, D7 | Below | 6 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | BAS, PRE | Unknown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | NEU, D7 | Within | 50 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HCT, D7 | Unknown | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | HCT, PRE | Above | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | WBC, PRE | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis | NEU, D7 | Above | 2 Participants |
Secondary
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis
Among haematological parameters assessed were basophils \[BAS\], eosinophils \[EOS\], hematocrit \[HCT\], hemoglobin level \[HGB\], lymphocytes \[LYM\], monocytes \[MON\], neutrophils \[NEU\], platelet count \[PLC\], red blood cells \[RBC\] and white blood cells \[WBC\], Haematological laboratory values were unknown, below, within or above the laboratory reference range defined for the specified time point and laboratory parameter.
Time frame: At Day 0 (PRE), at Day 7 and at Day 21
Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | BAS, D7 | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | BAS, D7 | Within | 61 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | PLC, D7 | Unknown | 6 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | MON, PRE | Below | 12 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | BAS, D7 | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | BAS, D7 | Unknown | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | BAS, PRE | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | PLC, D7 | Above | 9 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | LYM, D7 | Unknown | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | BAS, PRE | Within | 65 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | BAS, PRE | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | PLC, D21 | Unknown | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | LYM, PRE | Above | 18 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | BAS, PRE | Unknown | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | WBC, D42 | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | PLC, D21 | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | MON, D42 | Unknown | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | WBC, D42 | Within | 52 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | WBC, D42 | Below | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | PLC, D21 | Within | 57 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | PLC, D7 | Within | 51 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | WBC, D42 | Unknown | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | WBC, D21 | Above | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | PLC, D21 | Above | 6 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | LYM, PRE | Within | 47 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | WBC, D21 | Within | 61 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | NEU, PRE | Below | 6 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | LYM, PRE | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | WBC, D21 | Below | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | RBC, D7 | Below | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | MON, D7 | Within | 48 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | WBC, D21 | Unknown | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | WBC, D7 | Above | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | RBC, D7 | Within | 56 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | LYM, PRE | Unknown | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | WBC, D7 | Within | 54 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | WBC, D7 | Below | 6 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | RBC, D7 | Above | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HGB, D42 | Above | 4 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | WBC, D7 | Unknown | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | WBC, PRE | Above | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | RBC, D21 | Unknown | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | MON, D42 | Within | 41 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | WBC, PRE | Within | 59 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | WBC, PRE | Below | 4 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | RBC, D21 | Below | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | MON, PRE | Unknown | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | WBC, PRE | Unknown | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | RBC, D42 | Above | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | RBC, D21 | Within | 62 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HGB, D42 | Within | 49 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | RBC, D42 | Within | 51 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | RBC, D42 | Below | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | RBC, D21 | Above | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HGB, D42 | Below | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | RBC, D42 | Unknown | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | MON, D42 | Above | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | LYM, D42 | Above | 18 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HGB, D42 | Unknown | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HGB, D21 | Above | 4 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | NEU, PRE | Within | 57 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | PLC, D42 | Unknown | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HGB, D21 | Within | 55 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HGB, D21 | Below | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | NEU, PRE | Above | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | MON, D7 | Below | 13 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HGB, D21 | Unknown | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HGB, D7 | Above | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | NEU, D7 | Unknown | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | NEU, PRE | Unknown | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | RBC, PRE | Within | 62 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HGB, D7 | Within | 55 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | NEU, D7 | Above | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HGB, D7 | Below | 4 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HGB, D7 | Unknown | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | NEU, D7 | Below | 10 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | LYM, D42 | Below | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HGB, PRE | Above | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HGB, PRE | Within | 59 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | NEU, D7 | Within | 50 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | BAS, D21 | Within | 64 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HGB, PRE | Below | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HGB, PRE | Unknown | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | LYM, D42 | Unknown | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HCT, D42 | Above | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HCT, D42 | Within | 45 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | NEU, D21 | Unknown | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | LYM, D21 | Above | 21 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | MON, D42 | Below | 13 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HCT, D42 | Below | 9 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | NEU, D21 | Below | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | EOS, D21 | Within | 54 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HCT, D42 | Unknown | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HCT, D21 | Above | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | NEU, D21 | Within | 62 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | LYM, D21 | Within | 43 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HCT, D21 | Within | 54 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HCT, D21 | Below | 7 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | NEU, D21 | Above | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HCT, D7 | Within | 52 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | MON, D21 | Within | 45 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | MON, D21 | Below | 19 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | NEU, D42 | Unknown | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | MON, D7 | Unknown | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | MON, D21 | Unknown | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HCT, D7 | Below | 6 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | NEU, D42 | Below | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | MON, PRE | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HCT, D7 | Unknown | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HCT, PRE | Above | 4 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | NEU, D42 | Within | 50 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | NEU, D42 | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | LYM, D42 | Within | 36 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HCT, PRE | Within | 56 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HCT, PRE | Below | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | PLC, PRE | Unknown | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | LYM, D21 | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HCT, PRE | Unknown | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | PLC, D7 | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | EOS, D42 | Above | 9 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | EOS, D42 | Within | 42 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | PLC, D42 | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | LYM, D21 | Unknown | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | EOS, D42 | Below | 4 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | EOS, D42 | Unknown | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | PLC, D42 | Within | 50 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HCT, D7 | Above | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | EOS, D21 | Above | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | EOS, D21 | Below | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | PLC, D42 | Above | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | EOS, D21 | Unknown | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | EOS, D7 | Above | 4 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | RBC, PRE | Unknown | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | MON, D7 | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | EOS, D7 | Within | 50 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | EOS, D7 | Below | 7 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | RBC, PRE | Below | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | LYM, D7 | Above | 22 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | EOS, D7 | Unknown | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | EOS, PRE | Above | 4 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | LYM, D7 | Within | 38 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | EOS, PRE | Within | 49 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | EOS, PRE | Below | 12 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | RBC, PRE | Above | 2 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HCT, D21 | Unknown | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | EOS, PRE | Unknown | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | BAS, D42 | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | RBC, D7 | Unknown | 5 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | MON, PRE | Within | 53 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | BAS, D42 | Within | 55 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | BAS, D42 | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | BAS, D42 | Unknown | 3 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | BAS, D21 | Above | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | PLC, PRE | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | LYM, D7 | Below | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | BAS, D21 | Below | 0 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | BAS, D21 | Unknown | 1 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | PLC, PRE | Within | 54 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | PLC, PRE | Above | 11 Participants |
| Arepanrix/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | MON, D21 | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HCT, D42 | Below | 24 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | NEU, D42 | Within | 96 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | PLC, PRE | Within | 107 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | PLC, D7 | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | PLC, D7 | Within | 95 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | PLC, D42 | Above | 15 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | BAS, D7 | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HGB, D7 | Within | 98 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | LYM, D42 | Unknown | 5 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | MON, D7 | Unknown | 5 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HCT, D7 | Above | 7 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HCT, D21 | Unknown | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | MON, D21 | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | MON, D42 | Unknown | 5 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | MON, D42 | Below | 22 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | MON, D42 | Within | 87 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | MON, D42 | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | NEU, PRE | Within | 109 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | NEU, PRE | Above | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | NEU, PRE | Unknown | 5 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | NEU, D7 | Unknown | 5 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | NEU, D7 | Below | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | NEU, D7 | Within | 109 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | NEU, D7 | Above | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | NEU, D21 | Unknown | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | NEU, D21 | Below | 10 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | NEU, D21 | Within | 100 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | NEU, D21 | Above | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | NEU, D42 | Unknown | 5 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | NEU, D42 | Below | 12 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | NEU, D42 | Above | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | PLC, PRE | Unknown | 6 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | PLC, D42 | Unknown | 6 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | PLC, D42 | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | PLC, D42 | Within | 93 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | RBC, PRE | Unknown | 6 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | RBC, PRE | Below | 6 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | RBC, PRE | Within | 113 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | RBC, PRE | Above | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | RBC, D7 | Unknown | 5 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | PLC, PRE | Below | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | PLC, PRE | Above | 12 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | PLC, D7 | Unknown | 5 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | PLC, D7 | Above | 20 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | PLC, D21 | Unknown | 7 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | PLC, D21 | Below | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | PLC, D21 | Within | 89 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | PLC, D21 | Above | 18 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | NEU, PRE | Below | 9 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | RBC, D7 | Below | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | RBC, D7 | Within | 110 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | RBC, D7 | Above | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | RBC, D21 | Unknown | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | RBC, D21 | Below | 5 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | RBC, D21 | Within | 107 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | RBC, D21 | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | RBC, D42 | Unknown | 6 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | RBC, D42 | Below | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | RBC, D42 | Within | 103 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | RBC, D42 | Above | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | WBC, PRE | Unknown | 5 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | WBC, PRE | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | WBC, PRE | Within | 118 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | WBC, PRE | Above | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | WBC, D7 | Unknown | 5 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | WBC, D7 | Below | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | WBC, D7 | Within | 110 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | WBC, D7 | Above | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | WBC, D21 | Unknown | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | WBC, D21 | Below | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | WBC, D21 | Within | 107 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | WBC, D21 | Above | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | WBC, D42 | Unknown | 5 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | WBC, D42 | Below | 7 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | WBC, D42 | Within | 102 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | WBC, D42 | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | BAS, PRE | Unknown | 5 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | BAS, PRE | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | BAS, PRE | Within | 121 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | BAS, PRE | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | BAS, D7 | Unknown | 5 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | BAS, D7 | Within | 115 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | BAS, D7 | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | BAS, D21 | Unknown | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | BAS, D21 | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | BAS, D21 | Within | 112 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | BAS, D21 | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | BAS, D42 | Unknown | 5 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | BAS, D42 | Below | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | BAS, D42 | Within | 109 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | BAS, D42 | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | EOS, PRE | Unknown | 5 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | EOS, PRE | Below | 11 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | EOS, PRE | Within | 100 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | EOS, PRE | Above | 10 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | EOS, D7 | Unknown | 5 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | EOS, D7 | Below | 20 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | EOS, D7 | Within | 84 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | EOS, D7 | Above | 11 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | EOS, D21 | Unknown | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | EOS, D21 | Below | 14 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | EOS, D21 | Within | 90 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | EOS, D21 | Above | 8 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | EOS, D42 | Unknown | 5 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | EOS, D42 | Below | 8 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | EOS, D42 | Within | 94 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | EOS, D42 | Above | 7 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HCT, PRE | Unknown | 6 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HCT, PRE | Below | 22 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HCT, PRE | Within | 90 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HCT, PRE | Above | 8 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HCT, D7 | Unknown | 5 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HCT, D7 | Below | 26 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HCT, D7 | Within | 82 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | MON, D21 | Unknown | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | MON, D21 | Below | 18 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | MON, D21 | Within | 94 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HCT, D21 | Below | 32 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HCT, D21 | Within | 77 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HCT, D21 | Above | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HCT, D42 | Unknown | 6 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HCT, D42 | Within | 80 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HCT, D42 | Above | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HGB, PRE | Unknown | 5 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HGB, PRE | Below | 15 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HGB, PRE | Within | 96 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HGB, PRE | Above | 10 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HGB, D7 | Unknown | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HGB, D7 | Below | 9 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HGB, D7 | Above | 9 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HGB, D21 | Unknown | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HGB, D21 | Below | 10 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HGB, D21 | Within | 97 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HGB, D21 | Above | 5 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HGB, D42 | Unknown | 5 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HGB, D42 | Below | 13 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HGB, D42 | Within | 90 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HGB, D42 | Above | 6 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | LYM, PRE | Unknown | 5 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | LYM, PRE | Below | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | LYM, PRE | Within | 83 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | LYM, PRE | Above | 37 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | LYM, D7 | Unknown | 5 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | LYM, D7 | Below | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | LYM, D7 | Within | 73 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | LYM, D7 | Above | 39 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | LYM, D21 | Unknown | 4 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | LYM, D21 | Below | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | LYM, D21 | Within | 72 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | LYM, D21 | Above | 38 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | LYM, D42 | Below | 3 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | LYM, D42 | Within | 75 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | LYM, D42 | Above | 31 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | MON, PRE | Unknown | 5 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | MON, PRE | Below | 26 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | MON, PRE | Within | 95 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | MON, PRE | Above | 0 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | MON, D7 | Below | 19 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | MON, D7 | Within | 96 Participants |
| Arepanrix/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | MON, D7 | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HCT, D42 | Below | 5 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | PLC, PRE | Above | 6 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | PLC, D42 | Within | 59 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | MON, D7 | Within | 44 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HCT, D42 | Within | 48 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | EOS, D21 | Above | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | NEU, D7 | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | BAS, D7 | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HCT, D42 | Above | 6 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | BAS, D21 | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | EOS, PRE | Below | 7 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | LYM, D7 | Above | 23 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HGB, PRE | Unknown | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | EOS, D42 | Unknown | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | NEU, D7 | Within | 54 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | LYM, D42 | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HGB, PRE | Below | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | PLC, PRE | Below | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | PLC, D42 | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | RBC, PRE | Within | 58 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HGB, PRE | Within | 53 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | EOS, D42 | Below | 5 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | NEU, D7 | Below | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | PLC, PRE | Unknown | 5 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HGB, PRE | Above | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | EOS, PRE | Within | 48 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | MON, D7 | Below | 11 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | EOS, D42 | Within | 50 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HGB, D7 | Unknown | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | LYM, PRE | Above | 22 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | NEU, D7 | Unknown | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | PLC, D21 | Above | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HGB, D7 | Below | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | PLC, D42 | Unknown | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | NEU, PRE | Unknown | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HGB, D7 | Within | 51 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | MON, PRE | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | EOS, D42 | Above | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | BAS, D42 | Unknown | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HGB, D7 | Above | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | PLC, D7 | Below | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | NEU, PRE | Above | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | LYM, D42 | Above | 23 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HGB, D21 | Unknown | 6 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | LYM, D21 | Unknown | 6 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HCT, PRE | Unknown | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | EOS, PRE | Above | 5 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HGB, D21 | Below | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | BAS, D21 | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | NEU, PRE | Within | 52 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | RBC, PRE | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HGB, D21 | Within | 47 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HCT, PRE | Below | 5 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | LYM, D7 | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | NEU, D42 | Above | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HGB, D21 | Above | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | LYM, D42 | Within | 36 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | RBC, D21 | Above | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | LYM, D21 | Within | 36 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | RBC, D42 | Unknown | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | EOS, D7 | Unknown | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HCT, PRE | Within | 50 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | MON, D42 | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | RBC, D42 | Below | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | BAS, D42 | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | RBC, D21 | Within | 49 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | MON, PRE | Unknown | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | RBC, D42 | Within | 55 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | BAS, D7 | Within | 56 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | RBC, D7 | Unknown | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HGB, D42 | Unknown | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | RBC, D42 | Above | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | EOS, D7 | Below | 8 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | RBC, D21 | Below | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | NEU, D42 | Below | 10 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | WBC, PRE | Unknown | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | LYM, D21 | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HCT, D7 | Unknown | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | MON, D21 | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | WBC, PRE | Below | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | RBC, PRE | Unknown | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | RBC, D21 | Unknown | 6 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | BAS, D42 | Within | 59 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | WBC, PRE | Within | 57 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HCT, D7 | Below | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | EOS, D7 | Within | 46 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HGB, D42 | Below | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | WBC, PRE | Above | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HCT, PRE | Above | 5 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | RBC, D7 | Above | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HCT, D7 | Within | 48 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | WBC, D7 | Unknown | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | MON, D42 | Unknown | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | MON, D7 | Above | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | MON, D42 | Within | 38 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | WBC, D7 | Below | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | BAS, D21 | Within | 53 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | RBC, D7 | Within | 54 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | NEU, D42 | Unknown | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | WBC, D7 | Within | 55 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | PLC, PRE | Within | 51 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | MON, D21 | Unknown | 6 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HGB, D42 | Within | 49 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | WBC, D7 | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | MON, PRE | Within | 53 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | RBC, D7 | Below | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | EOS, D7 | Above | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | WBC, D21 | Unknown | 6 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | EOS, PRE | Unknown | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | NEU, PRE | Below | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | MON, D21 | Below | 10 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | WBC, D21 | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | BAS, D42 | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | NEU, D21 | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | NEU, D42 | Within | 48 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | WBC, D21 | Within | 53 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | MON, D7 | Unknown | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | MON, D21 | Within | 43 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HGB, D42 | Above | 6 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | WBC, D21 | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HCT, D21 | Unknown | 6 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | PLC, D21 | Within | 52 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | PLC, D42 | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | WBC, D42 | Unknown | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | LYM, D7 | Within | 33 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | LYM, D21 | Above | 17 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | MON, D42 | Below | 21 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | WBC, D42 | Below | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HCT, D21 | Below | 7 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | PLC, D21 | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | MON, PRE | Below | 7 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | WBC, D42 | Within | 56 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | EOS, D21 | Unknown | 6 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | NEU, D21 | Within | 50 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | LYM, PRE | Unknown | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | WBC, D42 | Above | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | LYM, PRE | Within | 37 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HCT, D21 | Within | 43 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | PLC, D21 | Unknown | 6 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | RBC, PRE | Above | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | BAS, PRE | Unknown | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | LYM, D7 | Unknown | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | EOS, D21 | Below | 5 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HCT, D21 | Above | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | BAS, PRE | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | BAS, D21 | Unknown | 6 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | PLC, D7 | Above | 5 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | NEU, D21 | Below | 3 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | BAS, PRE | Within | 60 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | PLC, D7 | Within | 50 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | LYM, PRE | Below | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | BAS, PRE | Above | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | LYM, D42 | Unknown | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HCT, D42 | Unknown | 1 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HCT, D7 | Above | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | BAS, D7 | Unknown | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | EOS, D21 | Within | 47 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | PLC, D7 | Unknown | 4 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | BAS, D7 | Below | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | NEU, D21 | Unknown | 6 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HGB, D7 | Above | 4 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | BAS, D7 | Within | 58 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | BAS, D7 | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | PLC, PRE | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | BAS, D21 | Unknown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | LYM, PRE | Within | 44 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | BAS, D21 | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | MON, D21 | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | BAS, D21 | Within | 61 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | PLC, PRE | Unknown | 2 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | NEU, PRE | Below | 6 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | BAS, D21 | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | RBC, D7 | Unknown | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | LYM, PRE | Above | 18 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | BAS, D42 | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | BAS, D42 | Within | 57 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | RBC, PRE | Above | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | BAS, D42 | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | EOS, PRE | Unknown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | RBC, PRE | Within | 56 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | LYM, D7 | Unknown | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | EOS, PRE | Below | 6 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | MON, D21 | Within | 48 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | EOS, PRE | Within | 51 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | RBC, PRE | Below | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | MON, PRE | Within | 46 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | EOS, PRE | Above | 5 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | EOS, D7 | Unknown | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | RBC, PRE | Unknown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | LYM, D7 | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | EOS, D7 | Below | 6 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HCT, D7 | Above | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | EOS, D7 | Within | 45 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | PLC, D42 | Above | 2 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | PLC, PRE | Within | 57 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | EOS, D7 | Above | 7 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | EOS, D21 | Unknown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | PLC, D42 | Within | 53 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | LYM, D7 | Within | 44 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | EOS, D21 | Below | 7 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | EOS, D21 | Within | 51 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | EOS, D21 | Above | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | PLC, D42 | Below | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | EOS, D42 | Unknown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | LYM, D7 | Above | 14 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | EOS, D42 | Below | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | PLC, D42 | Unknown | 2 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | EOS, D42 | Within | 47 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | EOS, D42 | Above | 7 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | PLC, D21 | Above | 4 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HCT, PRE | Unknown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | NEU, D42 | Above | 4 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | LYM, D21 | Unknown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HCT, PRE | Below | 6 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | LYM, D21 | Within | 38 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HCT, PRE | Within | 52 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | NEU, D42 | Below | 13 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | MON, PRE | Above | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HCT, PRE | Above | 4 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HCT, D7 | Unknown | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | NEU, D42 | Unknown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | LYM, D21 | Below | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HCT, D7 | Below | 6 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HCT, D7 | Within | 49 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | MON, D7 | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | MON, D21 | Unknown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | NEU, D21 | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | MON, D21 | Below | 13 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HCT, D21 | Unknown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | NEU, D21 | Within | 59 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HCT, D21 | Below | 7 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | LYM, D21 | Above | 22 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HCT, D21 | Within | 53 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | NEU, D21 | Below | 2 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | BAS, D42 | Unknown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HCT, D21 | Above | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HCT, D42 | Unknown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | NEU, D21 | Unknown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HCT, D42 | Below | 10 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | NEU, D7 | Above | 2 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | LYM, D42 | Unknown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HCT, D42 | Within | 46 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HCT, D42 | Above | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | NEU, D7 | Within | 50 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | MON, D7 | Unknown | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HGB, PRE | Unknown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HGB, PRE | Below | 4 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | NEU, D7 | Below | 6 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | LYM, D42 | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HGB, PRE | Within | 55 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | NEU, D42 | Within | 40 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HGB, PRE | Above | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | NEU, D7 | Unknown | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | LYM, D42 | Within | 40 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HGB, D7 | Unknown | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HGB, D7 | Below | 2 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HGB, D7 | Within | 52 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | NEU, PRE | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | MON, D7 | Within | 51 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | PLC, PRE | Above | 4 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HGB, D21 | Unknown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | NEU, PRE | Within | 56 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | LYM, D42 | Above | 17 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HGB, D21 | Below | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | PLC, D7 | Within | 51 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HGB, D21 | Within | 56 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | MON, D42 | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | MON, D7 | Below | 7 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | RBC, D21 | Above | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HGB, D21 | Above | 2 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | RBC, D42 | Unknown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | RBC, D21 | Within | 57 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | RBC, D42 | Below | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | RBC, D42 | Within | 52 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | RBC, D21 | Below | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | RBC, D42 | Above | 2 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HGB, D42 | Unknown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | WBC, PRE | Unknown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | RBC, D21 | Unknown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | MON, D42 | Within | 41 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | WBC, PRE | Below | 2 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | MON, PRE | Unknown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | WBC, PRE | Within | 60 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | RBC, D7 | Above | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | WBC, PRE | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HGB, D42 | Below | 4 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | WBC, D7 | Unknown | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | RBC, D7 | Within | 54 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | WBC, D7 | Below | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | PLC, D7 | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | WBC, D7 | Within | 56 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | RBC, D7 | Below | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | WBC, D7 | Above | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HGB, D42 | Within | 50 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | WBC, D21 | Unknown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | MON, D42 | Below | 16 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | WBC, D21 | Below | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | NEU, PRE | Unknown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | WBC, D21 | Within | 60 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | PLC, D21 | Within | 57 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | WBC, D21 | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | HGB, D42 | Above | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | WBC, D42 | Unknown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | PLC, D21 | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | WBC, D42 | Below | 5 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | WBC, D42 | Within | 50 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | PLC, D21 | Unknown | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | WBC, D42 | Above | 2 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | BAS, PRE | Within | 62 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | LYM, PRE | Unknown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | BAS, PRE | Unknown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | PLC, D7 | Above | 7 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | MON, D42 | Unknown | 1 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | BAS, PRE | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | MON, PRE | Below | 15 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | BAS, PRE | Above | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | PLC, D7 | Unknown | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | LYM, PRE | Below | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | BAS, D7 | Unknown | 3 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis | BAS, D7 | Below | 0 Participants |
Secondary
Number of Subjects With Serious Adverse Events (SAEs)
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Time frame: Throughout the entire study period (Day 0 - Day 385)
Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arepanrix/F1 Group | Number of Subjects With Serious Adverse Events (SAEs) | 2 Participants |
| Arepanrix/F2 Group | Number of Subjects With Serious Adverse Events (SAEs) | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Serious Adverse Events (SAEs) | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Serious Adverse Events (SAEs) | 0 Participants |
Secondary
Number of Subjects With Serious Adverse Events (SAEs)
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Time frame: Within 182 days (Days 0-181) post vaccination
Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arepanrix/F1 Group | Number of Subjects With Serious Adverse Events (SAEs) | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Serious Adverse Events (SAEs) | 2 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Serious Adverse Events (SAEs) | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Serious Adverse Events (SAEs) | 0 Participants |
Secondary
Number of Subjects With Serious Adverse Events (SAEs) - First Analysis
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Time frame: Within 42 days (Days 0-41) post vaccination
Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arepanrix/F1 Group | Number of Subjects With Serious Adverse Events (SAEs) - First Analysis | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Serious Adverse Events (SAEs) - First Analysis | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Serious Adverse Events (SAEs) - First Analysis | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Serious Adverse Events (SAEs) - First Analysis | 0 Participants |
Secondary
Number of Subjects With Serious Adverse Events (SAEs) - Preliminary Analysis
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Time frame: Within 21 days (Days 0-20) post vaccination
Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arepanrix/F1 Group | Number of Subjects With Serious Adverse Events (SAEs) - Preliminary Analysis | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Serious Adverse Events (SAEs) - Preliminary Analysis | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Serious Adverse Events (SAEs) - Preliminary Analysis | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Serious Adverse Events (SAEs) - Preliminary Analysis | 0 Participants |
Secondary
Number of Subjects With Serious Adverse Events (SAEs) - Second Analysis
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Time frame: Within 42 days (Day 0-41) post vaccination
Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arepanrix/F1 Group | Number of Subjects With Serious Adverse Events (SAEs) - Second Analysis | 1 Participants |
| Arepanrix/F2 Group | Number of Subjects With Serious Adverse Events (SAEs) - Second Analysis | 0 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Serious Adverse Events (SAEs) - Second Analysis | 0 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Serious Adverse Events (SAEs) - Second Analysis | 0 Participants |
Secondary
Number of Subjects With Vaccine Responses for Neutralizing Antibody Concentrations
Vaccine responses are defined as the incidence rate of vaccinated subjects with at least a 4-fold increase in post vaccination reciprocal titer relative to that prior to first vaccination. The vaccine strain assessed was Flu A/Neth/602/09 H1N1.
Time frame: At Day 0 (PRE) and at Day 21
Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 21, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arepanrix/F1 Group | Number of Subjects With Vaccine Responses for Neutralizing Antibody Concentrations | 41 Participants |
| Arepanrix/F2 Group | Number of Subjects With Vaccine Responses for Neutralizing Antibody Concentrations | 57 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Vaccine Responses for Neutralizing Antibody Concentrations | 27 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Vaccine Responses for Neutralizing Antibody Concentrations | 24 Participants |
Secondary
Number of Subjects With Vaccine Responses for Neutralizing Antibody Concentrations
Vaccine response was defined as at least a 4-fold increase in post vaccination reciprocal titer relative to that prior to first vaccination. The vaccine strain assessed was Flu A/Neth/602/09.
Time frame: At Day 0 (PRE) and at Day 42
Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 42, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arepanrix/F1 Group | Number of Subjects With Vaccine Responses for Neutralizing Antibody Concentrations | 31 Participants |
| Arepanrix/F2 Group | Number of Subjects With Vaccine Responses for Neutralizing Antibody Concentrations | 54 Participants |
| GSK2340273A/F1 Group | Number of Subjects With Vaccine Responses for Neutralizing Antibody Concentrations | 26 Participants |
| GSK2340273A/F2 Group | Number of Subjects With Vaccine Responses for Neutralizing Antibody Concentrations | 23 Participants |
Secondary
Seroconversion Factor (SCF) for HI Antibodies Against Flu A/CAL/7/09 Influenza Strain
SCF was defined as the geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the pre-vaccination reciprocal HI titer for the vaccine virus.
Time frame: At Day 182
Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 182, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.
| Arm | Measure | Value (GEOMETRIC_MEAN) |
|---|---|---|
| Arepanrix/F1 Group | Seroconversion Factor (SCF) for HI Antibodies Against Flu A/CAL/7/09 Influenza Strain | 31.0 Fold change |
| Arepanrix/F2 Group | Seroconversion Factor (SCF) for HI Antibodies Against Flu A/CAL/7/09 Influenza Strain | 26.6 Fold change |
| GSK2340273A/F1 Group | Seroconversion Factor (SCF) for HI Antibodies Against Flu A/CAL/7/09 Influenza Strain | 10.3 Fold change |
| GSK2340273A/F2 Group | Seroconversion Factor (SCF) for HI Antibodies Against Flu A/CAL/7/09 Influenza Strain | 7.8 Fold change |
Secondary
Titers for Neutralizing Antibodies Against the Flu A/Neth/602/09 Influenza Strain
Titers are presented as geometric mean titers (GMTs) and measured in titers.
Time frame: At Day 0 (PRE) and at Day 42
Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 42, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Arepanrix/F1 Group | Titers for Neutralizing Antibodies Against the Flu A/Neth/602/09 Influenza Strain | Flu A/Neth/602/09, PRE | 16.7 Titers |
| Arepanrix/F1 Group | Titers for Neutralizing Antibodies Against the Flu A/Neth/602/09 Influenza Strain | Flu A/Neth/602/09, D42 | 1389.3 Titers |
| Arepanrix/F2 Group | Titers for Neutralizing Antibodies Against the Flu A/Neth/602/09 Influenza Strain | Flu A/Neth/602/09, D42 | 1786.9 Titers |
| Arepanrix/F2 Group | Titers for Neutralizing Antibodies Against the Flu A/Neth/602/09 Influenza Strain | Flu A/Neth/602/09, PRE | 15.0 Titers |
| GSK2340273A/F1 Group | Titers for Neutralizing Antibodies Against the Flu A/Neth/602/09 Influenza Strain | Flu A/Neth/602/09, PRE | 12.0 Titers |
| GSK2340273A/F1 Group | Titers for Neutralizing Antibodies Against the Flu A/Neth/602/09 Influenza Strain | Flu A/Neth/602/09, D42 | 428.4 Titers |
| GSK2340273A/F2 Group | Titers for Neutralizing Antibodies Against the Flu A/Neth/602/09 Influenza Strain | Flu A/Neth/602/09, PRE | 13.6 Titers |
| GSK2340273A/F2 Group | Titers for Neutralizing Antibodies Against the Flu A/Neth/602/09 Influenza Strain | Flu A/Neth/602/09, D42 | 146.1 Titers |
Secondary
Titers for Neutralizing Antibodies Against the Flu A/Neth/602/09 Influenza Strain
Titers are presented as geometric mean titers (GMTs) and measured in titers.
Time frame: At Day 0 (PRE) and at Day 21
Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 21, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Arepanrix/F1 Group | Titers for Neutralizing Antibodies Against the Flu A/Neth/602/09 Influenza Strain | Flu A/Neth/602/09, PRE | 19.3 Titers |
| Arepanrix/F1 Group | Titers for Neutralizing Antibodies Against the Flu A/Neth/602/09 Influenza Strain | Flu A/Neth/602/09, D21 | 427.6 Titers |
| Arepanrix/F2 Group | Titers for Neutralizing Antibodies Against the Flu A/Neth/602/09 Influenza Strain | Flu A/Neth/602/09, D21 | 296.1 Titers |
| Arepanrix/F2 Group | Titers for Neutralizing Antibodies Against the Flu A/Neth/602/09 Influenza Strain | Flu A/Neth/602/09, PRE | 13.8 Titers |
| GSK2340273A/F1 Group | Titers for Neutralizing Antibodies Against the Flu A/Neth/602/09 Influenza Strain | Flu A/Neth/602/09, D21 | 231.1 Titers |
| GSK2340273A/F1 Group | Titers for Neutralizing Antibodies Against the Flu A/Neth/602/09 Influenza Strain | Flu A/Neth/602/09, PRE | 15.0 Titers |
| GSK2340273A/F2 Group | Titers for Neutralizing Antibodies Against the Flu A/Neth/602/09 Influenza Strain | Flu A/Neth/602/09, PRE | 15.3 Titers |
| GSK2340273A/F2 Group | Titers for Neutralizing Antibodies Against the Flu A/Neth/602/09 Influenza Strain | Flu A/Neth/602/09, D21 | 138.3 Titers |
Secondary
Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain
Titers are presented as geometric mean titers (GMTs) and measured in titers.
Time frame: At Day 0 (PRE) and at Day 182
Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 182, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Arepanrix/F1 Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain | Flu A/CAL/7/09, PRE | 9.6 Titers |
| Arepanrix/F1 Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain | Flu A/CAL/7/09, D182 | 296.2 Titers |
| Arepanrix/F2 Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain | Flu A/CAL/7/09, D182 | 267.9 Titers |
| Arepanrix/F2 Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain | Flu A/CAL/7/09, PRE | 10.0 Titers |
| GSK2340273A/F1 Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain | Flu A/CAL/7/09, PRE | 11.9 Titers |
| GSK2340273A/F1 Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain | Flu A/CAL/7/09, D182 | 122.7 Titers |
| GSK2340273A/F2 Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain | Flu A/CAL/7/09, PRE | 10.6 Titers |
| GSK2340273A/F2 Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain | Flu A/CAL/7/09, D182 | 82.8 Titers |
Secondary
Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain - First Analysis
Titers are presented as geometric mean titers (GMTs) and measured in titers.
Time frame: At Day 0 (PRE) and at Day 21
Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 21, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Arepanrix/F1 Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain - First Analysis | Flu A/CAL/7/09, PRE | 10.8 Titers |
| Arepanrix/F1 Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain - First Analysis | Flu A/CAL/7/09, D21 | 386.4 Titers |
| Arepanrix/F2 Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain - First Analysis | Flu A/CAL/7/09, D21 | 270.1 Titers |
| Arepanrix/F2 Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain - First Analysis | Flu A/CAL/7/09, PRE | 6.1 Titers |
| GSK2340273A/F1 Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain - First Analysis | Flu A/CAL/7/09, PRE | 10.5 Titers |
| GSK2340273A/F1 Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain - First Analysis | Flu A/CAL/7/09, D21 | 138.4 Titers |
| GSK2340273A/F2 Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain - First Analysis | Flu A/CAL/7/09, PRE | 10.9 Titers |
| GSK2340273A/F2 Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain - First Analysis | Flu A/CAL/7/09, D21 | 83.4 Titers |
Secondary
Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain - First Analysis
Titers are presented as geometric mean titers (GMTs) and measured in titers.
Time frame: At Day 0 (PRE) and at Day 42
Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 42, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Arepanrix/F1 Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain - First Analysis | Flu A/CAL/7/09, D42 | 1444.4 Titers |
| Arepanrix/F1 Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain - First Analysis | Flu A/CAL/7/09, PRE | 9.3 Titers |
| Arepanrix/F2 Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain - First Analysis | Flu A/CAL/7/09, D42 | 1238.5 Titers |
| Arepanrix/F2 Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain - First Analysis | Flu A/CAL/7/09, PRE | 5.7 Titers |
| GSK2340273A/F1 Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain - First Analysis | Flu A/CAL/7/09, PRE | 9.3 Titers |
| GSK2340273A/F1 Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain - First Analysis | Flu A/CAL/7/09, D42 | 413.5 Titers |
| GSK2340273A/F2 Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain - First Analysis | Flu A/CAL/7/09, PRE | 9.5 Titers |
| GSK2340273A/F2 Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain - First Analysis | Flu A/CAL/7/09, D42 | 228.0 Titers |
Secondary
Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain - Preliminary Analysis
Titers are presented as geometric mean titers (GMTs) and measured in titers.
Time frame: At Day 0 (PRE) and at Day 21
Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Arepanrix/F1 Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain - Preliminary Analysis | Flu A/CAL/7/09, PRE | 10.3 Titers |
| Arepanrix/F1 Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain - Preliminary Analysis | Flu A/CAL/7/09, D21 | 387.9 Titers |
| Arepanrix/F2 Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain - Preliminary Analysis | Flu A/CAL/7/09, D21 | 253.0 Titers |
| Arepanrix/F2 Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain - Preliminary Analysis | Flu A/CAL/7/09, PRE | 6.2 Titers |
| GSK2340273A/F1 Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain - Preliminary Analysis | Flu A/CAL/7/09, PRE | 9.8 Titers |
| GSK2340273A/F1 Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain - Preliminary Analysis | Flu A/CAL/7/09, D21 | 141.4 Titers |
| GSK2340273A/F2 Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain - Preliminary Analysis | Flu A/CAL/7/09, PRE | 10.9 Titers |
| GSK2340273A/F2 Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain - Preliminary Analysis | Flu A/CAL/7/09, D21 | 82.7 Titers |
Secondary
Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain - Second Analysis
Titers are presented as geometric mean titers (GMTs) and measured in titers.
Time frame: At Day 0 (PRE) and at Day 21
Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 21, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Arepanrix/F1 Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain - Second Analysis | Flu A/CAL/7/09, PRE | 10.5 Titers |
| Arepanrix/F1 Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain - Second Analysis | Flu A/CAL/7/09, D21 | 379.4 Titers |
| Arepanrix/F2 Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain - Second Analysis | Flu A/CAL/7/09, D21 | 377.3 Titers |
| Arepanrix/F2 Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain - Second Analysis | Flu A/CAL/7/09, PRE | 10.8 Titers |
| GSK2340273A/F1 Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain - Second Analysis | Flu A/CAL/7/09, PRE | 10.7 Titers |
| GSK2340273A/F1 Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain - Second Analysis | Flu A/CAL/7/09, D21 | 147.2 Titers |
| GSK2340273A/F2 Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain - Second Analysis | Flu A/CAL/7/09, PRE | 10.9 Titers |
| GSK2340273A/F2 Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain - Second Analysis | Flu A/CAL/7/09, D21 | 83.4 Titers |
Secondary
Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain - Second Analysis
Titers are presented as geometric mean titers (GMTs) and measured in titers.
Time frame: At Day 0 (PRE) and at Day 42
Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 42, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Arepanrix/F1 Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain - Second Analysis | Flu A/CAL/7/09, D42 | 1440.5 Titers |
| Arepanrix/F1 Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain - Second Analysis | Flu A/CAL/7/09, PRE | 9.2 Titers |
| Arepanrix/F2 Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain - Second Analysis | Flu A/CAL/7/09, PRE | 11.1 Titers |
| Arepanrix/F2 Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain - Second Analysis | Flu A/CAL/7/09, D42 | 1671.6 Titers |
| GSK2340273A/F1 Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain - Second Analysis | Flu A/CAL/7/09, PRE | 9.3 Titers |
| GSK2340273A/F1 Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain - Second Analysis | Flu A/CAL/7/09, D42 | 413.5 Titers |
| GSK2340273A/F2 Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain - Second Analysis | Flu A/CAL/7/09, D42 | 228.0 Titers |
| GSK2340273A/F2 Group | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain - Second Analysis | Flu A/CAL/7/09, PRE | 9.5 Titers |